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Abstract
Current research has shown that inappropriate exposure of the developing rodent fetus
and neonate to exogenous oestrogens can cause long-term deleterious effects in the
reproductive tract, hypothalamus, and to some extent the pituitary gland. However, at
present there is only limited information about the effects of neonatal oestrogen
treatment on the function and morphology of the anterior pituitary gland (and
gonadotroph cells in particular). The aim of this thesis was to investigate the effects of
neonatal estrogen exposure on the hypothalamic-pituitary-gonadal (HPG) axis, with
particular emphasis on determining the basic features of any changes in pituitary
gonadotroph function and morphology.
Four main animal studies were undertaken to investigate the effects of neonatal exposure
to oestrogens in both marmoset and rat models. In the first study, the emphasis was on
the potent synthetic estrogen Diethylstilbestrol (DES), as this has been shown in
numerous studies to have significant long-term effects on the HPG axis. Neonatal male
rats were treated with a low dose (O.ljag) or a high dose (10pg) of DES. These animals
were blood sampled on days 26 (pre-pubertal), 35 (pubertal) and 90 (adult), and plasma
LH, FSH, inhibin B, and testosterone levels, the number of gonadotroph cells, LH and
FSH mRNA, and numbers of Leydig and Sertoli cells per testis were determined. The
results of this study showed that DES had direct effects on the testes (reduction in Sertoli
cells and alteration in Leydig cell function), which resulted in a suppression of plasma
inhibin B and testosterone levels, and hence altered negative feedback at the level of the
pituitary, which resulted in elevated LH and FSH levels (despite no significant increase
in LH and FSH mRNA in adulthood).
The second study was composed of two parts. The first part was an in vivo study where
male and female rats were administered DES neonatally, blood samples were collected
in adulthood and were assayed for LH, FSH, inhibin B and testosterone. The results
from this study revealed that neonatal DES treatment had differential effects on
circulating levels of reproductive hormones in males and females, with male rat plasma
hormone levels being more susceptible to disruption with DES than female plasma
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hormone levels. The second part of this study was an in vitro study, where the
pituitaries from these in vivo tracked animals were collected and cultured, to investigate
the potential effects of neonatal estrogen treatment solely at the level of the pituitary,
without any hormonal signals occurring from the gonads. Primary pituitary cells were
cultured with various activin and/or GnRH treatments to test whether these hormonal
treatments would stimulate LH (and FSH) release from the primary pituitary cells, and
to investigate whether the neonatal DES treatments would alter the cells' ability to
respond to these treatments. LH and FSH concentrations in the primary pituitary
cultures were assayed and there was found to be no significant difference in LH and
FSH concentrations between control rats and those treated neonatally with DES.
The third study was a small pilot study which investigated the effects of neonatal
treatment with either a GnRH antagonist alone or in combination with DES on adult
male rat pituitary function. Both treatment regimes were shown to have significant
effects on circulating hormone levels, both in vivo and in vitro, especially the GnRH
antagonist + DES treatment, suggesting that plasma hormone levels were more
susceptible to disruption with DES in combination with treatment with a GnRH
antagonist.
The last study, was a soy study in marmosets to address health concerns about the
possible effects of feeding human infants soy formula milk (SFM), as in North-America
25% of infants are now weaned on SFM. Male Marmoset co-twins were either
administered SFM or standard cow's milk formula (SMA) in neonatal life (days 4 to 45),
blood samples, pituitaries and testes were collected after the 6-week treatment period.
Blood testosterone levels were assayed and pituitary gonadotroph cells and testicular
Leydig and Sertoli cells were counted. Plasma testosterone levels were found to be
significantly suppressed in the SFM animals and there was a significant elevation in the
number of Leydig cells in the SFM marmosets after the 6-week treatment period. There
was found to be no significant difference in the number of LH and FSH immunopositive
pituitary gonadotroph cells between SMA and SFM fed marmosets. The results from
this male marmoset soy study have indicated that SFM suppresses testosterone plasma
levels and increases the number of Leydig cells per testis in neonatal life, without
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causing any major changes in both pituitary gonadotroph cell number or morphology.
The long-term effects of neonatal testosterone suppression and increased Leydig cell
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Chapter 1 Literature review
Chapter one: literature review
1.1 Introduction
Regulation of normal reproductive development and physiology is an extremely
complex process involving coordinated interaction of neurotransmitter systems,
hypothalamic releasing factors, pituitary hormones, and growth factors. The
reproductive system is part of the endocrine system, which contains an elegant feedback
system with control centres at the level of the hypothalamus and the pituitary gland, and
with target organs such as the testes or ovaries. There are also smaller local feedback
loops involving paracrine and autocrine signals at the levels of the pituitary, testes and
ovaries, which maintain organ or cell homeostasis. The major players within the
hypothalamic-pituitary gonadal axis (HPG) are Gonadotrophin Releasing Hormone
(GnRH), Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), inhibin,
oestrogen (females) and testosterone (males). GnRH is secreted from hypothalamic
neurons in a pulsatile manner and interacts with specific high-affinity GnRH receptors
on gonadotroph cells in the anterior pituitary to stimulate the release of the
gonadotrophins LH and FSH. In males, LH acts via specific receptors on Leydig cells of
the testis to stimulate the production of testosterone. FSH acts on specific receptors on
testicular Sertoli cells to stimulate the production of inhibin B. Testosterone exerts
negative feedback at the level of the hypothalamus and on LH production by pituitary
gonadotrophs, and inhibin B negatively regulates FSH production by pituitary
gonadotrophs. In females, GnRH-induced release of gonadotrophins stimulates the
secretion of oestradiol and progesterone by the ovary, these then exert negative feedback
control over GnRH, FSH and LH secretion. Oestradiol, in addition to exerting negative
feedback on LH and FSH secretion, can also exert positive feedback by inducing the
preovulatory surge of LH secretion. FSH-induced inhibin secretion from the ovary
negatively regulates FSH secretion from the pituitary gonadotroph cells.
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The reproductive health of animals in adult life can be affected by several environmental
influences acting at different stages of development, resulting in reprogramming of the
HPG axis. Numerous studies have shown that oestrogens, administered during the
neonatal period of development, can have life-long effects on the function of the HPG
axis. The experimental work described in this thesis was performed to gain a greater
understanding about the effects of neonatal oestrogen treatment on the HPG axis in both
males and females, and to investigate which parts of the HPG axis were most susceptible
to oestrogen disruption. This review of the literature will discuss the set-up of the HPG
axis, its function in adult life and effects of neonatal oestrogen disruption on feedback
along the HPG axis.
1.2 Sexual differentiation into males or females
Sexual determination in mammals is genetically and hormonally controlled. Genetic sex
is determined by inheritance of either an X or Y chromosome from the male gamete
(Jost et ai, 1973). A specific region of the Y chromosome, the testis-determining region
Sry, functions dominantly and induces differentiation of the sexually indifferent
embryonic gonads into testes. In the absence of Sry, gonads develop as ovaries (Gubbay
et al., 1990; Koopman et ai, 1990). Sex differentiation is the developmental process
that takes place in the reproductive tract of the fetus after the gonad has started to
differentiate into a testis or an ovary. In humans, if the gonad is a testis, the first
recognisable structural change is the formation at 7-8 weeks of testicular or sex cords
composed of Sertoli cells (Gilbert, 1994; Huhtaniemi, 1994). From 8 to 10 weeks, these
cells secrete anti-Miillerian hormone or AMH (also called Mtillerian inhibitory
substance or MIS), a glycoprotein related to the transforming growth factor (3 (TGF-[3)
superfamiliy. Its role is to induce regression of the Miillerian ducts (Gilbert, 1994).
Germ cells derived from the dorsal endoderm of the yolk sac make a long migration into
the gonad in the fourth and fifth weeks (Monk & Martin, 1981). At about 7 weeks,
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mesonephric stromal cells invade the gonad and differentiate into Leydig cells
(Huhtaniemi, 1994). By 9 weeks the newly formed Leydig cells begin to secrete
testosterone (Figure 1.2). The onset of testosterone secretion by the fetal gonad is
thought to be regulated by chorionic gonadotrophin (CG) rather than pituitary LH,
because LH secretion does not start until 10 weeks and becomes pulsatile at 11 to 12
weeks (Segaloff & Ascoli, 1993; de Roux & Milgrom, 2001). In the normal male fetus,
testicular descent begins at 10 weeks and serum testosterone levels peak at 12 to 16
weeks. The final migration of the testis from the abdominal cavity to the scrotum is
completed by 25 to 35 weeks (Heyns & Hutson, 1995). Thus, the key factor about
masculinisation of the male is that all of the hormones involved originate from the testes.
Testes formation does not itself require hormones but all other aspects of
masculinisation are dependent upon normal testes function and the consequent
production of adequate amounts of hormones (Sharpe, 2001) (Table 1.2).
Hormone Cellular source Role/site of action
Anti-mullerian hormone Sertoli cells Miillerian duct regression
Androgens (testosterone,
androstendione)







Sertoli cells and Leydig
cells
Multiple tissues, including
Wolffian ducts and Sertoli
cells
Table 1.2: The production and sites of action of hormones produced by the fetal testes
that are thought to play a role in male reproductive development.
Therefore, any disturbance of testicular development or function during early life could
have effects on the functioning of the reproductive system. Furthermore, testis cell
development (as opposed to testes formation) is itself also dependent on the local action
of these same hormones. In contrast to the process of masculinisation, relatively little
attention has been given, until recently, to the importance of testes development in fetal
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and neonatal life in terms of ensuring future fertility (Sharpe et al., 1999). In the human
male, fetal masculinisation and reproductive ability in late puberty are events that are
separated by 15 or more years, yet one is dependent on the other. Thus abnormal
development of the testes in either fetal or neonatal life could have life-long
consequences on reproductive function.
Ovaries differentiate much later than testes. The first germ cells (oocytes) migrate into
the ovary from the dorsal endoderm of the yolk sac at 11 to 12 weeks (Ginsburg et al.,
1999). The number of oocytes reaches a lifetime maximum of 6 million to 7 million by
20 weeks and declines to 2 million by term (Ginsburg et al., 1999). The fetal ovaries are
not thought to play any part in female sex differentiation. They secrete little oestrogen
even though follicles begin to develop at about 16 weeks and primordial follicles
containing granulosa cells are present by 20 weeks. Like the testis, the ovary descends









Figure 1.2: Sexual differentiation in mammals. Adapted from Sharpe, 2001.
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1.3 The pituitary gland
The pituitary gland is a small oval shaped gland that lies at the base of the brain. It is
often referred to as the 'master' endocrine gland as all other endocrine organs depend
upon its secretions for stimulation. Together with the hypothalamus, it plays a pivotal




















Arcuate nucleus containing parvocellular




Figure 1.3: A schematic diagram of the hypothalamus and pituitary gland, connected
by the pituitary stalk. Adapted from Essential Reproduction, Johnson and Everitt, 2000.
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1.3.1 Pituitary gland location and structure
The pituitary gland is located within the skull on the ventral surface of the brain. It lies
within the hypophyseal fossa of the sphenoid bone, overlapped by a circular fold of dura
mater, the diaphragma sellae, which has a small central opening through which the
pituitary stalk, or infundibulum passes. The pituitary has an extremely rich blood supply
derived from the internal carotid artery via its superior and inferior hypophyseal
branches. Venous drainage is by short vessels which emerge over the surface of the
gland and enter neighbouring dural venous sinuses.
The pituitary gland, or hypophysis as it is also known, consists of two major
subdivisions, the anterior lobe (or adenohypophysis) and the posterior lobe (or
neurohypophysis). The posterior lobe is further divided into the infundibular process
and the infundibular stem (or pituitary stalk) which connects to the median eminence.
The posterior lobe is made up of neural tissue and is connected to the rest of the brain
via the stalk. The infundibular process contains terminals of neurones whose cell bodies
reside in the hypothalamus. Thus there is a direct neural link between the posterior
pituitary and the brain (Knobil, 1981). The anterior lobe of the pituitary is further
subdivided into the pars distalis, pars intermedia, and pars tuberalis. The pars tuberalis
surrounds the infundibular stem like a cuff and extends upwards to lie beneath a portion
of the median eminence (Table 1.3.1). Unlike the posterior lobe, the anterior pituitary
contains no nerve fibres and terminals and so is not in direct neuronal contact with the
hypothalamus. Instead it is connected to the brain by a vascular connection, the
hypothalamo-hypophyseal-portal system. Most of the blood supplied to the anterior
lobe comes from this portal system. In some species, it accounts for over 90% of the
total blood supply (Knobil, 1980). In addition to blood flowing down the stalk from the
brain to the anterior pituitary, a small proportion of blood flows up the pituitary stalk.
This provides a direct vascular link from the anterior pituitary back to the hypothalamus
(Bergland & Page, 1978).
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Median eminence ~"
Neurohypophysis Infundibular stem _ Infundibulum
Neural lobe "** Posterior lobe
(infundibular process) >-
"*"* Pars intermedia _
Adenohypophysis Pars tuberalis "~T Anterior lobe
Pars distalis
_
Table 1.3.1: Terminology of the subdivisions of the hypophysis.
The anterior and intermediate lobes of the pituitary gland contain at least six different
endocrine cell types, each of them defined by the hormones they produce. These six
endocrine cell types include adrenocorticotrophic hormone (ACTH) in corticotrophs,
melanocyte stimulating hormone (MSH) in melanotrophs, growth hormone (GH) in
somatotrophs, prolactin (PRL) in lactotrophs, thyroid stimulating hormone (TSH) in
thyrotrophs and luteinizing hormone (LH) and follicle stimulating hormone (FSH) in
gonadotrophs. There is also an embryonic cell type referred to as the rostal tip
'thyrotroph' (Watkins-Chow & Camper, 1998; Sheng & Stern, 1999; Dasen &
Rosenfeld, 2001). The anterior lobe also contains folliculostellate cells. These comprise
a group of SlOO-antigen-positive non-endocrine cells whose function remains poorly
defined. They are postulated to play an important role as a source of paracrine factors
that act locally to modulate pituitary responses to hypothalamic and peripheral signals
(Allaerts et al., 1990a; Renner et al., 1996). Electrophysiological and morphological
studies have suggested that folliculostellate cells form a functional network of
interconnecting cells that facilitate synchronisation and long-term communication
among different parts of the pituitary gland (Stojilkovics, 2001). These cells also have
been viewed as a pool of progenitor cells that are capable of differentiating into
specialised endocrine cells under certain conditions (Inoue et al., 2002). Folliculostelate
cells are known to contain annexins. Annexins are phospholipid- and calcium-binding
proteins and they are thought to play an essential role in the manifestation of the early
Chapter 1 Literature review 8
delayed feedback effects of glucocorticoids in the anterior pituitary gland (Ahluwalia et
al., 1996; Buckingham & Flower, 1997).
1.3.2 Pituitary gland development
The pituitary gland develops in tandem with the specific hypothalamic nuclei that
ultimately regulate homeostatic responses in the mature organism (Watkins-Chow &
Camper, 1998; Sheng & Stern, 1999; Dasen et al., 2001). The pituitary gland originates
from two embryonic tissues. The anterior and intermediate lobes are derived from the
oral ectoderm and the posterior lobe from the neural ectoderm (Schwind, 1928;
Kaufman, 1992) (Figure 1.3.2). Three main stages of pituitary gland formation have
been defined in the rat (Sheng et al., 1997; Li et al., 1994). The first stage of pituitary
organogenesis is the formation of a rudimentary pouch (or placode). This event occurs
near embryonic day 8.5 (E8.5) (Kusakabe, 1984). The placode of the pouch appears
initially as a thickening of the oral ectoderm at the roof of the presumptive oral cavity.
Subsequently, it evolves upwards to form an epithelial bud, the rudimentary pouch. The
second stage of organogenesis is the formation of a definitive pouch, also known as
Rathke's pouch. During this stage, the rudimentary pouch continues to extend upwards.
Meanwhile, the posterior part of the presumptive diencephalon evaginates downwards to
form an infundibulum. Throughout development, the neural epithelium and the oral
ectoderm destined to form the pituitary are kept in close contact, while migration of
mesodermal and neural crest cells into the surrounding space separates the presumptive
brain and oral cavities. Thus, a definitive pouch is formed, the main body of which is
situated in the brain cavity, with a stalk connecting to the oral cavity (Schwind, 1928;
Kaufman, 1992; Camper et al., 1990; Bach et al., 1995). By E12.5, the pouch is
completely detached from the oral cavity and the ventral wall of the pouch is
proliferating to become the anterior lobe. Thereafter, individual hormone-secreting cells
emerge from the pouch in a sequential order and Rathke's pouch is transformed into a
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pituitary gland (Rhodes et al., 1994; Voss & Rosenfeld, 1992). The six mature
endocrine cell types emerge in a temporally and spatially specific fashion from El2.5 to
E17.5, with corticotrophs and rostal tip thyrotrophs emerging first at embryonic day 12.5
and subsequently from E15.5 to E17.5 somatotrophs, lactotrophs, thyrotrophs
gonadotrophs and melanotrophs emerging (Figure 1.3.2). There seems to be little or no
change in the gonadotroph cell population within the adult pituitary, since cell division
of gonadotrophs is almost never observed, even after castration (McNeilly JR,
unpublished data). Furthermore, ablation of gonadotrophs in fetal life using the alpha
gonadotrophin subunit promoter (Kendall et al., 1991; Seuntjens et al., 1999), the FSH(3
promoter (Markkula & Huhtaniemi, 1996) or the LH(3 promoter (McNeilly, 2001) to
drive ablation agents has been shown to result in a permanent and partial depletion of
gonadotroph cells in adulthood. This confirms that there are no progenitor cells within
the pituitary gland that can repopulate the gonadotroph pool of cells.
Figure 1.3.2: Timescale of rat pituitary development. Pituitary cell types arise in a
temporally and spatially specific manner: E12.5 corticotrophs (C), E12.5 rostral tip
thyrotrophs (Tr), and subsequently from E15.5 to E17.5 somatotrophs (S), lactotrophs
(L), thyrotrophs (T), gonadotrophs (G) and melanotrophs (M). Adapted from Scully &
Rosenfeld, 2002.
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In primates, FSH and LH are detectable in the pituitary by embryonic week 10, and their
content increases until embryonic week 25-29. The pituitary starts to release
gonadotrophins into the general circulation by embryonic week 11-12. Circulating
gonadotrophins reach peak levels at midgestation, and subsequently both LH and FSH
levels decline during late gestation (Grumbach et al., 1974; Clements et al., 1976). The
gonadotrophs in primate fetuses have been shown to respond to GnRH by releasing LH
and FSH (Weinstein et al., 1974; Mueller et al., 1981; Matwiji et al., 1987; Dumesic et
al., 1991). A sex difference in fetal gonadotrophin levels has been observed during
midgestation, where pituitary content and circulating concentrations of LH and FSH in
females are higher than those in males (Matwijiw & Faiman, 1989; Winter et al., 1977).
Since it has been shown that circulating fetal testosterone levels are high in male fetuses
as compared with circulating oestrogen levels in females during midgestation, both the
sex difference in gonadotrophin levels and the decrease in gonadotrophin levels towards
late gestation in fetuses have been attributed to the development of the negative
feedback mechanism by the gonadal steroid hormones from the fetal gonads, as well as
from the placenta (Grumbach, 1976). A study in which castration in male rhesus
monkeys at E98-104 was shown to increase circulating gonadotrophin levels as high as
those in female monkeys at similar ages has supported this notion (Resko et al., 1980).
Negative feedback by ovarian steroids is operative in the female primate during late
gestation, when oestrogen secretion is elevated (Grumbach et al., 1974). In sheep
fetuses during late gestation, LH release has been shown to be pulsatile, and
orchidectomy in males, but not ovariectomy in females, has been shown to result in an
increase in the pulse amplitude of LH (Mesiano et al., 1991).
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1.4 Hypothalamic Gonadotrophin Releasing Hormone (GnRH)
Although the anterior pituitary gland has been known since the mid-1940s to be
controlled by chemical signals originating in the central nervous system (Harris, 1948),
it was not until 1971 that the gonadotrophin releasing peptide, pGlu-His-Trp-Ser-Tyr-
Gly-Leu-Arg-Pro-GlyNH2 was isolated from hypothalamic extracts (Schally et al.,
1971). The hypothalamus is a relatively small area at the base of the brain. It is part of
the diencephalon and lies between the midbrain and the forebrain. The hypothalamus
has many neurocrine, behavioural and autonomic functions, which include the regulation
of sexual and ingestive behaviours, the control of body temperature, and the integration
of the cardiovascular and hormonal responses to stress. The gonadotrophin releasing
peptide is a decapeptide and is known as luteinizing hormone releasing hormone
(LHRH) or gonadotrophin releasing hormone (GnRH). It is synthesised in specialised
hypothalamic neurons and packaged into storage granules that travel by axonal transport
to the external zone of the median eminence of the pituitary gland. The GnRH molecule
is synthesised in specialised hypothalamic neurons as part of a pre-hormone that is
enzymatically cleaved at dibasic residues to release the active decapeptide (Seeburg et
al., 1987). Although GnRH is resistant to exopeptidases, owing to its blocked N- and
C-termini, it is rapidly degraded by endopeptidases and is cleared from the circulation
with a half-life of approximately 5 minutes. The amino acid sequence of GnRH is
conserved among the mammalian peptides, but at least six isoforms occur in other
species (Sherwood et al., 1993). In mammals GnRH is secreted episodically into the
capillaries of the hypothalamo-hypophyseal portal system and reaches the anterior
pituitary gland, where it binds specifically to receptors on gonadotroph cells and
stimulates the release of luteinizing hormone (LH) and follicle stimulating hormone
(FSH). Two distinct releasing factors were originally thought to control the secretion of
LH and FSH, but the ability of GnRH to stimulate the release of both gonadotrophic
hormones and to initiate puberty (Hoffman & Crowley, 1982) has established its
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importance as the primary regulator of mammalian gonadotrophin secretion. Although
the circulating profiles of LH and FSH are sometimes divergent, this is attributable to
factors other than the existence of two releasing hormones. These include differences in
the gonadal steroid hormone milieu, the independent regulation of FSH secretion by
inhibin and the different circulating half-lives of the two hormones. Also the LH- and
FSH-secreting gonadotrophs appear to be differentially regulated by the frequency of the
pulsatile stimulation by GnRH (Marshall & Kelch, 1986; Padmanabhan and McNeilly,
2001).
The pulsatile mode of the GnRH secretion reflects the synchronised activity of many of
the 1500 or so GnRH neurons that form a network within the hypothalamus. Each burst
of GnRH secretion is followed by a prominent pulse of LH release into the systemic
circulation. Such LH pulses occur at intervals of 30-120 minutes in various species, and
about once per hour in humans. Decreases in the rate of stimulation by GnRH, or
sustained treatment with GnRH, are both associated with impaired secretion of both LH
and FSH (Knobil, 1989; Millar et al., 1989). The co-ordinated activity of the scattered
GnRH neurons is attributed to a neural pacemaker that is termed the GnRH pulse
generator (Knobil, 1989). The nature of the pulse generator has yet to be established,
but its activity reflects a pattern of electrical activity in the mediobasal hypothalamus
that is correlated with episodic increases in circulating LH levels in the rhesus monkey
(Knobil, 1981; Sealfon et al., 1997). Thus, the pulsatile nature of GnRH secretion is
essential for the physiological maintenance of normal gonadotroph function, and
ultimately for normal reproductive capacity (Millar et al., 1987).
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1.4.1 GnRH receptor
The actions of GnRH in the anterior pituitary gland are mediated by a calcium-
mobilizing seven transmembrane domain receptor that is coupled to phospholipase C-(3
through Gq/11 proteins. The GnRH receptor is the smallest of the G protein coupled
receptor (GPCR) family, owing to its lack of the C-terminal cytoplasmic tail that is
present in all such receptors (King et al., 1997; King & Millar, 1995). Agonist
activation of the GnRH receptor is followed by rapid stimulation of phosphoinositide
hydrolysis to produce the two second messenger molecules, inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG). The resulting stimulation of calcium mobilisation and
influx, and the activation of protein kinase C (PKC), lead to rapid exocytosis of
secretory granules from pituitary gonadotrophs and the release of LH and FSH into the
circulation (Stojilkovic et al., 1994; Sealfon et al., 1994). The consequences of GnRH-
induced activation of IP3 and calcium signalling pathways in pituitary gonadotrophs
include changes in plasma membrane channel activity, increased gonadotrophin
synthesis and release, and changes in gene expression (Sealfon et al., 1997).
1.4.2 Differential regulation of gonadotrophins by GnRH
FSH and LH are structurally related glycoproteins composed of a common a-subunit
and a hormone specific (3-subunit. The subunits are not covalently linked and can be
readily dissociated by low pH, or heat treatment (Pierce and Parsons, 1981).
Heterodimers formed by recombination of the subunits have the endocrine properties
characteristic of the hormone from which their (3-subunit is derived (Hertan et al., 1999).
The cystine knot disulphide bonds found in both a- and (3-subunits are crucial for
gonadotrophin activity. This is thought to be because they assume the roles of a
hydrophobic core in stabilising the conformation of each subunit (Pierce and Parsons,
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Table 1.4.2a: Summary of the main properties of the gonadotrophins LH and FSH,
including their composition, molecular weights and target cells.
Pituitary gonadotrophs are bihormonal (Liu et al., 1998; Currie & McNeilly, 1995), but
under certain physiological and experimental conditions, monohormonal cells have been
identified (Childs et al., 1994; Taragnat et al., 1998). Despite the bihormonal nature of
gonadotroph cells, they are capable of differentially regulating the secretion of LH and
FSH. LH is stored intracellularly and is released mainly in response to pulses of GnRH.
This is known as a regulated secretory pathway (Burgess & Kelly, 1987). However, a
small quantity of LH can be released via a constitutive pathway (McNeilly et al., 1991).
FSH on the other hand, is largely secreted via a 'constitutive-like' pathway, however
there is also evidence that FSH may be released by an alternative 'regulated' pathway
(Farnworth, 1995) (Figure 1.4.2).
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Figure 1.4.2: Differential gonadotrophin secretion. LH is secreted mainly via a
regulated pathway, whereas FSH is secreted via a 'constitutive-like' pathway. Adapted
from McNeilly et al., 2003.
There are three aspects of differential regulation of LH and FSH which are important to
recognise. The first is the requirement to allow the release of FSH and LH in different
amounts at the same time, from the same gonadotroph cell. Secondly, LH is released in
discrete pulses that are not usually accompanied by release of FSH. Some FSH pulses
may be associated with GnRH, and hence LH pulses, but the increase in plasma FSH
concentrations often precedes that of either GnRH or LH (Padmanabhan et al., 1997).
Thirdly, sufficient LH, in particular, must be stored within the gonadotroph cells to
allow enough LH to be released to maintain the preovulatory LH surge. With a half-life
in plasma of only approximately 20 minutes (McNeilly et al., 1982), the maintenance of
the LH plasma levels during the preovulatory surge has been shown to require the
GnRH
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release of up to 80% of the total pituitary content in sheep pituitaries (Brooks et al.,
1993; Currie & McNeilly, 1995; Crawford et al., 2002).
Granins are thought to play a role in regulated secretion of gonadotrophins, as there has
been shown to be a correlation between granin regulation and granule morphology in
gonadotroph cells (Huttner et al., 1995). In sheep it has been observed that although LH
and FSH are co-localised within the same gonadotroph cell, at a gross morphological
level they can be seen to be packaged separately (Thomas & Clarke, 1997). At the
ultrastructural level, LH has been shown to be packaged in electron-dense core granules
(Currie & McNeilly, 1995; Crawford et al., 2002), while FSH appears to be present in
less dense granules. Additionally, granules containing an FSH-positive electron-light
matrix surrounding an LH-positive electron-dense core have also been observed.
Studies in sheep, monitoring the changes in morphology of gonadotrophs after the
preovulatory LH surge have clearly illustrated that LH and FSH are mainly packaged in
separate granules.
Other studies in the rat (Watanabe et al., 1991), mouse (Crawford et al., 2002) and sheep
(Currie et al., 1995) have investigated the role of the granin class of proteins in the
organisation of granule formation. These granins are glycoproteins which aggregate at
low pH and high salt concentrations, bind calcium, and are closely associated with both
LH and FSH. Secretogranin II (Sgll) has been shown to be present within the electron-
dense core granules associated with LH, and in mice it has been shown that it is these
granules that are released in response to a GnRH pulse (Crawford et al., 2002).
Chromogranin A (Cg A) is also associated with granules but appears to be associated
with FSH in electron light-dense bodies (Wantanabe et al., 1991). The properties of the
main granins are summarised in Table 1,4.2b.
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Granin Properties References
Secretogranin II 86kDa, associates with LH Wantanabe et al., 1991;
Thomas et al., 1998
Chromogranin A 70kDa, co-localises with
LH and FSH
Wantanabe et al, 1991
Chromogranin B lOOkDa, co-localises with
other granins
Pohl et al., 1990; Bassetti et
al., 1990
Table 1.4.2b: Summary of the properties of the granins associated with gonadotrophins.
1.5 Male HPG axis in neonatal life
The neonatal period of brain-pituitary-gonadal function is a very important period in
development. This period is involved with testicular descent, control of Sertoli cell
number, masculinisation of the brain, development of social and sexual behaviour,
pubertal maturation of gonadotrophin secretion, the setting of the threshold of testicular-
pituitary feedback interactions, and development of the immune system (Figure 1.5a).
The need to have a greater understanding of the neonatal period of hypothalamic-
pituitary-testicular development has been emphasised by the fact that a range of
reproductive disorders such as testicular cancer, hypospadias, and cryptorchidism in
males are thought to stem from disruption occurring along the HPG axis during this
developmental period. There have also been reports expressing concern about a
potential decrease in sperm counts over the past 50 years (Sharpe & Skakkeback, 1994),
and it has been suggested that potential alterations along the neonatal HPG axis caused
by the action of (environmental or synthetic) oestrogenic agents could play a role in this,
together with other factors such as changes in life style and diet (Sharpe &
Skakkeback, 1994).














Figure 1.5a: Summary of the role of neonatal brain-pituitary-testicular interactions
during neonatal life.
The early postnatal period of male primates is associated with the activation of the
hypothalamic-pituitary-testicular axis. Circulating levels of LH and FSH begin to rise in
male infants during the second week of postnatal life, reach a peak between 2 and 4
months, and decline thereafter, reaching juvenile levels by one year of age (Forest,
1990). Total testosterone levels rise commensurate with the increase in neonatal LH,
reaching peak values that approach the low normal adult male range between 1 and 3
months of age, and then fall in concert with declining LH values to juvenile levels by 6
to 8 months of age (Forest, 1990) (Figure 1.5b). Comparable patterns of neonatal
endocrine changes have been reported in the chimpanzee, rhesus monkey, and marmoset
(Steiner & Bremner, 1981; Fuller et al., 1982; Mann et al., 1983, 1984; Lunn et al.,
1994).
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Figure 1.5b: Schematic diagram illustrating the pattern of LH, FSH, and testosterone
secretion during development in the primate. The bottom panel shows the marked
increase in Sertoli cell number during the neonatal period, while testis size does not
increase until the activation of the hypothalamic-pituitary axis at puberty. Adapted from
Mann & Sharpe, 1996.
LH secretion is pulsatile in the neonate, and the pituitary-testicular axis of the neonate
responds to exogenous GnRH challenge in a similar manner to that of the adult (Plant,
1982; Mann et al., 1984), suggesting that the central nervous system mechanisms
controlling this axis may be fully functional during this period. However, unlike the
adult, this active period of gonadotrophin and testosterone secretion in the neonate is
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transitory and secretion falls to a low level characteristic of the juvenile period before
being reactivated at the time of puberty (Mann et al., 1984; Lunn et al., 1994). It
remains unclear as to whether the elevation of neonatal testosterone represents a true
increase in the availability of bioactive hormone. While total circulating levels of
testosterone increase in infants, free testosterone concentrations may not show a
comparable change in magnitude (Huhtaniemi et al., 1986) since there is also an
elevation of sex hormone-binding globulin (Bolton et al., 1989). Salivary testosterone
levels, an index of the free fraction of serum steroid (Riad-Fahmy et al., 1982), actually
decline from the day of birth through 6 months of age in infant boys (Huhtaniemi et al.,
1986). On the other hand, the free androgen index (ratio of testosterone to sex hormone-
binding globulin) is ten times higher in boys than girls (Bolton et al., 1986), and the rise
of total serum testosterone is paralleled by a similar pattern of change in unbound
testosterone in infant boys (Forest, 1990).
In male rats, the neonatal period shows many similarities with primates, however there
are differences. Neonatal rodents are relatively underdeveloped when compared with
neonatal primates, however as in primates, the hypothalamo-pituitary-gonadal axis is
already established in the new-born male rat (Swerdloff et al., 1971; Grady 1986; Lopez
& Negro-Vilar, 1988; Lalau et al., 1990). But, from a developmental point of view, the
rat is born with a reproductive system comparable to that observed in humans at 150
days of gestation life (Lalau et al., 1990). In the male rat the serum concentrations of
LH fluctuate during postnatal development until adulthood is reached. Two peaks in LH
serum concentrations have been observed: the first one starts in the second week,
reaches its maximum at approximately 14 days of age and is followed by a rapid decline,
whereas the second peak is present during the peripubertal period, between days 40 and
45 (Ojeda & Ramirez, 1972; Dohler & Wuttke, 1975; Chiappa & Fink, 1977). In
contrast, the hypothalamic content of GnRH increases steeply between days 5 and 9,
with a less marked increase rate in hypothalamic GnRH content afterwards, until the
adult stage is reached (Chiappa & Fink, 1977). Interestingly, it has been reported that
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the infantile female rat is more sensitive to GnRH compared with the neonatal and
juvenile rat (Ojeda & Ramirez, 1972), and a corresponding sharp peak in GnRH receptor
density in the pituitaries of female infantile rats was also observed (Dalkin et al., 1981).
However, during this developmental stage, it was also noted that male pituitaries showed
only a discrete increase in GnRH-binding capacity, and the largest receptor density was
observed in 30-day old rats (Dalkin et al., 1981). In rodents, there is no prolonged
neonatal testosterone rise as is the case for primates, the neonatal testosterone surge is
restricted to a matter of hours around the day of birth (Forest, 1990).
Sperm production in adult life is dependent upon neonatal Sertoli cell proliferation. The
number of Sertoli cells in the adult testis determines both testis size and daily sperm
production. This relationship occurs because each Sertoli cell has a fixed capacity for
the number of germ cells that it can support (Orth et al., 1988), though this capacity has
been shown to vary amongst species (Sharpe, 1994). Only immature Sertoli cells
proliferate, so the final number of Sertoli cells is determined before adulthood (Figure
1,5c). There appear to be fundamental differences between species as to when Sertoli
cells proliferate. In rodents, all Sertoli cell proliferation occurs in fetal and neonatal life,
whereas in rhesus monkeys proliferation has been shown to occur predominantly in the
peripubertal period. However, as more data has been obtained from more species, a
general interpretation is now possible (Plant & Marshall, 2001). This indicates that
Sertoli cells proliferate during two periods of life, in fetal or neonatal life and in the
peripubertal period in all species. In some species (e.g. rhesus monkey), one period may
be far more important than the other (Plant & Marshall, 2001), whereas in most species
proliferation of Sertoli cells occurs in both periods, although the fetal or neonatal period
is thought to be more important. As the number of Sertoli cells determines the number
of spermatozoa produced per day, it is vital that the correct number of Sertoli cells is
generated. Hormones, in particular FSH, have been shown to be important for
generating the correct number of Sertoli cells. But also growth hormone, various
paracrine growth factors (Sharpe, 1994; Sharpe et al., 1999) and even LH and
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testosterone have been shown to play a role in rhesus monkeys (Ramaswamy et ah,
2000). FSH increases the rate of proliferation of Sertoli cells. In contrast, thyroid
hormones have been shown to alter the period in which proliferation can occur by
regulating the maturation of Sertoli cells. It has been demonstrated that neonatal FSH
concentration is very important, as its suppression can reduce the final number of Sertoli
cells by approximately 40%, whereas an experimental increase of plasma FSH by
injection or by neonatal hemicastration has been shown to increase the number of Sertoli
cells by 18 to 49% (Hess et ah, 1993; De Franca et al., 1995; Sharpe et ah, 2003a).
At around the onset of puberty, Sertoli cells undergo a radical change in their
morphology and function, indicating a change from an immature proliferative state to a
mature non-proliferative state. Adjacent Sertoli cells start to form tight junctions with
each other to create a unique compartment in which meiotic and post-meiotic steps of
spermatogenesis can proceed, as well as allowing formation of a fluid-filled lumen. As
a result, the germ cells developing in the adluminal compartment become sealed off
from direct access to many nutrients and thus they become dependent upon the secretion
of such factors by the Sertoli cells (Jegou, 1992; McLaren et ah, 1993; Sharpe, 1994).
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Figure 1.5c: Timing of proliferation of Sertoli cells (SC) in different species. The blue
line indicates the change in relative number of SC for that species, where there are gaps
in reported data, a dashed blue line is shown. The green line shown in the marmoset
panel indicates what happens to the number of SC in animals treated neonatally with a
GnRH antagonist to suppress gonadotrophin secretion. From Sharpe et al., 2003a.
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1.5.1 Adult male HPG feedback system
The adult male reproductive feedback system consists of the hypothalamus, the anterior
pituitary gland and the testes. The testes have two important functions in the adult male:
the production of sperm and the synthesis of testosterone. Control of both functions is
guided by the central nervous system (CNS) in an elegant endocrine feedback loop with
FSH and LH as the key hormonal signals. LH acts primarily on Leydig cells in the
testicular interstitium to promote the synthesis of testosterone (T), while FSH acts
exclusively on the Sertoli cells and germ cells to facilitate spermatogenesis. FSH and
LH secretion from the anterior pituitary is regulated by hormonal signals from both the
CNS and the gonads, including testosterone and its metabolites and inhibin (Figure
1.5.1).
Secretion of LH and FSH is under control of GnRH, synthesised in a pulsatile manner in
the hypothalamus and carried by the hypothalamo-hypophyseal-portal system to the
gonadotroph cells of the anterior pituitary. Binding of GnRH to receptors on the
pituitary gonadotrophs causes the release of both FSH and LH. Direct measurement of
GnRH in the hypothalamo-hypophyseal-portal blood of sheep has shown that each rise
in serum LH is preceded by a GnRH pulse in the portal blood (Clarke & Cummins,
1982). Gonadal hormones can decrease gonadotrophin release both by decreasing
GnRH release from the hypothalamus and by affecting the ability of GnRH to stimulate
gonadotrophin secretion from the pituitary itself. For example, administration of
exogenous testosterone has been shown to lead to a marked slowing in GnRH pulse
frequency in men (Matsumoto et al., 1984). Testosterone administration has also been
shown to inhibit LH and FSH by a direct pituitary effect (Sheckter et al., 1989).
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Figure 1.5.1: The hypothalamic-pituitary-gonadal feedback system in adult males.
Pulsatile GnRH stimulates LH and FSH (to a smaller extent) release from the anterior
pituitary. These stimulate the testicular Leydig cells to secrete testosterone, which feeds
back onto the pituitary and hypothalamus, and the testicular Sertoli cells to secrete
inhibin which negatively regulates FSH secretion from the pituitary.
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The regulation of GnRH release at the hypothalamus is also mediated in part by
aromatisation of testosterone to oestradiol (Carreau et al., 1999, Saez, 1994). The
biosynthesis of oestrogens from androgens is catalysed by the key enzyme complex
named aromatase, composed of a specific form of cytochrome P450 aromatase
(P450arom), and a ubiquitous flavoprotein, the NADPH-cytochrome P450 reductase
(Simpson et al., 1994; Simpson, 1997). The major protein hormone product of the
gonads is inhibin, a 32kDa glycoprotein with two isoforms, termed inhibin A and B.
The inhibins, activins and follistatin were isolated on the basis of their ability to modify
the secretion of FSH by the pituitary gland (Ling et al., 1985, 1986; Robertson et al.,
1985, 1987; Vale et al., 1992; Ueno et al., 1987). Activins are members of the
transforming growth factor [3 (TGF(3) superfamily of growth and differentiation factors.
Homo- or heterodimeric activin proteins are formed by linking (3A- or PB-subunits
through disulphide bonds, and at least three forms of activins with biological activity
have been described: activin A (pApA), activin B (PBPB) and activin AB (pApB)
(MacConell et al., 1999). The isolation of activins followed that of inhibins, which are
dimeric proteins composed of an a- and a P-subunit (Gray et al., 2002; de Kretser et al.,
2000). Activin is produced in various tissues and stimulates synthesis of FSH by direct
action on gonadotroph cells, whereas inhibin is primarily produced by the gonads and
acts to counteract the effects of activin by reducing the secretion of FSH (Vale et al.,
1999). Inhibin blocks activin effects by competing with activin for receptor binding
(Chapman et al., 2001; Gray et al., 2002). Follistatin is a monomeric protein,
structurally unrelated to the TGFp superfamily, that acts primarily by binding to activin
and preventing its interaction with its receptor (Michell et al., 1993a; De Winter et al.,
1996). Inhibin, activin and follistatin are produced by the ovary and are released into the
circulation. However, the activin and inhibin subunits and follistatin are also produced
in the pituitary gland itself by the gonadotroph cells and folliculostellate cells in
different species, including the rat (Wilson & Handa, 1998; Kogawa et al., 1991),
human (Uccella et al., 2000), and sheep (Baratta et al., 2001; Farnworth et al., 1995).
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Thus these hormones may have autocrine or paracrine effects on the synthesis and
secretion of FSH. Activin exerts its biological effects by interacting with four types of
transmembrane receptors (types IA, IB, IIA, and IIB) with protein serine/threonine
activity (Attisano & Wrana, 1996). The type II receptors are involved in initial ligand
binding, leading to recruitment and phosphorylation of type I receptors by the kinase
domain of type II receptors. Once phosphorylated, type I receptors exhibit kinase
activity on Smad proteins. Smad-2 and Smad-3 are specific to activin signalling and are
phosphorylated by activated activin receptors on serine residues. Phosphorylation of
Smad-2 and Smad-3 allows complex formation with Smad-4, a common effector shared
by different TGFP family pathways (Heldin & Ostman, 1996). Once formed, the Smad-
2/Smad-4 or Smad-3/Smad-4 complex translocates into the nucleus to activate the
transcription of specific target genes. However, it has been suggested that the Smad
signalling pathway might not be the sole pathway activated by the activin receptors.
Other members of the activin family, such as TGF(3l, have been shown to activate other
signalling pathways in addition to Smads, including the kinases extracellular regulated
kinase 1/2 (ERK1/2) and phosphatidylinositol 3'-kinase (PI3K) (Vinals & Pouyssegur,
2001). The activin receptor subtypes and the Smad proteins have been characterised in
the ovary (Drummond et al., 2002; Van den Hurk & van de Pavert, 2001) and the
pituitary, including the gonadotroph-derived L(3T2 cell line (Dalkin et al., 1996;
Cameron et al., 1994; Pernasetti et al., 2001).
Although inhibins are part of the larger TGF(3 superfamily, attempts so far to identify
inhibin-specific type I and type II receptors have been unsuccessful (Woodruff, 1999).
However, inhibins have been shown to bind to activin type II receptors through their |3-
subunits. This binding does not lead to recruitment or phosphorylation of the type I
receptor and thereby provides a mechanism for the inhibins to antagonise the actions of
the activins (Attisano et al., 1996; Lebrun & Vale, 1991; Mathews & Vale, 1991;
Martens et al., 1997; Xu et al., 1995). However, recently, two proteins were identified
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as candidate inhibin receptors: betaglycan and inhibin binding protein/pl20
(InhBP/pl20) (Lewis et al., 2000; Chong et al., 2000).
The properties of these two proteins and their potential mechanisms for activin
antagonism are summarised in Table 1.5.1.
Property Betaglycan InhBP/pl20






Also expressed in Leydig
cells and in various ovarian
cell types. Expression has
also been detected in non-
reproductive tissues.
Highly expressed in the
anterior pituitary.
Dynamically regulated in
the rat pituitary across the







Binds inhibins with high
affinity
Binds inhibin A with high
affinity and forms a higher
affinity complex in the
presence of activin type II
receptors. Can also bind
inhibin B, although the
affinity of this association
has not yet been reported.
Originally purified through
affinity chromatography,
but does not bind inhibin A
or B in standard receptor
binding assays.
Binds inhibins with high
specificity
In addition to inhibins,
betaglycan binds TGF(3l-3.
Does not bind activin A.
Does not bind inhibin A or




Forms a high affinity
complex with ActRIIA and
inhibin A, which blocks







Table 1.5.1: Properties and proposed mechanisms of betaglycan and inhibin binding
protein/pl20 (InhBP/pl20) inhibin receptors. Adapted from Bernard et al., 2002.
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1.6 Female HPG axis in neonatal life
In contrast to male primates, where there is a sharp elevation in circulating LH (and FSH
to a lesser extent for the first 3 postnatal months) and testosterone levels shortly after
birth, lasting approximately 4 to 6 months (Corbier et al., 1990; Faiman & Winter, 1974;
Winter et al., 1975), in neonatal females LH levels are only very slightly elevated during
the first few months of life. FSH levels on the other hand, are high for the first 5 months
(Faiman & Winter, 1974; Winter et al., 1975). A moderate elevation of oestrogen levels
has been observed, starting during late gestation and continuing through the neonatal
period. After the first six months of life, circulating levels of FSH, LH, and gonadal
steroids are all low and the hypothalamo-pituitary-gonadal feedback system enters a
quiescent stage until the time of puberty (Figure 1.6) (Faiman & Winter, 1974).
Birth
Fetal Neonatal Pubertal
Figure 1.6: Schematic diagram illustrating the pattern of LH, FSH and oestrogen
secretion during development in the female primate.
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1.6.1 Adult female HPG feedback system
GnRH, LH and FSH control the reproductive cycle in adult females. The reproductive
cycle is known as the menstrual cycle in primates and the oestrus cycle in rodents. It
can be divided into two phases, follicular and luteal, which are separated by the LH
surge (Figures 1.6.1a, b and c). The rodent oestrus cycle is divided into four stages,
oestrus, met-oestrus, di-oestrus and pro-oestrus. The rodent oestrus cycle is similar to
the menstrual cycle of primates, but there are some differences (Greenwald and Wang,
1994). In rodents, there is a high level of FSH due to reduced circulating levels of
inhibin, which produces relatively large follicles. Therefore, the follicles require a
shorter period of growth and hence the follicular phase is short, lasting 1 or 2 days
(Greenwald and Choudary, 1969). If the ovum remains unfertilised, the corpus luteum
degenerates within 2 to 3 days (Marshall, 1984).
Pulsatile GnRH stimulation of pituitary gonadotrophs results in acute secretion of both
LH and FSH. Although LH and FSH are both secreted from the same gonadotroph cells
in response to pulses of GnRH, the relative plasma concentrations of LH and FSH vary
throughout the reproductive cycle, with predominance of FSH in the early follicular
phase and LH predominance in both the luteal and late follicular phases. The rise in
plasma FSH during the luteal-follicular transition is critical for follicular development
and also induces granulosa cell LH receptors and the aromatase enzyme system.
Although the exact mechanisms governing the differential secretion of LH and FSH are
not entirely clear, at least two mechanisms are involved. Firstly, ovarian secretory
products exert selective feedback actions on gonadotroph cells. Oestradiol (Marshall et
al., 1983) and the inhibin peptides (Hayes et al., 1998; Vale et al., 1992; Michel et al.,
1993b) specifically inhibit FSH secretion, as occurs during the luteal phase. The
decrease in plasma levels of both inhibin and oestradiol with the demise of the corpus
luteum in the human menstrual cycle is associated with the intermenstrual rise in FSH
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which initiates the growth of follicles in the next cycle (Groome et al., 1996). Increases
in serum activin A, a peptide hormone that enhances FSH production, is thought to play
a role in the rise of FSH during the luteal-follicular transition (Muttukrishna et al.,
1996). In addition, oestradiol concentrations above a certain threshold greatly augment
LH release, this positive feedback action of oestradiol is integral to the midcycle LH
surge. The second mechanism by which differential gonadotrophin secretion occurs
involves alterations in GnRH pulse frequency. In vivo studies performed in
ovariectomised monkeys and sheep have demonstrated that faster frequencies (i.e. once
hourly) of pulsatile exogenous GnRH favour LH secretion. However, slow pulse
frequencies (i.e. every 3 to 4 hours) favour FSH secretion, such that plasma FSH
increases, while LH decreases (Wildt et al., 1981; Clarke et al., 1984). In vitro and in
vivo studies in a GnRH-deficient rat model have demonstrated that fast GnRH pulses
(i.e. every 15 minutes) favoured LH mRNA expression, whereas slow GnRH pulses (i.e.
every 120 minutes) resulted in preferential expression of FSH mRNA (Kirk et al., 1994).
In this GnRH-deficient rat model, GnRH pulse frequency was also found to regulate
FSH production via changes in gonadotroph activin and follistatin. Expression of
activin pB was enhanced by slow (every 30 minutes) frequencies of GnRH stimulation.
In turn, intragonadotroph activin |3B subunit was found to enhance FSH transcription
and stabilise FSH mRNA (Dalkin et al., 1999). On the other hand, fast GnRH pulse
frequencies were found to augment expression of intragonadotroph follistatin, which
acts to reduce production of FSH mRNA by binding to and inactivating activin PB (Kirk
et al., 1994). Thus, a regulatory system is present within pituitary gonadotroph cells that
effects differential expression of FSH and LH mRNA as a function of the pattern of
GnRH pulse stimulation.
Studies utilizing frequent blood sampling and pulse detection analysis have shown that
there are changes in the frequency of LH (and by inference GnRH) pulses throughout
the menstrual cycle (Reame et al., 1984; Filicori et al., 1986,1984; Backstrom et al.,
1982;). LH pulse frequency increases from approximately one pulse per 90 minutes in
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the early follicular phase to one pulse every 60 minutes during the midcycle LH surge,
and subsequently decreases to one pulse every 3 to 4 hours during the luteal phase. The
exact mechanisms controlling alterations in GnRH pulse frequency throughout the
menstrual cycle are not fully understood, however, it has been shown that progesterone
appears to play a dominant role. Progesterone has been shown to slow GnRH pulse
frequency when given to women in the follicular phase and when given to
ovariectomised, oestradiol-replaced sheep (Soules et al., 1984; Goodman et al., 1981).
Thus ability of progesterone to slow GnRH pulse frequency requires the presence of
oestradiol. It has been suggested that this is perhaps a reflection of the ability of
oestradiol to induce hypothalamic progesterone receptors (MacLusky and McEwen,
1978; Romano et al., 1989).
Thus, in the primate menstrual cycle, during the luteal phase, oestradiol and
progesterone from the corpus luteum slow GnRH pulse frequency to approximately one
pulse every 3 to 4 hours. This slow GnRH pulse frequency favours FSH synthesis and,
in concert with oestradiol actions and inhibin A to restrain FSH secretion, leads to an
increase in FSH stores in pituitary gonadotrophs. In the absence of fertilisation, the
corpus luteum regresses in the late luteal phase and oestradiol, progesterone and inhibin
A levels decrease. FSH levels begin to increase in the late luteal phase, resulting in the
recruitment of ovarian follicles, one of which later develops into a dominant Graafian
follicle. Whereas FSH levels exceed that of LH in the first 5 days of the follicular phase,
oestradiol and inhibin B from the dominant follicle limit FSH secretion in the later
follicular phase. GnRH pulse frequency gradually increases to one pulse every 60
minutes during the late follicular phase (McCartney et al., 2002). This, in combination
with the actions of the high levels of oestradiol to augment LH release, triggers the LH
surge. Subsequent ovulation and formation of the corpus luteum causes large amounts
of oestradiol and progesterone to be secreted, and therefore GnRH pulse frequency is
slowed again and hence FSH synthesis is favoured for subsequent release.
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Figure 1.6.1a: Schematic diagram illustrating feedback control of FSH and LH
secretion during the follicular phase in primates.
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Figure 1.6.1b: Schematic diagram illustrating the control of the LH surge at ovulation
in primates.















Figure 1.6.1c: Schematic diagram of the feedback control during the luteal phase in
primates. PR is progesterone receptor.
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1.7 Oestrogen receptor in males and females
More than 40 years ago Jensen and Jacobsen (Jensen & Jacobsen, 1962) came to the
conclusion, based on the specific binding of oestradiol-17(3 in the uterus, that the
biological effects of oestrogen had to be mediated by a receptor protein. For 24 years
this protein was extensively studied in several laboratories and in 1986, two groups
reported the cloning of this oestrogen receptor (ER) (Green et al., 1986; Greene et al.,
1986). Until 1995, it was assumed that there was only one ER and that it was
responsible for mediating all of the physiological and pharmacological effects of natural
and synthetic oestrogens and anti-oestrogens. However, in 1995, a second ER, ER(3 was
cloned from a rat prostate cDNA library (Kuiper et al., 1996). The former ER is now
called ERa. Since then several groups have cloned ERp from various species
(Tchoudakova et al., 1999; Todo et al., 1996; Tremblay et al., 1997) and have identified
several ER[3 isoforms (Moore et al., 1998; Ogawa et al., 1998; Petersen et al., 1998).
ERa and ERP belong to the steroid/thyroid hormone superfamily of nuclear receptors,
members of which share a common structural architecture (Evans, 1988; Giguere et al.,
1988). They are composed of three independent but interacting functional domains: the
NH2-terminal or A/B domain, the C or DNA-binding domain, and the D/E/F or ligand
binding domain. Binding of a ligand to ER triggers conformational changes in the
receptor and this leads, via a number of events, to changes in the rate of transcription of
oestrogen-regulated genes. These events, and the order in which they occur in the
overall process, are currently not completely understood, but they include receptor
dimerisation, receptor-DNA interaction, recruitment of and interaction with coactivators
and other transcription factors, and the formation of a preinitiation complex (Kraus et
al., 1995; McKenna et al., 1999; Rachez et al., 1998).
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In the pituitary gland, ERa is expressed at high levels in lactotrophs, at somewhat lower
levels in gonadotrophs, and at generally low levels in other pituitary cell types (Couse et
al., 1999; Scully et al., 1997). Full length ERa is expressed at higher levels in female
rats than in males, and oestrogen treatment of females has been shown to result in little
change in full-length ERa mRNA levels (Mitchner et al., 1998; Friend et al., 1995).
Treatment of neonatal male rats with oestrogen has been shown to permanently decrease
both ERa and ER(3 mRNAs, suggesting an imprinting effect of steroid (Tena-Sempere
et al., 2001). Gender-specific regulation of ERa has also been noted with some
hypothalamic peptides, as treatment of males with a GnRH antagonist has been shown to
suppress ERa mRNA, while treatment of females showed no effect (Schreihofer et al.,
2000).
In the rat testes, both ERa and ERp are expressed, but the expression profiles of these
two receptors are different. In rodent testes, ERa is localised in the nuclei of the Leydig
cells (Fisher et al., 1997), while ER(3 is localised in germ cells and Sertoli cells, and fetal
Leydig cells (Saunders et al., 1997; Van Pelt et al., 1999). In the excurrent ducts of
adult male rats, both ERa and ERp are expressed (Fisher et al., 1998; Hess et al., 1997).
In the rat ovary, ERa is expressed primarily in the thecal and interstitial regions,
whereas ERP is primarily expressed in the granulosa cells (Schomberg et al., 1999).
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1.8 Endocrine disruption of the HPG axis
A number of synthetic chemicals have been shown to be able to mimic endogenous
hormones and bind to oestrogen receptors, and it has been suggested that alterations in
the normal pattern of reproductive development seen in some populations of wildlife are
linked with neonatal (and/or fetal) exposure to these chemicals (Bicknell et al., 1995;
Lemini et al., 1997; Golden et al., 1998). There have been numerous reports of
reproductive and developmental abnormalities ranging from snails to humans that have
been associated with exposure to environmental hormones (primarily oestrogens). A
brief overview of some of the most studied endocrine disrupting chemicals and their
observed effects in wildlife and humans are summarised in Table 1.8.
Some of these endocrine disrupting compounds are highly persistent industrial products,
such as polychlorinated biphenyls (PCBs) and organochlorine pesticides, such as
dichlorodiphenyl trichloroethane (DDT). They can persist for decades and show the
characteristic of bioaccumulation within the food chain (Colborn et al., 1993, Kavlock &
Ankley, 1996; Bigsby et al., 1999). Others are less persistent such as Bisphenol A,
which was first used as the monomer to manufacture polycarbonate plastic and resins,
and it is now one of the top 50 chemicals in production in the world (Kirschner, 1996).
Dioxins and dioxin-like PCBs are toxic by-products of the manufacture of chlorinated
chemicals, and they are also formed during the incineration of chlorinated chemicals if
the disposal process is not performed at the required high temperature of 300°C.
Because of the range of chemical classes and the number of suspected endocrine
disrupting chemicals, these compounds present a complex issue. For the purpose of this
thesis, only phytoestrogens and the synthetic estrogen diethylstilbestrol (DES) will be
discussed in depth.
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Contaminant Species Observation References
Mammals
DDT Humans Oligospermia, impotence,
hypogonadism, decreased libido,










Gulls Abnormal development of ovarian
















Seals Impaired reproductive functions Tyler et al.,
1998




Table 1.8: Overview of some endocrine disrupting compounds and their effects
observed in wildlife and humans.
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Contaminant Species Observation References
Invertebrates






Isoflavones Cattle Infertility Hughes Jr, 1988
and
Coumestans Sheep Infertility Hughes Jr, 1988





Table 1.8: Continuation of overview of some endocrine disrupting compounds and their
effects observed in wildlife and humans.
1.8.1 Diethylstilbestrol (DES) effects on HPG axis
DES is a potent synthetic oestrogen (Figure 1.8.1) that has been thoroughly studied in
both humans and animals.
Oestradiol
Figure 1.8.1: Diagram illustrating the chemical structures of oestradiol and the
synthetic oestrogen DES.
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Between 1947 and 1971 over 1,000,000 American women were exposed to DES when
their mothers took the drug during pregnancy to prevent miscarriage. Girls exposed as
fetuses to DES during the first three months of pregnancy subsequently exhibited
changes in the tissue and/or structure of their uterus, cervix, or vagina (Herbst et al.,
1971). These changes resulted in later fertility problems and also placed them at risk of
developing a rare form of cancer, clear-cell adenocarcinoma of the vagina or cervix, at a
young age (Elerbst et al., 1971, 1979). DES was also introduced into the environment
because of its oestrogenic activity to accelerate the growth of cattle. It was estimated
that in 1971 alone as much as 27,000 kilograms of DES were used in livestock feed lots
(Metzler, 1981). For the purpose of this thesis, DES was used as a positive control to
investigate the effects of neonatal oestrogen exposure on the development and function
of the HPG axis, and additionally to gain some insight into the potential mechanisms by
which (less potent) oestrogenic endocrine disrupting compounds, such as
phytoestrogens, might be exerting their effects.
1.8.1.1 DES disruption of the male HPG axis
The treatment of pregnant females with a high dose of DES has been shown to interfere
with the action of Mullerian-inhibiting hormone on Mullerian duct regression in male
mice (McLachlan et al., 1975) and humans (Driscoll & Taylor, 1980), such that the
utricular remnant in the prostate, which is of Mullerian origin, was enlarged. The
exposure of rats and mice to high (microgram per kilogram body weight) doses of DES
during prenatal or neonatal life has been shown to interfere with the normal development
of the prostate in rodents (Turner et al., 1989; Prins, 1992; Pylkkanen et al., 1993; vom
Saal et al., 1997; Gupta, 2000). Squamous metaplasia of the prostatic and coagulating
gland and the ductal epithelium in male mice and rats has also been reported after
exposure to DES during early life (McLachlan et al., 1975). The exposure of rats and
mice to DES during development has also been shown to alter circulating gonadotrophin
Chapter 1 Literature review 42
levels and gonadal hormone levels (Atanassova et al., 1999), decrease pituitary
responsiveness to GnRH and blunt LH secretion in rats (Register et al., 1995; Faber et
al., 1993), inhibit Sertoli cell proliferation (Atanassova et al., 1999), suppress Leydig
cell development and function (Sharpe et al., 2003); and cause abnormal development of
the rete testis (Aceitero et al., 1998; Fisher et al., 1999; McKinnell et al., 2001a),
efferent ducts (Fisher et al., 1997), epididymis (Atanassova et al., 2001; McKinnell et
al., 2001), vas deferens (Atanassova et al., 2001; McKinnell et al., 2001) and the
seminal vesicles (Williams et al., 2001). Neonatal treatment with high, but not with
lower doses of DES, has also been shown to suppress expression of the androgen
receptor in all of the tissues affected adversely by DES (McKinnell et al., 2001).
However, in some studies, some effects of exposure to DES during development were
not noticeable prior to the exposed animals reaching old age. For example, Arai and
colleagues have shown that the treatment of male rats with DES during the first month
after birth did not result in observable malignancies at 6 to 9 months of age. But by 20
months (old age), squamous cell cancer was detected with the involvement of the
dorsolateral prostate, coagulating glands, and ejaculatory ducts (Arai et al., 1978).
Other studies with DES have involved the use of very low doses that are considered
relevant for predicting the effects of exposure to concentrations of oestrogenic endocrine
disruptors encountered by humans and wildlife. The dose issue is important because it
has been shown that exposure to high or low doses of DES can result in opposite effects
on some of the developing reproductive organs in males (vom Saal et al., 1997; Gupta,
2000). For example, fetal exposure to DES has been shown to alter the number of live
pups per litter, the sex ratio of the litters, the anogenital distance of the male and female
offspring at birth and the bodyweight of offspring at birth. In most cases it was found
that the dose-response relationship was complex, with effects at the highest dose
examined being the opposite of the effects seen at the lower doses of DES (vom Saal et
al., 1997).
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1.8.1.2 DES disruption of the female HPG axis
Exposure to DES during differentiation of the reproductive system has been implicated
in the etiology of clear cell vaginal adenocarcinoma in women (Herbst, 1981; Bern,
1992; Mittendorf, 1995). In mice, neonatal exposure to clinically relevant doses of DES
has been shown to result in vaginal lesions (Bern et al., 1987). DES has been shown to
induce uterine hypoplasia acutely in neonatal rats (Medlock et al., 1988, 1992). Uterine
hypoplasia has also been observed in adult women exposed as fetuses to DES
(Mittendorf, 1995). The same treatment has been shown to inhibit uterine gland
differentiation in human fetal uteri transplanted into DES-treated nude mice, and these
studies have suggested that the DES-induced effects might not be due to changes in the
brain-pituitary-gonadal axis (Cunha et al., 1987). The effects of DES that are dependent
on the presence of ovaries (ovarian-dependent) as opposed to independent of the
presence of ovaries have been examined in mice (Iguchi & Takasugi, 1987). DES has
been found to lower uterine oestrogen receptor levels in adulthood when administered
during postnatal days 1 to 5 in rats (Medlock et al., 1992). However, in adult females,
changes in oestrogen receptors induced by exposure to DES have been shown to be
reversible, whereas changes in oestrogen receptors induced by exposure to DES during
early uterine development have been shown to be permanent and irreversible (Bern et
al., 1987; Iguchi et al., 1988). Changes in uterine epithelial as well as myometrial
morphology and function have been observed following treatment with DES during
prenatal (Wordinger et al., 1991) or early neonatal (Brody & Cunha, 1989) life in
rodents, and these changes are thought to be mediated by DES binding to oestrogen
receptors in the mesenchyme (Stumpf et al., 1980).
DES exposure during development has also been shown to alter the immune system in
mice (Ways et al., 1980; Blair et al., 1987) and humans, which have shown evidence of
a hyperactive immune response (Ways et al., 1987) and an increased incidence of
autoimmune diseases (Noller et al., 1988).
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1.8.2 Phytoestrogen effects on HPG axis
Not all oestrogenic chemicals are synthetic, there are also some natural chemicals
present in the environment that can mimic the action of oestrogens such as
phytoestrogens (Kang et al., 2001; Tyler et al., 1998). The phytoestrogens are
ubiquitous within the plant kingdom, being synthesised in plants from phenylpropanoids
and simple phenols (Rolfe, 1988). Phytoestrogens are a diverse group of polyphenolic
non-steroidal plant compounds that bind to oestrogen receptors, and exert their
characteristics of endogenous steroidal oestrogens. Based on their chemical structure,
phytoestrogens can be classified into four main groups, i.e. isoflavonoids, flavonoids,
stilbenes, and lignans. Isoflavones are the most studied group of phytoestrogens and are
found almost exclusively in the family Leguminosae (King & Young, 1999). A large
number of isoflavones has been identified from plants, with daidzein (Denis et al., 1999)
and genistein (Lee et al., 1991) being the principal isoflavones. They occur in plants as
the inactive glycosides daidzin (Potter et al., 1998) and genistin (Bakhit et al., 1994),
and their respective 4'-methyl ether derivatives, formononetin and biochanin A.
A great number of isoflavonoids have been tested in a competition binding assay to
assess their relative binding affinities (Branham et al., 2002). The oestrogen receptor
relative binding affinities of the isoflavonoids tested were found to decrease in the
following order : 17(3-oestradiol (control) > coumestrol > genistein > equol > daidzein >
biochanin A. Isoflavones have been found to have a relatively greater binding affinity
for ER(3 than for ERa, but are 102 to 105 times less active than steroidal oestrogens.
They are, however, frequently present in the human body in much higher quantities than
endogenously produced oestrogens (Kuiper et al., 1997,1998; Morito et al., 2001;
Schmitt & Stopper, 2001). Some isoflavones are able to inhibit several key enzymes in
oestrogen and androgen biosynthesis, including 5a-reductase (Evans et al., 1995), 17(3-
hydroxysteroid oxidoreductase (Makela et al., 1998), and aromatase (Adlercreutz et al.,
1993), and can stimulate the synthesis of sex hormone-binding globulins (SHBG)
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(Mousavi & Adlercreutz, 1993). Isoflavones have also been reported to have selective
oestrogen receptor modulator (SERM) activity, in that they have both weak oestrogenic
and anti-oestrogenic properties (Whitten et al., 1992; Park et al., 2000).
Early developmental exposure to oestrogenic compounds is known to cause reproductive
tract abnormalities, decreases in reproductive organ weights, alter neonatal gonadal
hormone levels, and to potentially compromise sperm production and sperm quality in
experimental animals, and possibly wildlife populations and humans (Jensen et al.,
1995; Toppari et al., 1996; Tyler et al., 1998; Sharpe et al., 2002). These findings have
raised concern over exposure to oestrogenic isoflavonoids and other exogenous weak
oestrogens in our food and water supplies. Because of the weak oestrogenic activity of
genistein and other isoflavones, there has been considerable debate over the possible risk
and/or health benefits of isoflavone consumption during the sensitive stages of fetal and
infant development (Lamartiniere et al., 1998; Bouker & Hilakivi-Clarke, 1993; Sharpe
et al., 2002). In the United States, 25% of infants are now fed solely with soy formula
milk after birth (Klein, 1998; Lonnerdal, 1994), and there are concerns that the high
isoflavonoid content of soy formula milk might exert adverse effects on the developing
infant (Irvine et al., 1995; 1998, Setchell et al., 1997, 1998). Central to the debate on
the safety of soy formulas are reports of adverse health effects of isoflavones on animal
reproductive systems. One of the most well-known complications of isoflavones are the
reproductive disorders observed in sheep that graze on clover with a high isoflavone
content, often referred to as clover disease (Adams, 1990). This clover disease was
caused by extremely high concentrations of equol, a potent oestrogenic isoflavone, on
the mature reproductive system of seasonal breeding ruminant animals at a critical
endocrinological period when disruption of complex and usually well-orchestrated
hormonal events caused infertility.
Millions of American infants have been fed soy formula over the past three decades.
Several studies so far have demonstrated that soy formula supports normal growth and
development in term infants (Formon et al., 1971; Businco et al., 1992; Churella et al.,
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1994; Kohler et al., 1984; Graham et al., 1970). When growth was studied over the first
year of life, body weight gains and body length of infants were virtually the same
whether the infants were fed soy formula milk or cow's milk based formula or breastfed
(Lasekan et al., 1999). More recently, a study was undertaken on 811 young adults
between 20 and 34 years of age who were fed either cow's milk formula or soy formula
milk as infants, to determine the long-term health consequences of early soy intake
(Strom et al., 2001). The study found that there were no significant differences in
growth, development, puberty, reproductive function, or pregnancy outcomes (Strom et
al., 2001). However, it must be taken into account that the number of subjects was low
and that the subjects were too young to determine the risk of developing chronic
diseases that occur later in life.
Because of obvious ethical and safety reasons, data on the fetal plasma isoflavone
concentrations are essentially non-existent, and the data on infant plasma concentrations
are extremely limited. However, there are two studies that have provided some insight
into the likely isoflavone exposure throughout the life cycle. Adlercreutz et al., have
demonstrated that there are significant concentrations of isoflavonoids transported from
the mother to the fetus in Japanese women who consumed their usual diet rich in
isoflavone sources, including soy foods (Aldercreutz et al., 1999). Setchell et al., has
reported the plasma isoflavone concentrations of infants fed breast milk, cow's milk
formula or soy formula milk, as well as the approximate plasma oestradiol
concentrations of women and infants (Setchell et al., 1997), however, the number of
subjects was limited in both studies. The plasma concentrations obtained from these
studies are summarised in Table 1.8.2.
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Parameter
Approximate plasma concentrations
Oestradiol (nmol/L) Isoflavones (nmol/L)
Maternal 148 233
Cord blood 148 299
Cow's milk formula fed neonate 0.00002 25
Soy formula milk fed neonate - 7000
Breast milk fed neonate - 25
Table 1.8.2: Approximate plasma concentrations of oestradiol and isoflavones in
Japanese women and infants. Based on data from Setchell et al., 1997 and Adlercreutz
et al., 1999.
The mean total maternal plasma isoflavonoid concentration of Japanese women who
consumed their normal diets was found to be approximately 233nmol/L (range 19-
744nmol/L) and the mean concentration of isoflavonoids in cord blood was 299nmol/L
(range 58-83lnmol/L) (Setchell et al., 1997; Adlercreutz et al., 1999). This suggests
that isoflavonoid phytoestrogens could be transferred from the mother to the developing
fetus. Although the oestrogenic potency of isoflavones is estimated to be lower than that
of oestradiol, the plasma isoflavone concentrations are approximately 50 to 100 times
higher in infants fed soy formula milk than the oestradiol levels achieved by women
during pregnancy (Setchell et al., 1997; Adlercreutz et al., 1999).
As yet, no human data support the toxicity of soy foods, especially regarding
reproductive competency. In countries in which soy has been consumed at the greatest
daily intake for centuries, the population has increased at normal rates (Adlercreutz et
al., 1999). It has been shown that women who consume soy foods that result in high
circulating concentrations of isoflavones are capable of conceiving, taking the pregnancy
to term, delivering normal infants, and lactating normally (Lasekan et al., 1999).
Because these women consumed soy foods before pregnancy, and continued eating soy
during pregnancy and during lactation, it has been suggested that soy foods, including
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soy formula milk, do not seem to have great adverse effects on early human
development or later reproductive function (Setchell et ai, 1997; Adlercreutz et al.,
1999). However, it must be taken into consideration that no large long-term studies,
sampling different ethnic groups of the general population, have been performed as yet.
1.9 Aims of this thesis
The experimental work undertaken in this thesis focuses mainly on investigating the
potential short-term and long-term effects of neonatal oestrogen treatment on the
function of the hypothalamic-pituitary-gonadal axis. The main focal point of these
studies was the anterior pituitary gland, in particular investigating whether pituitary
function was affected by neonatal oestrogen treatment and if pituitary function could be
re-programmed on a permanent basis. Both in vivo and in vitro approaches were
undertaken to explore the neonatal oestrogen effects on both male and female pituitary
function, and comparisons were made for oestrogen-induced effects in both males and
females. The potent synthetic oestrogen, DES, was used during these studies as a
positive control for neonatal oestrogen disruption of the HPG axis, as DES has been
shown extensively to cause long-term effects along multiple facets of the HPG axis in
both males and females. The information gathered from these DES studies then
provided a valuable link to the next set of studies undertaken, which investigated the
potential effects of less potent environmental oestrogens, namely phytoestrogens, on the
HPG axis. These phytoestrogen experiments were undertaken to address health
concerns of feeding human infants soy formula milk, which is rich in phytoestrogens.
The experimental chapters will be presented as follows: chapter 3 examined whether
treatment of DES in infant rats caused any significant short-term or long-term changes in
pituitary function. Potential pituitary changes were evaluated by measuring the number
of immunopositive gonadotrophs and the mRNA levels for each of the gonadotrophins,
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and by assaying plasma hormone levels. Data obtained from the testes of these animals
collected by Richard Sharpe's laboratory, were included to shed light upon potential
altered feedback along the pituitary-testicular axis. Chapter 4 involved setting up a
primary pituitary cell culture system from individual rat pituitaries to explore the
potential effects of neonatal DES treatment on pituitary function in vitro, without
feedback occurring from the testes and hypothalamus. Both adult male and female
pituitaries were cultured from rats that were tracked in vivo, by measuring circulating
pituitary and gonadal hormone levels. Cultured pituitary cells from these in v/vo-tracked
neonatally DES-treated rats were administered GnRH and/or activin treatments and
gonadotrophin output was measured. DES-induced effects on male and female
pituitaries were compared and contrasted. Chapter 5 investigated the effects of neonatal
treatment with a long-acting GnREl antagonist on its own or in combination with
neonatal DES treatment on pituitary function. This treatment regime was included to
investigate the potential effects of DES on GnRH, and hence by removing GnRH it was
tested whether DES would still have effects at the level of the pituitary gland. Chapter 6
addressed health concerns of feeding human infants phytoestrogen-rich soy formula
milk. Pituitary function was investigated in both rats and marmoset monkeys. Finally,
chapter 7 summarised the main findings and conclusions of the experimental work and
suggested several avenues which might lead further to the present understanding of
neonatal oestrogen disruption of the HPG axis.
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Chapter two: general materials and methods
2.1 Animals and treatments
Both marmoset and rat studies were performed according to the Animal Scientific
Procedures Act (1986) under Project Licence approval by the UK Home Office. The
marmoset study was also approved by the local Ethical Reviews Process (ERP) for
studies in primates, and the rat studies were also approved by the University of
Edinburgh ERP.
2.1.2 Wistar rats
Wistar rats bred at the MFAA (University of Edinburgh Animal House) were kept under
standard conditions and maintained on a standard diet (Rat breeding diet, SDS, Dundee,
UK) that contains soy meal. Beginning on postnatal day 2, groups of three to six rats
were subjected to one of the following treatments administered by subcutaneous
injection: (a) diethylstilbestrol (DES) (Sigma Chemical Co., Poole, Dorset, UK) at a
dose of lOpg or O.lpg in 20pl corn oil on days 2,4,6,8,10 and 12; (b) lOmg/kg of a long-
acting GnRH antagonist (GnRHa) (Antarelix; Europeptides, Argenteuil, France) in 20 pi
5% mannitol on days 2 and 6; (c) combined treatment of DES 0.1 pg (as in treatment a)
with GnRHa (as in treatment (b) ); (d) s.c. injection of 20pl corn oil alone (control).
During the various rat studies a number of male and female rat blood samples were
taken at various stages of development, ranging from days 18,25,35 to day 90
(prepubertal, pubertal, adolescent, adulthood). Rats were anesthetized with flurothane
and blood samples were taken with a heparinized syringe either from the tail vein during
treatment or directly from the heart, for blood samples collected shortly before animals
were killed. Blood samples were centrifuged at 3000rpm for 30 minutes at 4°C for
plasma separation and the plasma was stored at -20°C until used for assay. Rats that
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had terminal blood samples taken were killed using flurothane and cervical dislocation.
Rats that did not have terminal blood samples taken were killed using CO, and cervical
dislocation. Specific treatments are detailed further in each individual chapter of this
thesis.
2.1.3 Marmosets
Captive-bred common marmosets (Callithrix jacchus) were maintained in a colony that
has been self-sustained since 1973. There were a total of 30 newborn male marmosets,
of which 26 were 13 pairs of male co-twins. Only co-twins were used in the soy study
detailed in chapter six (one SMA-fed, one SFM-fed), as marmosets tend to show
considerable between-animal variability but co-twins tend to be highly comparable.
This enabled pair-wise evaluation of data and also minimized the use of animals.
Treatment of infant marmosets commenced at day 4 or 5 of age. During the daytime
(approximately 8 hours on weekdays and approximately 2 hours at weekends), the infant
marmosets were separated from their mothers and left in the care of their fathers in the
family cage. Normally it is the fathers or older siblings that care for the infant
marmosets (apart from feeding) and this daytime separation from the mothers caused no
obvious problems or distress for either infants or mothers. When the mother was absent
from the family cage, the infant marmosets were removed at set intervals and were hand-
fed with either standard (cow's milk-based) formula milk (SMA Gold; SMA nutrition,
Taplow, Berkshire,UK) or with SFM (soy-based milk) formula (Wysoy; SMA nutrition)
from day 4 or 5 until day 35 to 45. The formula powders were added to tapwater and
heated and diluted according to manufacturer's guidelines. The suspension was
administered to the infant in a 1ml syringe with a soft silicon rubber tube fitted to the
end and the infant was allowed to drink as much milk as it wanted to. Each animal was
weighed prior to feeding and the amount of formula milk taken was recorded. Infants
were fed 3 to 4 times during weekdays and 1 to 2 times at weekends. After the last
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formula feed of the day, the infant was returned to its mother and she was allowed to
breastfeed them until the following morning.
Approximately half-way through the study (day 18-20), a 0.2ml blood sample was
obtained from the femoral vein of each infant using a 1ml syringe fitted with a 27G
needle. Animals were not sedated for this procedure as it caused them very minimal
discomfort. On day 35-45, seven sets of co-twins were killed via i.p. injection of an
overdose of sodium pentobarbitone (Euthatal; Rhone Merieux Ltd, Harlow, Essex, UK).
Immediately after death, a terminal blood sample was taken by cardiac puncture with a
heparinized syringe and the plasma was separated by centrifugation and stored at -20°C
until used for assay. Blood samples were also collected on day 35-45 from the
remaining 16 animals (8 SMA-fed, 8 SFM-fed), including six sets of co-twins, but their
treatments were then discontinued and the animals were returned to their cages. These
marmosets are currently growing to adulthood so that the possibility of any long-term
effects to the SFM-exposure can be investigated.
2.2 Tissue collection and processing
2.2.1 Rat tissue
For the in vivo rat studies, anterior pituitaries were carefully removed and placed either
directly into liquid nitrogen for subsequent messenger RNA (mRNA) analysis or were
immersion fixed in Bouin's for 6 hours at room temperature before being processed, for
subsequent immunocytochemical analysis. The Bouin's fixed tissue was transferred into
70% ethanol before being processed for 17.5 hours in an automated processor and
embedded in paraffin wax.
For the in vitro rat primary pituitary cell culture, both the rats and the surrounding bench
area were first swabbed with 70% ethanol and anterior pituitaries were removed using
autoclaved surgical instruments. Each surgical instrument was cleaned thoroughly with
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70% ethanol before use on each rat to minimize the risk of transferring an infection into
the cell culture system. Anterior pituitaries were placed in ice-cold Dulbecco's
Modified Eagle's Medium Nutrient Mixture F-12 HAM (DMEM HAM F-12) (Sigma,
UK) supplemented with 10% fetal calf serum, 50U/ml streptomycin, 50U/ml penicillin
and 5ml L-glutamine (Becton Dickinson Labware, Oxon, UK) for transportation back to
the cell culture facility.
2.2.2 Marmoset tissue
Marmoset anterior pituitaries were dissected free of connective tissue and immersion-
fixed for 5.5 hours in Bouin's fluid before being processed in an automated Leica TP-
1050 processor and embedded in paraffin wax, for subsequent morphological evaluation
and cell quantification studies.
2.3 Molecular biology
Unless otherwise stated, general chemicals were purchased from Merck-BDH (UK),
Roche (UK) or Sigma-Aldrich (UK), and were Analar grade. All water used in reaction
mixtures was double distilled and deionised before autoclaving.
2.3.1 Guidelines for use of RNA
RNA molecules are easily digested by RNases, therefore a number of strict guidelines
were followed when handling RNA. Gloves and separate RNA-designated labcoats
were worn at all times, RNase-free Gilson pipettes and RNase-free pipette tips
containing filters (Promega, UK) were used for the transfer of all solutions and RNase-
free water treated with 0.1% diethyl pyrocarbonate (DEPC) (Sigma,UK) was used to
make up reaction mixtures.
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2.3.2 RNA extraction from anterior pituitary tissue
RNA was extracted from rat anterior pituitary tissue in accordance with the RNAzol-B
method. This method is based on the unique property of RNAzol-B, which promotes
formation of complexes of RNA with guanidinium and water molecules and abolishes
hydrophilic interactions of DNA and proteins. In effect, DNA and proteins are
efficiently removed from the aqueous phase, while RNA remains in this phase during
the sample extraction with RNAzol-B. Unless otherwise stated, tissues were kept on ice
at all times and all reactions were carried out on ice. Firstly the pituitary tissue samples
were homogenized with RNAzol-B (2ml per lOOmg of tissue) with a motor
homogenizer (Techmate Ltd. UK). 0.2ml of chloroform per 2ml of homogenate was
added to the samples, the samples were covered tightly and shaken vigorously for 15
seconds and were then left on ice for 5 minutes. The cell suspension was subsequently
centrifuged at 12000g for 15 minutes at 4°C. After addition of chloroform and
centrifugation, the homogenate formed two phases: the lower blue phenol-chloroform
phase and the colourless upper aqueous phase, proteins and DNA were in the interphase
and organic phase. The aqueous phase, containing the RNA, was transferred to a fresh
tube and an equal volume of isopropanol was added, before storing the samples
overnight at -70°C. The following day, samples were centrifuged for 15 minutes at
12000g at 4°C. The RNA precipitate (which was invisible before centrifugation) formed
a small white-yellow pellet at the bottom of the tube. The supernatant was removed and
the RNA pellet was washed once with 75% ethanol (0.8ml ethanol per 50-100|ig DNA)
by vortexing vigorously and subsequent centrifugation for 8 minutes at 7500g at 4°C.
At the end of the procedure, the pellet was dried for 10-15 minutes on the bench, taking
care not to overdry the pellet as this greatly decreases its solubility. The RNA pellet was
then dissolved in 0.1% sodium dodecyl sulphate (SDS) (Sigma, UK) by vigorous
vortexing for at least 20 minutes. The amount and purity of the DNA was measured on
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a spectrophotometer and required a 260/280 ratio of 1.8 or higher for further use. RNA
samples were kept at -70°C for long-term storage.
2.3.3 DNase treatment of pituitary samples
RNA was DNase treated using the Ambion DNA-free kit. This kit is specifically
designed to remove contaminating DNA from RNA preparations and to subsequently
remove the DNase and divalent cations from the sample. Using DNA-free,
contaminating DNA is removed to levels below the limit of detection by routine PCR.
To the RNA, 0.1 volume of 10 x DNase I Buffer and 1 jliI of DNase I was added. The
samples were mixed gently and incubated at 37°C for 20-30 minutes. The DNase
Inactivation Reagent was resuspended by flicking and gently vortexing the tube.
Subsequently, 5|il of the Inactivation Reagent slurry was added to each sample, taking
care to insert the pipette tip well below the surface and observing that the aliquot
withdrawn was completely white without a significant amount of clear fluid. This
ensured the efficient removal of DNase and divalent cations. To prevent the Inactivation
Reagent from precipitating out, it was mixed briefly before addition to each sample.
Thereafter the samples were incubated at room temperature for 2 minutes, the tubes
were flicked once during incubation to re-disperse the DNase Inactivation Reagent.
Finally the samples were centrifuged at 13000g for 2 minutes. The RNA solution was
removed from the pelleted DNase Inactivation Reagent and stored at -70°C.
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2.3.4 Spectrophotometrical analysis of nucleic acids
After DNase treatment the quantity and quality of the nucleic acids was assessed using a
spectrophotometer. The optical density (OD) of the samples was measured at 2 distinct
wavelengths, 260 and 280nm, in the ultraviolet region. Nucleic acids were detected at
260nm, whereas proteins and complex carbohydrates were detected at 280nm. High
quality preparations possess a 260:280 ratio of approximately 2 for RNA and 1.8 for
The Genejockey software programme (P.Taylor, MRC) was used to design
oligonucleotide primers and they were manufactured by Genosys (UK). The primers
were generally 18-20 base-pairs in length and had a melting temperature (Tm) in the
range of 55-65°C. The following empirical formula was used to determine the
appropriate Tm:
Tm = [(G+C) x 4C] + [(A+T) x 2C] (where G is guanine, C is cytosine, A is
adenine, and T is thymine.)
The RNADRAW (Microsoft, UK) software programme was used to check that there was
no secondary structure formation (i.e. hairpin loop formation and intramolecular
annealing) within the primers. Any primer sequences containing secondary structures
were discarded. Since there is over 95% amino acid sequence homology between mouse
and rat for LH|3, FSH(3, GAPDH, aGSU and GnRH receptor (GnRHr), mouse primers
were used for all Reverse Transcriptase Polymerase Chain Reactions (PCR). However,
for Real-Time PCR specific rat primers were designed as this method requires 100%
homology between primer sequence and amino acid sequence for efficient product
amplification.
DNA.
2.3.5 Design of oligonucleotide primers
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2.3.6 Reverse Transcriptase Polymerase Chain Reaction (PCR)
The Polymerase Chain Reaction process is a widely used technique for rapid and
efficient amplification of cDNA reverse transcribed from RNA to analyse gene
expression. The GeneAmp RNA PCR kit from Perkin Elmer (Applied Biosystems,
USA) was used for both Reverse Transcriptase PCR and Real-Time PCR. This kit
performs the reverse transcription of RNA to cDNA using cloned Murine Leukemia
Virus (MuLV) Reverse Transcriptase for subsequent amplification with AmpliTaq DNA
Polymerase, all in a single reaction tube. MuLV Reverse Transcriptase is an RNA-
dependent DNA polymerase that uses single stranded RNA as a template in the presence
of a primer to synthesise a complementary DNA strand and it is suitable for synthesis of
first strand cDNA. Before starting the Reverse Transcriptase step in the PCR, each
RNA sample (which had been DNase treated previously) was diluted to 50ng/pl with
distilled water. Subsequently 6pl of the 50ng/jLLl stock for each sample was added to the
(xl) mastermix (Table 2.3.6a) to make 30pl cDNA. The mastermix volume was adapted
according to the number of RNA samples present. The appropriate non-enzyme control
was also carried out, where a mastermix was prepared in which the MuLV was replaced
with distilled water.
Reaction components Quantity










Table 2.3.6a: Volumes of reaction components used for the RT-PCR reaction mixture.
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The mastermix contents were mixed by carefully pipetting up and down and they were
transferred to PCR tubes in 24|ol aliquots for each sample, to which 6jol of RNA of each
sample was added. The Reverse Transcriptase step was completed by running the
samples for 45 minutes on the following heat-cycle programme (Table 2.3.6b) on the
PCR machine:
Step Incubation RT RT inactivation
TIME 70 minutes 30 minutes 5 minutes
TEMPERATURE 25°C 48°C 95°C
Table 2.3.6b: Incubation, reverse transcriptase (RT) and RT inactivation steps used
during the RT-PCR reaction.
Subsequently the prepared cDNA was cut with the appropriate primers (Table 2.3.6c) in
the following mastermix:




Distilled water 15.72(01 16.55|il
10 x Buffer 2.5)0.1 2.5(0.1
NTP 0.5|ol 0.5(ol
Magnesium Chloride 1.5(0.1 1.5(0.1
Forward primer 1.04|ol 0.625(ol
Reverse Primer 1.04(0.1 0.625(ol
Taq polymerase 0.2jol 0.2)ol
TOTAL VOLUME 22.5(0.1 22.5)01
Table 2.3.6c: Reaction mixture components and the primers used for the RT-PCR
reaction.
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Thereafter, each sample from the reaction mix was put through the following reaction
cycles (Table 2.3.6d) for 45 minutes:
Hot start 95°C 15 minutes
Denaturing 95°C 15 seconds
Annealing 59°C 15 seconds
Extension 72°C 30 seconds
72°C 10 minutes
Table 2.3.6d: Reaction cycles used during the RT-PCR reaction.
2.3.7 Agarose gel electrophoresis
RNA molecules were separated out by agarose gel electrophoresis. A 2% agarose gel
was prepared containing 0.89M Tris Borate, 0.0025M ethylenediaminetetraacetate
(EDTA) and 2.5jal Ethidium Bromide (Sigma,UK) and was microwaved until the
agarose had completely dissolved. 3pl Orange G (Sigma,UK) was added to each sample
before loading onto gel, and samples were electrophoresed for approximately 1.5 hours.
2.3.8 Quantitative Real-Time PCR
The quantitative Real-Time PCR technique was used for mRNA detection as there was
generally insufficient RNA present in the pituitary samples to run Northern Blots. The
selection of specific PCR products during a Taqman reaction is dependent upon there
being present within the reaction a third oligonucleotide. As depicted below, the third
oligonucleotide has two fluorescent dye labels attached to it. One is a quencher dye,
TAMARA, whilst the other is a reporter dye, which can be one of several available, e.g.
FAM (5-carboxyfluorescein) and TET (tetrachloro-6-carboxyfluorescein). Whilst intact,
in solution, the presence of the quencher results in a reduced level of detectable
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fluorescence due to energy transfer between reporter and quencher dye. The probe is
designed to anneal specifically to the amplicon sequence defined by the PCR primers.
During PCR, if the target of interest is present, the probe specifically anneals between
the forward and reverse primer sites. As Taq polymerase extends from the primers, it
will encounter the probe bound to one of the template strands. Initially this results in
displacement of the 5'-end of the probe (including the reporter dye), giving rise to a Y-
shaped structure. At the same time, the specific endonuclease activity of the Taq
polymerase cleaves the 5' end of the probe, releasing a 3-6 base oligonucleotide
containing the reporter dye still attached. The remainder of the probe is then continually
cleaved until the resulting probe fragment has a melting temperature (Tm) below that of
the extension reaction. This oligonucleotide fragment is displaced from the target and








Figure 2.3.8a: Schematic diagram of the Taqman Real-Time PCR reaction, showing
the probe annealing between the forward and reverse primer sites.
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The 5'-3' nucleolytic activity of Taq cleaves the probe between the reporter and the
quencher dyes only if this probe hybridises to the target, i.e. Taq does not digest free
probe (Figure 2.3.8a). This process occurs in every cycle of PCR and does not interfere
with the exponential accumulation of the product. The separation of the reporter dye
from the quencher dye results in an increase in detectable fluorescence of the reporter.
This increase is measured and is directly proportional to the target amplification during
PCR. Because the probe is in excess, every copy of the template made generates a
























Figure 2.3.8b: Schematic diagram showing the polymerisation, strand displacement,
cleavage, and final polymerisation completion steps in the Taqman Real-Time PCR
reaction.
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2.3.9 Primers and probes design for Real-Time PCR
Primers and probes were designed using Primer Express software (PE Biosystems,
Warrington, Cheshire, UK) and synthesised by Biosource. Ribosomal 18S primers and
probes were from a Taqman Ribosomal RNA Control Reagents kit (VIC labelled probe;
PE biosystems). Forward primers, reverse primers and probes were designed for rat
LH(3 and FSH(3. Whilst designing the primers and probes several important features




Tm higher than Primer Tm 50-150 base pairs in
length
20-80% GC 20-80% GC
As close to the probe as
possible without
overlapping
Length 9-40 base pairs Length 9-40 bases
< 2°C difference in Tm
between the forward and
reverse primers
No G on the 5' end
No more than 2 G's or C's
in last 5 bases at 3' end
< 4 contiguous G's
Must not have more G's
than C's
Table 2.3.9: Summary of the properties of primers and probes for Real-Time PCR.
The sequence for the rat FSH(3 primers and probe were: forward, 5'-
CGGTGAAATGAAAGAATAAGGAACA-3' (7771.13kDa, annealing temperature
62°C), reverse 5'-TTTTGGATATCATGGTCCTTCAAG-3' (7314.72kDa, annealing
temperature 60°C) and probe, 5'-FAM-TGGACATTGCCATTCACCCACCCTT-
TAMARA-3' (7478.81kDa, annealing temperature 64°C). The primers and probe were
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validated using a Real-Time amplification plot from which the comparative CTwas
plotted against the log of the RNA (Figures 2.3.9a and b). The gradient of this graph
needed to be between -0.1 and 0.1 to ensure validation, the gradient for FSH(3 primers
and probes was 0.093.







i 1 0— 1 1 1 1 1
-0.4 -0.2 0 0.2 0.4 0.6 0.8 1
log RNA
Figure 2.3.9a: Validation of the FSH(3 primers and probes for the Real-Time PCR
reaction. Ct is the cycle threshold.
Figure 2.3.9b: Reaction cycles obtained for the validation of FSH primers and probes.
3 -
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Numerous sequences for rat LHP primers and probes were tried and tested, but since the
LHp sequence is rich in G's and C's at the 3'-end there were some initial problems
validating the primers and probes. The most successful sequences for the rat LHP
primers and probe were found to be: forward, 5'-
ACTGTCCTAGCATGGTTCGAGTACT-3' (7613.91kDa, annealing temperature
68°C), reverse 5'-AGCTCACGGTAGGTGCACACT-3' (6397.15kDa, annealing
temperature 60°C) and probe, 5'-FAM-CTGCCTTGCCTCCCGTGCCTC-TAMARA-3'
(6226.96kDa, annealing temperature 66°C). The LHP primers and probe were validated
for Real-Time PCR using the standard curve method, where a standard curve is drawn
for the LHP calibrator samples and for the internal 18S controls, and samples are read
off the standard curve (Figures 2.3.9c,d,e). This is another common method used for
validating primers and probes.
Log RNA
Figure 2.3.9c: Validation of the LHp primers and probes for the Real-Time PCR
reaction using the standard curve method. Standard curve for LHP calibrator samples.
The copy number of each gene is extrapolated on the basis of a standard curve. When
the known concentrations (expressed in logarithmic form) of target gene are plotted
against the corresponding cycle threshold (Ct), the result is a line representing the linear
correlation between the two parameters. The equation describing this relationship is used
to extrapolate the gene copy number in experimental samples.
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25
Figure 2.3.9d: Validation of the LH(3 primers and probes for the Real-Time PCR







Figure 2.3.9e: Reaction cycles obtained for the validation of LH primers and probes.
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2.3.10 Real-Time PCR reaction and analysis
The cDNA was prepared as described previously, with the following modifications.
6jiM of the reverse and forward primers, 4(iM of the probe and ribosomal 18S forward
and reverse primers were added to the mastermix and the PCR annealing temperatures
were also adapted appropriately. To measure cDNA expression, duplicate 24|il samples
were placed in a PCR plate, a no template control (containing water) was also included
in duplicate. Wells were sealed with optical caps and the PCR reaction was carried out
using an ABI Prism 7700 (Applied Biosystems). Data were analysed and processed
using Sequence Detector version 1.6.3 (Applied Biosystems) as instructed by the
manufacturer. Briefly, the software calculates the reaction cycle number at which the
fluorescence reaches a determined level for both 18S control and LHp/FSH(3. By
comparing this to an internal positive control, relative expression can be determined.
Results are expressed as relative expression to an internal positive standard included in
all reactions.
2.4 Radioimmunoassay (RIA)
This assay is based upon competition of l25I-peptide and peptide (either standard or
unknown) binding to the limited quantity of antibodies specific for peptide in each
reaction mixture. As the quantity of standard or unknown in the reaction increases, the
amount of l25I-peptide able to bind to the antibody is decreased. By measuring the
amount of l25I-peptide bound as a function of the concentration of peptide in standard
reaction mixtures, it is possible to construct a standard curve from which the
concentration of peptide in unknown samples can be determined. The antibody-peptide
complexes can be detected using a gammacounter.
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The concentrations of LH and FSH in rat plasma samples, cell culture media and
intracellular protein extracts were measured by RIA using reagents supplied by Dr A
Parlow (NIDDK, Torrance, CA, USA), with all samples from each experiment being
assayed in duplicate.
2.4.1 Iodination of antigens
Antigens were iodinated in the hotlab, where the local Health and Safety Rules and
Radiation Protection Safety were strictly adhered to. All monitoring records and all
isotope usage and disposal records were completed after iodination. A pre-iodination
sweep check of the bench areas using a Geiger counter was always carried out and
any contamination found was reported to the Area Radiation Protection Officer. All
contaminated beakers and flasks were soaked in Decon detergent (Sigma, UK) after use.
i25I-LH and l25I-FSH antigens were separated from unreacted l25I using a PD 10 Column
(Amersham Pharmacia Biotech, UK). Firstly, the PD 10 Column was prepared by
cutting off the end of the Column with scissors, which allowed the stabilizing solution to
drip out into a flask. The Column was subsequently washed with 2 washes of 5ml 1%
BSA/PBS buffer and 1ml of the buffer was loaded above the level of the Column
packing. The Column was then clamped off so that it was ready to load with the
iodinated preparation. The iodinated preparation was prepared in the hotlab designated
fume hood, using the Iodogen method. 500|lCi of Na l25I in 5jll1 was added into the
Iodogen tube followed by lOOpl of 5(tg rat LH (rLH) or rat FSH (rFSH). After
vortexing, the reaction was allowed to proceed for 60 seconds when 400|ll of 0.1M PBS
buffer was added. The reaction mixture was then loaded into the PD10 column and
0.5ml fractions were collected using a Gilson model 201 fraction collector. l25I-rLH or
l25I-rFSH were eluted in 5 to 7 ml of PBS buffer. Peak fractions were pooled and stored
in a lead-lined container at -20°C.
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2.4.2 LH and FSH rat plasma and cell culture media RIA
Unless otherwise stated, 50jil of sample was diluted in 100|il assay buffer (0.05M
phosphate buffer pH7.5 with 0.45M NaCl, 0.05% Tween and 0.1% BSA; Sigma
Aldrich, UK) using a Microlab automatic pipettor and added to 3ml plastic test tubes.
50jil of primary antibody was subsequently added to each tube, mixed and incubated
overnight at 4°C. The appropriate tracer was diluted in assay buffer to give 5000-7000
counts per 20 seconds and was added to each tube and incubated overnight at 4°C.
Following addition of the tracer, 50|ll of the secondary antisera and 50|ll of normal
serum were added to the tubes, mixed and incubated overnight at 4°C (Table 2.4.2).
Finally, the immunocomplexes were separated by addition of 1ml 0.9% saline, 4% PEG
6000 and 0.2% Triton X-100 and centrifugation at 3000rpm in a Sorvall Omnispin R
centrifuge (Dupont, UK) for 30 minutes at 4°C. Supernatants were removed and tubes
were left to dry at room temperature. Radioactivity was measured using a 1261
Multigamma counter (Wallac, UK) and data were analysed using AssayZap (P.Taylor,
MRC).
AssayZap plots a standard curve using a 4 parameter fit which uses the Bo and NSB
values to estimate the upper and lower limits of the curve and then finds the best
estimated fit through the standard points. The programme then adjusts this fit by
weighting individual points according to how closely they agree with the estimated fit,
effectively ignoring outlying points. The programme keeps a record of quality controls
and provides a constantly updated measure of the inter-assay coefficient of variation, as
well as calculating the intra-assay coefficient of variation for each of the quality
controls.





Total counts - - 50|il -
NSB 150)il - 50|ll 50|il
Bo lOOpl 50|il 50)il 50|il
Standards/Sample lOOpl 50jil 50jll1 50|il
Table 2.4.2: Summary of the volumes of buffer and primary and secondary antibody
used for LH and FSH RIA. The limits of detection for LH and FSH RIA were
0.60ng/ml to 80.0ng/ml, and the inter- and intra-assay coefficients of variation were
<10%.
2.4.3 RIA sera and dilutions
The antisera dilutions used for LH and FSH RIA are outlined in Table 2.4.3.










rLH NIDDK rLH-S-11 1:600,000 SAPU 1:400 1:16
rFSH NIDDK rFSH-S-11 1:100,000 SAPU 1:400 1:16
Table 2.4.3: Summary of antibody dilutions used for LH and FSH RIA. Antibodies
were obtained from the Scottish Antibody Production Unit (SAPU), Carluke, Scotland.
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Many of the cell culture plasma samples did not read on the standard curve. LH levels
were typically higher than the highest value on the standard curve and FSH levels were
typically much lower than the lowest value on the standard curve. Therefore LH cell
culture samples were diluted 1:12 for assaying. FSH samples were initially freeze-dried
overnight and re-suspended in assay buffer in order to make the samples more
concentrated, after which they read on the standard curve. However, since this method
was very elaborate and time-consuming a series of dilutions were tried and tested, of
which a 3-fold increase in sample concentration was found to lie within the appropriate
range of the standard curve.
2.4.4 Marmoset and rat plasma testosterone Enzyme-Linked
Immunosorbent Assay (ELISA)
Levels of testosterone in plasma were measured using an enzyme-linked immunosorbent
assay (ELISA) adapted from an earlier radioimmunoassay method (Corker and
Davidson, 1978). Plasma, to which was added trace amounts of [3H] testosterone
(Amersham International, Little Chalfont, Bucks, UK) was extracted twice with 10 vols
hexane:ether (4:1, v/v) and the organic phase dried down under N2 at 55°C. The
efficiency of extraction averaged 75%. The second antibody was immobilized to an
ELISA plate by addition of lOOjll acid-purified donkey anti-goat/sheep IgG (250-350
mg/ml) diluted in 0.1 mol/1 sodium carbonate buffer, pH 9.6. The plate was sealed and
incubated overnight at 4°C. The wells were then washed twice with 0.1% Tween-20 and
incubated for 10 minutes at room temperature with 0.2 ml of the same solution to block
non-specific binding sites. Samples, in duplicate, (50|al) were assayed after dilution in
0.1 mol/1 PBS, pH 7.4 containing 0.1% gelatin (Sigma,UK) and incubated overnight at
4°C with 50jj.l sheep anti-testosterone-3-cmo-bovine serum albumin (BSA) diluted
1:100 000 plus 50pl testosterone-3-cmo labelled with 1:20 000 horse-radish peroxidase
(Amdex; Amersham Pharmacia Biotech, St Albans, Herts, UK). The plate was washed
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several times with 0.1% Tween-20 before addition of 0.2 ml substrate (5 mmol/1 O-
phenylenediamine; Sigma) and 0.03% hydrogen peroxide diluted in 0.1 mol/1
citrate/phosphate, pH 5.0 to each well. The plate was then incubated in the dark for 10-
30 minutes until the colour reaction was optimal. The reaction was stopped by addition
of 50(ll 2mol/l sulphuric acid to each well and the optical density then read at 492 nm in
a plate reader. The limit of detection was 12pg/ml and the inter- and intra-assay
coefficients of variation were <15%.
2.4.5 Marmoset and rat plasma inhibin B ELISA
All incubations (except after addition of amplifier) took place at room temperature in an
airtight box, with the Immuno Plate always covered by a plate sealer (Life Technologies,
UK). 50|il of antibody in coating buffer (4.24g Na2C03, 4.04g NaHC03, 1000ml
deionised water adjusted to pH 9.6 with hydrochloric acid, Sigma UK) was added to
each well of the NUNC Immuno Plate (Life Technologies, UK) and incubated
overnight. The excess coating antibody was subsequently removed and the plate was
washed with washing solution (302g Tris, 450g NaCl, 25ml Tween, 2000ml deionised
water, Sigma UK) five times. lOOpd of the standard or sample and 50|il SDS were
added to polypropylene microtubes (Sigma,UK) and were left to float in boiling water
for 3 minutes. After allowing the tubes to cool for 10 minutes, 50|ll of 6% hydrogen
peroxide solution was added and incubated for 30 minutes, before adding lOOpl of assay
buffer (1.21g Tris, 0.9g NaCl, lOg Bovine Serum Albumin (BSA), 5.0ml Triton X-100,
100ml deionised water, Sigma UK). 100(il of sample and standard was added in
duplicate to the plate and incubated overnight. The following day the plates were
washed 10 times with washing solution before adding 50p,l of the secondary antibody
coupled to Alkaline Phosphatase (Sigma, UK) for 2 hours. Subsequently the plate was
washed again 10 times with washing solution before adding substrate solution for 2
hours. Then 50p.l of Amplifier Solution was added and incubated until colour in the top
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standard had an optical density reading of 2.0-2.5 (usually 40-45 minutes). Finally 50pl
of 0.5M HC1 stopping solution was added to stop the reaction and the plate was read on
a VICTOR plate reader at 490nm. The limit of detection was 60pg/ml and the inter-
and intra-assay coefficients of variation were <15%.
2.5 Imniunocytochemistry
In order for an immunocytochemical reaction to be viewed under a microscope, a
component of the reaction must carry a label. The first label to be attached to an
antibody was a coloured dye but the resulting intensity was too low for visualisation.
Nearly all labels that have been used subsequently require additional steps to enhance
them to a point of visibility. Fluorescent compounds, the first practical labels, require
excitation with light of a specific wavelength to make them emit visible light. Enzymes
must react with a substrate and chromogen to produce a visible deposit. Radioactive
labels require autoradiographic development. Biotin must itself be labelled or reacted
with labelled avidin. Labelling with an enzyme requires an additional large molecule
such as glutaraldehyde to cross-link the enzyme to the antibody, unless an antigen-
antibody reaction is used. A radioactive label may be conjugated to an antibody via
another molecule or through direct labelling, e.g. with l25I as described for LH and FSH
RIA (Section 2.4.2). Antibodies are easily labelled with biotin and kits for doing this are
readily available commercially.
2.5.1 Tissue fixation
The purpose of fixation is to preserve all components of a tissue sample in their true
situation, without diffusion. In addition, the tissue must be protected from osmotic
damage (swelling and shrinking). For immunological purposes the antigen to be
localised must be made insoluble, yet remain available for reaction with an applied
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antibody. Choice of fixative is very important for successful immunostaining and needs
to be adapted for the antigen molecule to be localised, taking into consideration the
structure of the antigen molecule and the mechanism of action of particular fixatives.
All rat and marmoset tissues were fixed with Bouin's solution. This fixative denatures
proteins by destroying the hydrophobic bonds which hold together the tertiary
conformation of the protein molecule. The primary and secondary structures are left
intact, so the amino acid sequences acting as antigenic sites remain available for their
antibodies. Bouin's is an acidic fixative (70% saturated aqueous picric acid, 10%
commercial formalin, 5% acetic acid) and therefore fixes rapidly because of the
preponderance of the active +CH2(OH) form of the formaldehyde. Bouin's-fixed
material was processed using paraffin, as antigens in paraffin blocks (and in sections
stored for a long duration at room temperature) retain their antigenicity indefinitely.
Bouin's fixative has been proven to be excellent for preserving the antigenicity of small
peptides (Stefanini et al., 1967).
2.5.2 Heat-mediated antigen retrieval
It has been shown (Shi et al., 1991) that some antigens previously unreactive in Bouins'-
fixed paraffin-embedded tissue could be 'retrieved' by heating sections in a solution of a
heavy metal salt in a microwave oven without deleterious effects on the structure of the
tissue. Subsequently, it was shown that the rather toxic heavy metal salts could be
replaced by simple buffers such as citrate buffer at pH6.0. It was shown that heat, rather
than microwaves, is important in the retrieval process, since boiling the sections in a
pressure cooker (Norton et al., 1994) or autoclaving them (Bankfalvi et al., 1994) in the
buffer solution achieved the same effect. It has been suggested (Morgan et al., 1994)
that heating provides the energy not only to rupture the bonds formed by the fixative
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with the protein antigen, freeing some antigens, but also to release tissue-bound calcium
ions which contribute to tighter bonds with the fixative.
Pressure cooking was only used for antigen retrieval of ERa. Slides were dewaxed and
rehydrated before being added to a Tefal Clypso pressure cooker containing 2 L of
citrate buffer pH6.0. This was set to pressure setting 2 and brought to the boil, until at
full pressure, which was indicated by steady hissing. After 5 minutes the pressure
cooker was removed from the heat and the pressure valve was opened to release
pressure. When the red pressure indicator valve had dropped, the slides were left to
stand in the buffer for 20 minutes. Subsequently cold tap water was added to the
pressure cooker to cool the slides. Once slides were sufficiently cooled, they were ready
for use in the next phase of immunocytochemistry.
2.5.3 LH and FSH 3,3'-Diaminobenzidine immunostaining
DAB immunostaining is one of the most commonly used staining methods (Figure
2.5.3a). It produces a dark brown insoluble precipitate at the site of reaction, using
hydrogen peroxide as the substrate and DAB as the chromogen. The tetrahydrochloride
of DAB is used as it is more soluble than the free base. This method is one of the most
sensitive available and provides a permanent preparation with good contrast. The
simplified mechanism of peroxidase reaction with DAB and H202 is shown in Figure
2.5.3b.
Prior to DAB staining it is important to block all endogenous peroxidase. Peroxidase is
an enzyme present in peroxisomes and suppression of its activity is carried out at any
stage before application of the peroxidase-linked reagent, usually with excess of the
enzyme's substrate, hydrogen peroxide, in methanol.
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Figure 2.5.3a: Schematic diagram of DAB immunostaining showing the biotinylated
antibody (A-B complex) reacting with Horse Radish Peroxidase (HRP) and
subsequently forming a brown precipitate by reacting with DAB.
Peroxidase + H202 (substrate)
I
Peroxidase/ H202 complex





(with oxidised haem group)
I
Oxidised DAB + peroxidase
Polymerised insoluble brown precipitate
(chelates osmium-electron dense product)
Figure 2.5.3b: The simplified mechanism of peroxidase reaction with DAB and H202,
to form a brown coloured precipitate.
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Unless otherwise stated, all incubations were performed at room temperature. Sections
were cut at 5|im and floated onto slides coated with either 2% 3-aminopropyltriethoxy-
silane (Sigma) or poly-lysine (BDH Chemicals, Poole, Dorset, UK) and dried overnight
at 50°C. The slides were dewaxed, rehydrated and endogenous peroxidase was blocked
using 3% (v/v) hydrogen peroxide in methanol. After washing in water, the sections
were washed twice (5 minutes each) in Tris-buffered saline (0.05 mol/1 TBS, pH7.4 and
0.85% NaCl). For FSH, slides were then blocked for 30 minutes with normal swine
serum (NSS; Diagnostics Scotland, Carluke, UK) diluted 1:5 in TBS containing 5%
BSA; for UH, slides were blocked with normal rabbit serum (NRS) diluted 1:5 in TBS
with 5% BSA. The primary antibodies were diluted in the appropriate blocking solution
(FSH 1:1000; M91 polyclonal anti-human FSH antibody, gift from Dr S Lynch,
Birmingham, Crawford et al., 2002) (LH 1:5000; 518B7, monoclonal anti-bovine LH,
from Dr J Roser, Department of Animal Science, UCCA, Matteri et al., 1987) and 100pl
was added to each slide before incubation at 4°C overnight in a light-proof humidity
chamber. The slides were then washed in TBS (2x5 minutes) before incubation for 30
minutes with a biotinylated second antibody, namely swine anti-rabbit (Dako, Ely, UK)
for FSH or rabbit anti-mouse (Dako,UK) for LH, diluted 1:500 in the appropriate
blocking serum. The slides were developed until the colour reached the required
intensity in the control sections, and the reaction was then stopped by immersing the
slides in distilled water. The slides were counterstained with haematoxylin before being
dehydrated by immersion in a graded series of ethanols and then being cleared in xylene.
A coverslip was fixed over the sections using Pertex mounting medium (Cell Path,
Hemel Hempstead, UK).
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2.5.4 LH and FSH dual fluorescent staining
Sections were washed in histoclear for 10 minutes before being hydrated in decreasing
concentrations of ethanol and washed thoroughly for 5 minutes in tap water. Then
sections were washed in Phosphate Buffered Saline (PBS, Sigma UK) for 2 x 5 minutes
before being incubated in blocking solution (1ml Normal Goat Serum, 1ml Normal
Swine Serum, 8ml PBS, 0.5g BSA, Sigma UK) for 1 hour at room temperature. The
blocking solution was carefully removed with a paper towel and the primary antibodies
diluted in blocking solution (LH 1:50, FSH 1:200) were added to each section and
incubated at 4°C overnight. The following day, the slides were washed twice in PBS
before being incubated with the secondary antibody diluted in PBS (LH 1:20 goat-anti-
mouse fluorescein isothiocyanate, (GAM-FITC, Dako); FSH 1:20 swine-anti-rabbit
tetramethyl rhodamine isothiocyanate (SAR-TRITC, Dako)), for 2 hours at room
temperature under dark conditions. Subsequently, the secondary antibody was removed
by washing the slides in PBS for 2 x 5 minutes, before mounting the slides in permafluor
(Sigma, UK) ready for viewing under the confocal microscope.
2.5.5 Aromatase or oestrogen receptor a (ERa) DAB staining
Pituitary tissue sections were cleared in histoclear for approximately 10 minutes and
hydrated in decreasing concentrations of ethanol and washed briefly in tap water. The
sections were then incubated with 3% hydrogen peroxide in methanol for 30 minutes to
block endogenous peroxidase. After a wash in water, the slides were transferred into
Tris buffered saline (TBS, 0.05M Tris pH 7.4, 0.8M saline) for 5 minutes. The sections
were blocked in normal rabbit serum (NRS, Diagnostics Scotland, Carluke, UK) diluted
1:4 in TBS containing 5% bovine serum albumin (BSA, Roche Diagnostics Ltd, Lewes,
UK) for 30 minutes at room temperature. The purified IgG fraction of the monoclonal
raised aromatase (0.5mg/ml, Turner et al., 2002) was diluted 1:50 in NRS/TBS/BSA,
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and the monoclonal mouse ERa (Novocastra, UK) was diluted 1:20 in NRS/TBS/BSA.
The sections were incubated with the antibody overnight at 4°C. A rabbit anti-mouse
biotinylated secondary antibody (DAKO, Cambridge, UK) was diluted 1:500 in
NRS/TBS/BSA and incubated with the tissue sections for 1 hour at room temperature.
Bound antibodies were visualised by incubating the sections with ABC-HRP complex
(DAKO) followed by incubation with 3,3'-diaminobenzidine (DAB, Sigma). Sections
were counterstained with haematoxylin and mounted.
2.5.6 Negative and positive controls
In order to check that the tissue sample was immunostained specifically, a negative
control was performed for every batch of samples stained. This was done by
substituting the primary antiserum with non-immune serum. A positive control sample,
known to contain the antigen in question, was also included every time an immunostain
was performed.
2.5.7 Digital photomicroscopy
Tissue sections were examined using an Olympus Provis microscope (Olympus Optical,
London, UK) and images were captured using a digital camera, Kodak DCS330
(Eastman Kodak, Rochester, NY, USA). Captured images were stored on a G4
Macintosh (Apple Macintosh, Apple Computer, Cupertino, CA) and montages were
compiled using Photoshop 5.0 (Adobe Systems Inc., Mountain View, CA).
2.5.8 Quantification of immunostaining for LH or FSH DAB staining
Quantification of immunopositive cells was done manually by examining
immunostained sections on a Zeiss Axioskop light microscope using a x40 objective.
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The number of immunopositive cells was determined by placing a 21mm diameter
graticule over a randomly selected area of the anterior pituitary. Within the graticule,
the number of immunopositive (nucleated) cells (brown) was counted and the total of
non-immunopositive cells (blue) was also counted, and the percentage of
immunopositive cells was calculated. Only cells with a nucleus visible were counted.
This was done for 4 randomly selected areas within the anterior pituitary.
2.5.9 Confocal microscopy for fluorescent staining
Immunofluorescence was analysed using a Zeiss Axiovert 100M microscope and
LSM510 scanning module with oil immersion x40, x63 and xlOO objectives (Zeiss,
UK). Scans were usually performed at 2048x2048 pixels resolution and data was
analysed using a Dell Optiplex Gxi computer (Zeiss, UK). Secondary antisera were
either conjugated with FITC or TRITC, which allowed antigen binding to be visualised.
The excitation and emission spectra for FITC (488nm) and TRITC (535nm) are distinct
which allowed co-localisation studies to be carried out. FITC excitation was carried out
using an argon laser whereas TRITC excitation was accomplished with a HeliumNeon
(HeNe) laser.
2.6 Static primary rat pituitary cell culture
2.6.1 Preparation of anterior pituitaries for culture
Unless otherwise stated, Dulbecco's Modified Eagle's Medium Nutrient Mixture F-12
HAM, Dulbecco's Modified Eagle's Medium, Dulbecco's Phosphate Buffered Saline
without calcium chloride and magnesium chloride and Dulbecco's Phosphate Buffered
Saline with calcium chloride and magnesium chloride were heated to 37°C in a hot
water bath prior to adding them to the cells. All primary pituitary cells were plated onto
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12-well plates coated with Matrigel (Becton Dickinson Labware, Oxford, Oxon, UK)
diluted 1:29 in Dulbecco's Modified Eagle's Medium (Sigma, UK). All cell culture was
carried out in a Biomat-2 class II microbiological safety cabinet which complies with
BS5726-1992 standards and cells were incubated in a 37°C, 5% C02 Gallenkamp
incubator.
Various methods were tried and tested for preparation of anterior pituitary cell culture.
The most successful method is described directly below, other methods tested and some
methods frequently used by other laboratories are outlined in Table 2.6.1.
The pituitary cells from the rat anterior pituitaries were mechanically dispersed using a
0.8mm x 40mm syringe needle which fractionated the tissue into smaller cell clumps.
These cell clumps were further dispersed by first passing them 2 times through a 10ml
syringe with a 0.8mm x 40mm needle attached and then by passing them another 3 times
through a 10ml syringe with a 0.6mm x 30mm needle attached to it. Subsequently the
cell suspension was centrifuged at lOOOg for 15 minutes at 4°C on a Centaur 2
centrifuge. The supernatant was aspirated off to remove all the cell debris. The cell
pellet was resuspended in 12 ml of Dulbecco's Modified Eagle's Medium Nutrient
Mixture F-12 HAM (Sigma, UK) supplemented with 10% fetal calf serum, 50 U/ml
penicillin, 50 U/ml streptomycin and 10ml L-glutamine (Becton Dickinson Labware,
Oxford, Oxon, UK). Pellet resuspension was obtained by passing pellet and media four
times through a 10ml syringe with a 0.8mm x 40mm needle attached to it. Making sure
to mix the cell suspension well, the cells were plated out onto 12-well plates coated with
Matrigel (Becton Dickinson Labware, Oxford, Oxon, UK).
81





























































































Table 2.6.1: Summary of pituitary cell dispersion methods used by other laboratories.
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2.6.2 Viable cell counts
Viable primary pituitary cells were assessed using the dye exclusion method, and
counted using a haemocytometer (Sigma, UK) after staining with 0.4% Trypan Blue
(Sigma,UK). A balanced salt solution was prepared by adding lOOp.1 of the cell
suspension to 400p.l sterile Dulbecco's Phosphate Buffered Saline with calcium chloride
and magnesium chloride (Sigma, UK). Subsequently, 0.5 ml of 0.4% Trypan Blue
solution (w/v) was transferred to a test tube, also to which 0.3ml of Dulbecco's
Phosphate Buffered Saline with calcium chloride and magnesium chloride (Sigma, UK)
and 0.2 ml of the cell suspension was added. The suspension was mixed well and was
allowed to stand for 5-10 minutes on ice. With the cover-slip in place, a Pasteur pipette
was used to transfer 20)ixl of the Trypan Blue-cell suspension mixture to one of the
chambers on the haemocytometer. The edge of the cover-slip was touched carefully
with the pipette tip to allow the chamber to fill by capillary action. The loaded
haemocytometer was viewed using an inverted Olympus CK2 microscope (Olympus,
Japan). All the cells in the 1mm corner squares were counted. Non-viable cells stained
blue, whereas viable cells didn't stain. The number of viable cells was counted. Each
square of the haemocytometer represents a total volume of 0.1mm3 or 10 4 cm3, since
lcm' is equivalent to approximately 1ml, the subsequent viable cell concentration per ml
was determined by the following calculation:
CEULS PER ML = the average viable cell count per square x dilution factor x 104
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2.6.3 Protein content extraction
Total protein was extracted from the primary pituitary cells using lOOmM sodium
carbonate. The cell medium was aspirated off the cells and cells were washed once in
Dulbecco's Phosphate Buffered Saline without calcium chloride and magnesium
chloride (Sigma, UK). Subsequently the cells were trypsinized by adding 500(0.1 trypsin
(Sigma, UK) to each well of the 12-well plate. The plates were placed in the incubator
(37°C, 5% C02) for 5 minutes to aid trypsinization. Once the cells were detached from
the plate, an equal volume (500(tl) of Dulbecco's Modified Eagle's Medium Nutrient
Mixture F-12 Mixture (Sigma, UK) was added to quench the trypsin. The trypsin-media
cell suspension was collected from each well and transferred to 2ml Eppendorf tubes.
All tubes were centrifuged at 2000rpm for 5 minutes at 4°C in an Eppendorf centrifuge.
The supernatant was removed and 100|il sodium carbonate was added to each tube. The
samples were left to stabilize at room temperature before putting them through 3 freeze-
thaw cycles, by incubating them in a dry ice-ethanol bath for 5 minutes and by then
placing them in a 37°C waterbath for 5 minutes. Lysates were then centrifuged at 13000
rpm for 20 minutes at 4°C in an Eppendorf centrifuge to remove cell debris. The
supernatant was transferred to new Eppendorf tubes and stored at -20°C.
2.6.4 Protein content quantification
Following Bradford's method (Bradford, 1976) total protein concentrations in cell
lysates were determined. A 200-fold dilution of the lysate was made in a total of 1ml
sterile water, which was vortexed briefly. 200|il of protein dye (Bio-Rad, UK) was
added to the diluted sample and mixed by inverting 5 times. 6 protein standards
containing 25, 12.5, 6.25, 3.125, 1.56 and 0.78(lg/ml bovine serum albumin (BSA,
Sigma, UK) were treated similarly. The optical density (OD) was measured at 595nm
after the samples were incubated at room temperature for 5 minutes.
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2.6.5 RNA extraction from cells
RNA was extracted from primary pituitary cells (cultured on 12-well plates) using
RNAzol-B (AMS Biotechnology, Witney), in accordance with the manufacturer's
guidelines. The medium was aspirated off the cells and the cells were washed once with
Dulbecco's Phosphate Buffered Saline without calcium chloride and magnesium
chloride (Sigma, UK). Unless otherwise stated, all reactions were carried out on ice.
For efficient RNA extraction, 3 wells were pooled together. Thus, 0.33ml of RNAzol-B
was added to each of the 3 wells, making a total of approximately 1ml. The contents of
each of the 3 wells was pooled together into one Eppendorf tube. Subsequently lOOjil
chloroform was added to each Eppendorf and was shaken vigorously for 15 seconds.
The samples were centrifuged at 12200rpm for 15 minutes at 4°C in an Eppendorf
5417R centrifuge and the supernatants were removed and transferred to new
Eppendorfs. An equal volume (approximately 600pl) of ice-cold isopropanol was added
to each Eppendorf, the contents were mixed by inverting tubes twice and were stored at
-70°C overnight. Thereafter, the samples were centrifuged at 12200g for 15 minutes at
4°C on an Eppendorf 5417R centrifuge and the supernatants were removed and
transferred to new Eppendorfs. 800pl of ice-cold 70% ethanol was added to each tube
and vortexed vigorously. The samples were centrifuged on an Eppendorf 5417R
centrifuge at 7500g for 8 minutes at 4°C and as much as possible of the ethanol was
aspirated off taking care not to dislodge the pellet formed. Any ethanol left in the tubes
was left to evaporate off on the bench. 5pl of 0.1% SDS (Sigma,UK) was added to each
sample and the pellets were resuspended by vortexing vigorously for at least 2 hours, or
until the pellet was completely dissolved. The purity of the RNA preparations was
assessed by spectrophotometrical analysis.
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2.6.6 Continuous culture of hypothalamic GT1-7 cells
GnRH-expressing GT1-7 cells were grown in monolayers on 75cm2 cell culture flasks in
Dulbecco's Modified Eagle's Medium (Sigma, UK) supplemented with 10% fetal calf
serum, 50 U/ml penicillin, 50 U/ml streptomycin and 10ml L-glutamine (Becton
Dickinson Labware, Oxford, Oxon, UK), maintained at 37°C in an atmosphere of 5%
C02. They were grown to approximately 60% confluency. The growth medium was
removed and replaced every 2-3 days. When cells reached maximum confluency (80%)
they were trypsinized as follows. The medium was aspirated off and the cells were
washed with Dulbecco's Phosphate Buffered Saline without calcium chloride and
magnesium chloride (Sigma, UK). Approximately 3ml of xl trypsin (Sigma, UK) was
added to the cells and incubated at 37°C, 5% CO, until the cells detached from the plate.
The trypsin was quenched with 3ml Dulbecco's Modified Eagle's Medium (Sigma, UK)
and the trypsin-cell suspension was aspirated off the plate and transferred to a 10ml
sterilin tube. The cells were centrifuged on a Centaur 2 centrifuge at 1500g for 5
minutes at room temperature, the supernatant was removed and the pellet was
resuspended in 10ml media. A 1:100 dilution of the cell suspension was made with PBS
and the cells were counted on a haemocytometer.
2.6.7 Immunofluorescent staining of primary pituitary cells
Cells were grown on 8-well chamber slides coated with Matrigel before fluorescent
staining. The cell culture medium was removed and the cells were washed with PBS
containing calcium and magnesium. Subsequently 200|ll of ice-cold methanol was
added to each well and was incubated at -20°C for 10 minutes. The methanol was
aspirated off and the cells were washed twice in PBS containing calcium and
magnesium. Then 200pl immunoblock solution, which contained PBS without calcium
and magnesium, 1% BSA, 10% FCS, penicillin, streptomycin and 0.2% NP-40, was
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added to each well and incubated for 30 minutes at room temperature. The
immunoblock-NP-40 solution was then aspirated off and the cells were washed twice
with 300pl PBS containing calcium and magnesium. After that 200|ll of immunoblock
solution without NP-40 was added to each well and incubated for one hour at room
temperature. Then the primary antibody (at a dilution of 1:50 for LH and FSH) was
added to each well and was incubated overnight at 4°C (Table 2.6.7). After primary
antibody incubation, the immunoblock-antibody solution was aspirated off and each well
was washed twice with PBS containing calcium and magnesium. Then the desired
amount of secondary antibody was added in 200p,l of immunoblock to each well and
was incubated in dark conditions for one hour at room temperature. Subsequently the
secondary antibody-immunoblock solution was aspirated off and each well was washed
twice with PBS containing calcium and magnesium. The top of the wells was removed,
to reveal a flat microscope slide with the cells attached to it, and placed in PBS
containing calcium and magnesium. The slide was removed from PBS and was























Table 2.6.7: Summary of the primary and secondary antibody dilutions used for
fluorescent staining of primary cultured pituitary cells.
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Chapter three: effects of neonatal oestrogen treatment
on male rat pituitary function
3.1 Introduction
The primary purpose of this long-term study was to investigate whether neonatal
oestrogen disruption, using the potent synthetic oestrogen DES, in male rodents could
permanently re-programme pituitary gland function. There is a substantial amount of
evidence in the literature that shows that exposure of male rodents to high levels of
exogenous oestrogens results in major morphological and functional abnormalities of the
HPG axis, including the testis and reproductive tract (Arai et al., 1983; Newbold et al.,
1985; Fisher et al., 1998, Khan et al., 1998; Sharpe et al., 1998). Many of these effects
have also been shown to have life-long consequences (Khan et al., 1998; Atanassova et
al., 2000). Furthermore, studies on the sons of women who were exposed to DES during
pregnancy have shown that a similar range of abnormalities can also be induced in
human males exposed to high levels of exogenous oestrogens in utero (Stillman, 1982;
Toppari et al., 1996). However, at this present time, the exact mechanisms underlying
the induction of these reproductive abnormalities are unclear. One mechanism that has
been proposed so far has suggested that DES-induced effects on the testis are indirect,
and result from suppression of gonadotrophin secretion by the pituitary gland during
DES treatment (Brown-Grant et al., 1975; Bellido et al., 1990).
The purpose for performing this study was based on recent findings by Richard Sharpe's
laboratory (Atanassova et al., 1999), which showed that neonatal treatment of male rats
with DES had permanent effects on the HPG axis in male rats. Atanassova et al.,
reported that neonatal treatment with 10|ig of DES significantly reduced testis weight,
germ cell volume, the number of Sertoli cells per testis (but no change in Leydig cells),
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plasma inhibin B concentrations and plasma testosterone concentrations and
significantly elevated plasma FSH levels in adulthood (Table 3.1) (Atanassova et al.,
1999). These effects, although to a much lesser extent, were also obtained for neonatal
rats treated with a lower dose (O.ljig) of DES.
Parameter Effect Statistical significance
Testis weight (mg) reduced p<0.001
Germ cell volume/testis (mm3) reduced p<0.001
Sertoli cells/testis (106) reduced p<0.001
Plasma FSH (ng/ml) elevated p<0.001
Plasma inhibin B reduced p<0.001
Leydig cells/testis (106) no change -
Plasma LH (ng/ml) no change -
Plasma testosterone reduced p<0.001
Table 3.1: Summary of effects observed by Atanassova et al., on testis and circulating
reproductive hormone levels in adult male rats treated neonatally with 10pg of DES.
Based on data from Atanassova et al., 1999.
In light of these findings, this in vivo DES study was performed to clarify whether a)
DES was having potential effects directly at the pituitary gland, or via altered negative
feedback from the testes to the pituitary gland, and b) whether any potential DES-
induced pituitary effects were transient or permanent.
To address these questions, male rats were injected during neonatal life (days 2,4,6,8,10
and 12) with either a low dose (O.lpg) or a high dose (lOpg) of DES. Blood samples
were collected on day 26 (early puberty), day 35 (mid puberty) and on day 90
(adulthood), and were assayed for gonadotrophins (LH and FSH) and inhibin B and
testosterone. The animals were either killed shortly after the DES was administered, at
18 days of age, or in adulthood, at 90 days of age, and both the pituitary and the testes
were collected for immunohistochemical analysis. The pituitaries were stained for LH
and FSH and the number of immunopositive cells was counted either at day 18 or at day
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90 for both DES treatment groups. The mRNA levels for the gonadotrophins after
treatment were measured by Real-Time PCR. Testes data were collected and produced
by Richard Sharpe's laboratory in parallel to my pituitary analyses. The testes were
weighed, stained for Leydig and Sertoli cells and the number of immunopositive cells
was counted for each. This enabled potential effects observed at the level of the
pituitary gland to be related to corresponding testes data and vice versa.
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3.1.2 Summary of analysis methods
The following approach was taken to investigate the short-term and long-term effects of
neonatal DES treatment on male rat pituitary gland function:
• Immunocytochemistry for LH and FSH in the anterior pituitary at day 18 (shortly
after DES treatment) and day 90 (adulthood). Enumeration of LH and FSH
immunopositive cells at day 18 and day 90.
• Measurement of plasma hormone levels of FSH, LH, inhibin B and testosterone
at days 26, 35 and 90.
• Real-Time PCR analysis ofmRNA levels of LH and FSH at days 18 and 90.
• Presentation of adult rat testis data, including testis weight, morphology, and
number of Leydig and Sertoli cells present per testis.
3.2 Animals and neonatal treatments
Male Wistar rats were bred in the University of Edinburgh MFAA and all-male litters of
8-12 pups were generated by cross-fostering pups on the first days of birth. They were
maintained under controlled conditions at 22-23°C ambient temperature, 55-60%
relative humidity, 12L:12D cycle, and were supplied with a standard diet (rat and mouse
breeding diet; SDS, Dundee, UK) that contains soya meal. Male rats were injected s.c.
with either a low dose (0.1 pg in 20pl corn oil) of DES (Sigma, UK), or a high dose
(lOpg in 20pl corn oil) of DES and control rats were injected s.c. with 20pl corn oil
only, on days 2,4,6,8,10 and 12 (neonatal period).
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Rats were injected on alternating days as DES is long-acting. Animals were
anaesthetized with flurothane and blood samples were collected from the tail vein at day
26 (early puberty), 35 (mid puberty) and 90 (adulthood), as shown in Figure 3.2, and
were assayed for LH, FSH, inhibin B and testosterone by RIA and EFISA respectively.
The methods for these assays can be found in Chapter 2. Rats were killed at day 90 by
C02 inhalation followed by cervical dislocation. The whole pituitary was removed and
the right testis was dissected out and weighed. The pituitaries and testes were
subsequently fixed for 5 hours in Bouin's fixative, after which the tissues were
transferred into 70% ethanol before being processed for 17.5 hours in an automated
TP1050 processor (Feica Corp., Deerfield, IF, USA) and embedded in paraffin wax.
Sections of 5|im thickness were cut, floated onto slides coated with 3% 3-
aminopropyltriethoxysilane (Sigma, UK), and dried overnight at 50°C before being used
for immunohistochemical analysis and cell enumeration.








=> DES: days 2,4,6,8,10,12
Day 26, 35, and 90
Day 18 or 90
Figure 3.2: Schematic outline for the neonatal DES treatment experiment, showing
the neonatal period during which rats were injected with DES and the days on which
blood samples were collected.
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3.2.1 Specific methods
Pituitary sections were stained for LH and FSH. The method used for
immunolocalisation of LH and FSH in the rat pituitary is described in detail in Chapter
2. A brief summary of the antibody dilutions and the methods of detection are
summarised in Table 3.2.1.
Primary Dilution Blocking Secondary Detection
antibody + solution antibody + method
source source
LH 151887) 1:5000 Normal Rabbit Biotinylated Avidin-biotin
Monoclonal Serum rabbit anti- conjugated
mouse raised (NRS, Scottish mouse horseradish
against bovine Antibody (DAKO,UK) peroxidase
(Gift from Dr Production (ABC-HRP,
JF Roser, Univ. Unit, Carluke, 1:500 DAKO, UK) and
of California Scotland) diaminobenzidine





FSH 1M94) 1:1000 Normal Swine Biotinylated Avidin-biotin
Polyclonal Serum swine anti- conjugated
rabbit antibody (NSS, Scottish rabbit horseradish
raised against Antibody (DAKO,UK) peroxidase
human Production (ABC-HRP,
(Gift from Dr S Unit, Carluke, 1:500 DAKO, UK) and
Lynch, Scotland) diaminobenzidine
Birmingham, diluted 1:5 in (DAB, DAKO,
UK) TBS with 5%
BSA
UK)
Table 3.2.1: Details of reagents used for immunocytochemistry for LH and FSH.
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For the enumeration of LH and FSH immunopositive cells in the anterior pituitary, a
21mm diameter graticule was used, as shown in Figure 3.2.1.
Figure 3.2.1: Method of quantification of gonadotroph cell numbers in the anterior
pituitary.
The number of immunopositive cells was determined by placing the 21mm graticule
over a randomly selected area in the anterior pituitary. As there was no automated stage
available for the microscope, the graticule area was selected at random manually, by
moving the graticule to a different area in the anterior pituitary without looking down
the microscope. Within the graticule, all the brown immunopositive cells (i.e. LH or
FSH immunopositive cells) and all the blue non-immunopositive cells were counted.
Only cells with a nucleus visible were counted. This was done for 5 randomly selected
areas of the pituitary and every fifth consecutive section of the pituitary gland. The
percentage of LH and FSH immunopositive cells and the ratio of LH to FSH cells could





3.3.1 Effect of DES treatment on plasma LH levels
Neonatal treatment with DES had significant age-dependent effects on plasma LH levels
(Figure 3.3.1). Treatment with either O.lpg DES (p=0.0023) or 10pg DES (p=0.011)
elevated plasma LH concentrations significantly in adulthood (day 90). LH levels were
suppressed slightly for both DES doses at days 26 and 35 of age, however this
suppression was small and not statistically significant
Figure 3.3.1: Plasma concentrations of LH at days 26, 35 and 90 of age, in male rats
treated neonatally with either O.lpg or 10pg DES. Values shown are means ± SEM for
4 rats per group. ** p<0.01, in comparison with respective controls.
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3.3.2 Effect of DES treatment on plasma FSH levels
Neonatal treatment with DES had significant effects on FSH levels, which were both
age- and dose dependent (Figure 3.2.2). Treatment with lOjig, but not with 0.1 pg DES,
suppressed plasma FSH levels significantly (p<0.01) at 26 days of age. Both treatments
resulted in elevation of plasma FSH levels at days 35 and 90, though this was only








day 26 day 35 adult
Figure 3.3.2: Plasma FSH concentrations at days 26, 35 and day 90 of age, in male rats
treated neonatally with either O.lflg or lOjlg DES. Values shown are means ± SEM for
4-8 rats per group. * p<0.05, *** p<0.01, in comparison to respective controls.
96
3.3.3 Effect of DES treatment on plasma testosterone levels
Plasma testosterone levels (Figure 3.3.3) were significantly suppressed in adulthood in a
dose-dependent manner (O.lpg DES p=0.025; lOpg DES p=0.0008). As the plasma LH
levels at day 90 (Figure 3.3.1) for these animals were significantly elevated, this
suggests that neonatal DES treatment could have had an effect on the function of the
testicular Leydig cells.
E
control DES 0.1 pg DES 10 |Xg
Figure 3.3.3: Plasma testosterone concentrations in adult rats treated neonatally with
O.lpg or lOpg DES. Values are means ± SEM. For control n=8, for O.lpg DES n=10,
for 10pg DES n=8. * p<0.05, *** p<0.001, in comparison to respective controls.
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3.3.4 Effect of DES treatment on plasma inhibin B levels
Plasma inhibin B levels (Figure 3.3.4) were significantly suppressed at day 90 for both
0.1 jig (p=0.0062) or 10|lg (p=0.05) DES treated rats. This corresponds with the
significantly elevated FSH levels (Figure 3.2.2) observed for these animals, as plasma















control DES 0.1pg DES 10 jig
Figure 3.3.4: Plasma inhibin B concentrations in adult rats treated neonatally with
0.1 jug or lOjig DES. Values are means ± SEM. For control n=8, for 0.1 pig DES n=9,
for lOjig DES n=4. * p<0.05, ** p<0.01, in comparison with respective controls.
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3.3.5 Short-term effect of DES treatment on the number of LH and FSH
immunopositive cells in the pituitary gland
The number of LH and FSH immunopositive cells in the pituitary gland was counted at
18 days of age, for rats treated neonatally with either the low or high dose of DES
(Figure 3.3.5a). There was a significant reduction in the percentage of FSH
immunopositive cells (p=0.181) for the high dose DES treated rats. There was also a
slight reduction in FSH immunopositive cells for the low dose DES treated rats but this
reduction was not statistically significant. There was no significant change in the
percentage of LH immunostained cells for both doses of DES, though values were















control DES 0.1 pg DESIOgg
Figure 3.3.5a: Number of LH and FSH immunopositive gonadotrophs at day 18, after
neonatal treatment with either the low dose or high dose of DES. Values are means ±
SEM. For control n=6, for 0.1 |ig DES n=4 and for 10pg DES n=4. ** p<0.01, in
comparison with respective control values.
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Figure 3.3.5b demonstrates the significant suppression of FSH immunopositive staining
for the high dose DES treated rats at day 18. Interestingly, though LH immunopositive
staining was lower than in controls, this was nowhere near as dramatic as for FSH.
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Figure 3.3.5b: Immunocytochemistry for LH and FSH in the anterior pituitary gland of
control rats and rats treated neonatally with lOjlg (high dose) DES. Note the significant
suppression of FSH immunopositive staining at day 18 for the high dose DES treated
rats (D) when compared with control (B), whereas a more marginal effect was evident
for LH (compare C with A).
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3.3.6 Long-term effect of DES treatment on the number of LH and FSH
immunopositive cells in the pituitary gland
In adult rats treated neonatally with either the low or high dose of DES, there was no
difference in the percentage of LH (0.1 |lg DES p=0.169, lOjlg DES p=0.177) and FSH
(0.1 jug DES p=0.778, 10(ig DES p=0.113) immunopositive cells in the anterior pituitary
gland when compared to controls (Figure 3.3.6a). Figure 3.3.6b also demonstrates this
by showing the immunostaining for LH and FSH in controls and rats administered the
high dose of DES neonatally. Since in adulthood there was no longer any suppression of
FSH immunopositive staining (as observed at day 18), this implies that this DES-
induced FSH reduction was acute and did not persist to adulthood.
Figure 3.3.6a: Mean percentage of LH and FSH immunopositive cells at day 90, after
neonatal treatment with DES. Values are means ± SEM. For control n=3, for low dose
DES n=3 and for high dose DES n=3.
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Figure 3.3.6b: Immunocytochemistry for LH and FSH in adult pituitary gonadotrophs
for control rats and rats injected neonatally with high dose DES. Note there was no
significant difference in immunopositive staining in adulthood (day 90) for both LH
(compare A to C) and FSH (compare B to D) for high dose DES neonatally treated
animals.
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3.3.7 Effect of neonatal DES treatment on LH and FSH mRNA levels at
day 18 in the anterior pituitary gland
Real-Time PCR analysis of mRNA levels for LH and FSH in pituitaries from rats aged
18 days revealed a dramatic significant reduction in FSH mRNA levels (p=0.009) in
animals treated with lOjig DES, but there was no significant change in LH mRNA levels
(Figure 3.3.7a). The reduction in FSH mRNA correlated well with the significant
reduction in FSH immunopositive cells observed at day 18 (Figures 3.3.6a and b), and
possibly also explains the marked suppression of plasma FSH levels at day 26 (Figure
3.3.2). There was no significant change in either LH or FSH mRNA in rats treated with
0.1 jig DES.
Figure 3.3.7: Messenger RNA levels in 18 day old rats treated neonatally with 0.1 jig or
lOjig DES. Values are means ± SEM. For control n=4, for low dose DES n=2 and for
high dose DES n=2. ** p<0.01, in comparison with respective control values.
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3.3.8 Effect of neonatal DES treatment on LH and FSH mRNA levels at
day 90 in the anterior pituitary gland
Real-Time PCR analysis ofmRNA levels for LH and FSH in pituitaries for rats aged 90
days revealed that there was no significant difference with controls (Figure 3.3.8). This
correlates well with the immunostaining for LH and FSH cells observed for these rats
(Figures 3.3.6a and b), as there was no significant change in the number of
immunopositive cells. This suggests that DES only had a short-term effect on FSH
mRNA levels.
Figure 3.3.8: Messenger RNA levels for 90 day old rats treated neonatally with either a
low or high dose of DES. There was no significant difference in LH and FSH mRNA
levels for both 0.1 pg DES (LH p= 0.786 and FSH p=0.864) and lOpg DES (LH p=0.831
and FSH p=0.612) treated rats. Values shown are the means ± SEM. For control n=8,
for low dose DES n=10 and for high dose DES n=6.
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3.3.9 Effect of neonatal DES treatment on testicular morphology and
function in adulthood
Adult testis weight was dose-dependently reduced in rats treated neonatally with DES
(Table 3.3.9). This implies that DES may have permanently altered some or all of the
cellular components of the testis, and this has been explored in parallel studies that have
been published (Atanassova et al., 1999; Sharpe et al., 2003b). These findings are
summarised below to aid interpretation of the present findings on LH, FSH and pituitary
function.










(Atanassova et al., 1999)





(Atanassova et al., 1999)
32.3 ± 6.6 32.3 ±5.4 27.0 ±6.0
Sertoli cells/testis (106)
(Atanassova et al., 1999)




Table 3.3.9: Summary of testis weight, and Leydig and Sertoli cell number per testis
for adult rats treated neonatally with DES. Values are the means ± SEM. For data from
Atanassova et al., controls n=12 and DES treated n=5 (Atanassova et al., 1999).
As the testis weights for the DES-treated rats were significantly reduced both for the
animals used during my study and for the Atanassova et al., study, it can be assumed
that the Leydig and Sertoli cell numbers per testis for my study showed the same pattern;
i.e. that there was a significant reduction in the number of Sertoli cells, but no change in
the number of Leydig cells per testis.
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In adult rats treated neonatally with DES, there was no significant change in Leydig cell
number per testis (Table 3.3.9 and Figure 3.3.9). Thus the pronounced reduction in
blood testosterone levels reported earlier in this chapter (Figure 3.3.3) was not due to
any decrease in the number of Feydig cells in the testis. In contrast, rats treated
neonatally with DES exhibited a significant and dose-dependent reduction in the number
of Sertoli cells per testis (Table 3.3.9). This change correlated with the reduced
concentrations of inhibin B in plasma that were found in similarly treated rats, and
suggests that the fall in inhibin B levels was due to a reduction in Sertoli cell number per
testis.
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Figure 3.3.9: Immunoexpression of the Leydig cell marker 3(3-HSD (brown staining) in
the adult testis following neonatal treatment with vehicle (control, A) or with lOpg DES
(B) or 0.1 (ig DES (C). From Sharpe et ah, 2003.
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3.3.10 Summary of the changes in the hypothalamic-pituitary-gonadal axis








Figure 3.3.10: Summary of DES-induced effects on the function of the rodent HPG
axis in adulthood. AP is anterior pituitary and A is change.
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3.4 Discussion
The primary aim of this long-term study was to determine whether neonatal treatment
with the potent oestrogen, DES, would induce changes in pituitary gland function, and
whether potential pituitary effects would be long-lasting. There have been numerous
reports in the literature showing that neonatal treatment of male rats with high doses of
DES can induce a range of developmental abnormalities, including inhibition of Sertoli
cell proliferation (Atanassova et al., 1999), suppression of Leydig cell development and
function (Sharpe et al., 2003b), and abnormal development of the rete testis (Aceitero et
al., 1998; Fisher et al., 1999; McKinnell et al., 2001b), efferent ducts (Fisher et al.,
1997, 1999), epididymis (Atanassova et al., 2001; McKinnell et al., 2001b), vas deferens
(Atanassova et al., 2001; McKinnell et al., 2001b), seminal vesicles (Williams et al.,
2000, 2001) and the prostate (Prins and Birch, 1995). However, in contrast, studies
using lower (but still physiologically substantial) doses of DES have failed to induce
most of the gross structural changes in the testis, caused by administering a high dose of
DES (Atanassova et al., 2001; Rivas et al., 2002). Coincident with the DES induction
of these testicular abnormalities, neonatal treatment with high, but not low, doses of
DES have also been shown to grossly suppress expression of the androgen receptor in all
of the testicular tissues affected adversely by DES treatment (McKinnell et al., 2001b).
However, until now, it was unclear whether neonatal DES treatment in rodents had any
direct effects on the morphology and function of the anterior pituitary gland, and more
specifically on the pituitary gonadotroph cells. The results from this study showed that
shortly after the neonatal DES treatment, at 18 days of age, DES significantly reduced
the number of FSH-immunopositive gonadotroph cells (p<0.01) in the pituitary. This
significant change was only induced by the high dose (lOjag) of DES and not by the low
dose (0.1 |lg) of DES. On the other hand, there was found to be no significant change in
LH-immunopositive staining at 18 days of age, for both doses of DES. As the vast
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majority of gonadotroph cells are bi-hormonal (i.e. contain both LH and FSH) (Liu et
al., 1998; Currie and McNeilly, 1995) and there was no significant change in the total
number of cells present within the anterior pituitary gland, this suggests that neonatal
lOjlg DES treatment depleted FSH from the gonadotroph cells, without abolishing the
entire gonadotroph. The mRNA analysis of these 18 day old rat pituitaries revealed that
there was a significant reduction in FSH mRNA levels for these rats (p<0.01), but there
was no significant change in LH mRNA levels. Plasma hormone levels measured
shortly after the treatment period, at days 26 (early puberty) and 35 (mid puberty) of age,
showed that circulating LH levels were slightly suppressed for both DES doses at days
26 and 35, although this was not statistically significant. FSH concentrations on the
other hand, were significantly suppressed (p<0.001) for the 10(ig DES treated animals at
26 days of age. Both DES treatments resulted in an elevation of plasma FSH at 35 days
of age, but this change was not statistically significant.
In adulthood, at 90 days of age, there was no longer a significant suppression of FSH-
immunopositive staining or suppression of FSH mRNA levels, suggesting that the
neonatal DES treatment did not have any significant long-lasting effects on FSH-
immunopositive staining or on FSH mRNA levels in the anterior pituitary. However,
circulating plasma levels of LH were significantly elevated for both doses of DES
(p<0.01) at day 90, and both doses caused an elevation in plasma FSH levels, although
this was only statistically significant for the 0.1|Ltg DES treated rats (p<0.05).
LH acts primarily on the testicular Leydig cells to promote the synthesis of testosterone,
and subsequently testosterone exerts negative feedback on hypothalamic GnRH release
and on the pituitary (Matsumoto et al., 1984; Shecter et al., 1989). In adulthood,
neonatal DES treatment caused a marked reduction in circulating testosterone levels for
both doses of DES (0.1 fig DES p<0.05 and lOflg DES p<0.001). Interestingly, there
was no significant DES-induced change on the number of Leydig cells present per testis.
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This suggests that the DES-induced suppressed testosterone concentrations in adulthood
were caused by a lack of the Leydig cells to produce and secrete testosterone, and not
due to a reduction in the total number of Leydig cells present per rat testis. Since
testosterone exerts negative feedback at the level of the pituitary and hypothalamus, and
as testosterone levels were suppressed after DES treatment, this caused altered feedback
to both the hypothalamus and pituitary and as a result plasma LH levels were elevated in
adulthood (p<0.01). FSH on the other hand, acts primarily on testicular Sertoli cells to
promote the synthesis of inhibin B, which subsequently negatively regulates FSH
production and secretion from the pituitary gland (Jensen et al., 1997; Nachtigall et al.,
1996). At day 90, there was a significant increase in circulating FSH levels for both
doses of DES treatment (p<0.05). Neonatal DES treatment also induced a significant
reduction in the number of Sertoli cells per testis (0. l|LLg DES p<0.01 and 10p,g DES
p<0.001) and a significant suppression of plasma inhibin B levels (0.1 pg DES p<0.01
and lOpg DES p<0.05). This suggests that the suppressed inhibin B levels were due to a
reduction in the number of Sertoli cells per testis, this resulted in a significant increase in
plasma FSH levels, as inhibin B negatively regulates FSH production and secretion from
the pituitary gland.
The hormones FSH and testosterone play important roles in spermatogenesis, although
in nonseasonal animals testosterone is thought to be the most important regulatory factor
(Sharpe, 1994). In addition, the most important factor that determines the ceiling of
sperm production and output in all mammals is the number of Sertoli cells per testis
(Sharpe, 1994). Sperm production in adult life is dependent upon neonatal Sertoli cell
proliferation. The number of Sertoli cells in the adult testis determines both testis size
and daily sperm production. This relationship occurs because each Sertoli cell has a
fixed capacity for the number of germ cells that it can support (Orth et al., 1988). As the
number of Sertoli cells per testis determines the number of spermatozoa produced per
day, it is vital that the correct number of Sertoli cells is generated in neonatal life
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(Sharpe, 1994). It has been demonstrated that the neonatal FSH concentration is very
important as FSH increases the rate of Sertoli cell proliferation (Hess et al., 1993; De
Franca et al., 1995; Sharpe et al., 2003a). Thus, as plasma FSH levels were significantly
reduced at day 26 for the DES-treated rats, this suggests that this caused a decrease in
Sertoli cell proliferation during the neonatal period and hence resulted in there being a
lower number of mature Sertoli cells present per testis in adulthood for these treated
animals (Figure 3.3). The reduced number of Sertoli cells in adulthood subsequently
caused the suppressed circulating inhibin B levels and hence altered negative feedback






Figure 3.4: Summary of neonatal DES effects on adult Sertoli cell number, and
circulating plasma inhibin B and FSH levels.
In conclusion, neonatal DES treatment has been shown to have direct effects on the
function of the pituitary gonadotrophs during the neonatal period, by significantly
reducing the number of FSH-immunopositive cells and by significantly suppressing FSH
mRNA levels and plasma FSH concentrations at day 18. This resulted in reduced
proliferation of testicular Sertoli cells during the neonatal period and permanently
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lowered the number of Sertoli cells per testis in adulthood, and hence caused a life-long
suppression of plasma inhibin B levels and a permanent elevation of plasma FSH levels.
In adulthood however, the pituitary gonadotrophs appeared to recover from this neonatal
DES insult, as there was no longer a suppression of FSH immunopositive staining and
FSH mRNA levels. But, plasma inhibin levels remained suppressed and plasma FSH
levels remained elevated in adulthood due to a permanent alteration in Sertoli cell
number. DES also appeared to have direct effects on testicular function as neonatal DES
treatment caused a permanent reduction in the ability of the Leydig cells to produce and
secrete testosterone. To shed more light on DES-induced effects directly at the pituitary
gland, in the next chapter an in vitro system will be set-up to examine DES-induced
pituitary effects without any feedback occurring from the testis.
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Chapter four: comparison of effects of neonatal
oestrogen treatments on responsiveness of adult male
and female rat pituitaries
4.1 Introduction
The experiments described in this chapter are concerned with investigating potential
alterations to adult male and female rat pituitary function, both in vivo and in vitro, after
neonatal exposure to the synthetic estrogen, DES. This chapter builds upon results
described in the previous chapter, where the short- and long-term in vivo effects of DES
on the male HPG axis were investigated. In females, neonatal DES exposure has been
shown to have a number of significant effects along the HPG axis, including vaginal
lesions and clear cell vaginal adenocarcinoma (Herbst, 1981; Mittendorf, 1995; Bern et
al., 1987), uterine hypoplasia (Mittendorf, 1995), disruption of ovarian steroidogenesis
(Nagai et al., 2003), decreased uterine oestrogen receptor (Medlock et al., 1992), and
decreased pituitary responsiveness to GnRH (Register et al., 1995; Faber et al., 1993).
Similarly, in males, neonatal DES treatment has also been shown to have significant
effects on the HPG axis including, suppression of Leydig cell development and function
(Sharpe et al., 2003b), inhibition of Sertoli cell proliferation in early life (Atanassova et
al., 1999), abnormal prostate development (Turner et al., 1989; Gupta, 2000), abnormal
development of the rete testis (Fisher et al., 1999), alteration of circulating
gonadotrophin levels and gonadal hormone levels (Atanassova et al., 1999) and
decreased pituitary responsiveness to GnRH (Register et al., 1995; Faber et al., 1993).
This chapter focuses on comparing and contrasting between neonatal DES-induced
effects on the adult male and adult female HPG axes. Two major long-term studies are
described in this chapter; the first study investigated the effects of neonatal DES
treatment on both the adult male and female HPG axes, with particular emphasis on
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pituitary gonadotrophins and feedback along the HPG axis. The second study involved
setting up a primary pituitary cell culture system from the adult male and female rats
treated neonatally with DES. The purpose for this was to investigate to a greater extent
any possible DES-induced effects directly at the level of the pituitary, without any
feedback occurring from the gonads. Therefore, the neonatally DES treated male and
female rats were killed in adulthood and the pituitaries were removed and cultured. The
primary pituitary cells were assessed for their phenotypic characteristics and their
functional capacity.
Hormones and growth factors produced by the hypothalamus, pituitary and gonads
maintain a normal reproductive cycle and regulate genital, gonadal, and sexual
development in both males and females. For example, in the female, growth and
maturation of follicles and ovulation depend upon endocrine, paracrine, and autocrine
acting hormones (de Ketser et al., 2000; Pezzani et al., 2001). FSH and LH are both
involved in the activation and regulation of the reproductive axis. Hormones produced
by the gonads regulate FSH and LH synthesis and secretion in a feedback loop. One
such gonadal hormone that inhibits FSH synthesis by the pituitary is inhibin (Burger et
al., 1998; Hayes et al., 1998). In females, the ovary is the major source of inhibin
synthesis. Granulosa cells in developing follicles, or lutein cells in the corpus luteum,
secrete inhibin in response to gonadotrophins and various other factors (Knight and
Glister, 2001). In females, it has been established that inhibin B is secreted from
developing preantral and small antral follicles from the beginning of the follicular phase,
with a peak following the FSH increase and a progressive fall during the luteal phase
(Groome et al., 1996). In males, inhibin B is produced by testicular Sertoli cells and the
other gonadal hormone, testosterone, is produced by Leydig cells (Matsumoto et al.,
1984; Sharpe, 1994).
For the in vivo part of this study, neonatal male and female rats were administered DES
from days 2 to 12. The males received either a low dose (0.1 (tg) or a high dose (lOpg)
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of DES, whereas the female animals were administered a low dose of DES only (O.ljig),
as there were insufficient female animals available for treatment. In adulthood, blood
samples were collected and basal levels of the gonadotrophins and gonadal hormones
(inhibin B and testosterone for males, inhibin B for females) were measured. Thereafter,
to test whether neonatal DES treatment affected pituitary responsiveness to GnRH, the
rats were administered a 30 minute GnRH pulse, and gonadotrophin hormone and
gonadal hormone levels were measured in response to GnRH.
For the in vitro part of this study, the intention was to set up a primary cell culture
system using just one pituitary gland, as this would have enabled us to track pituitary
responsiveness after DES treatment for each rat individually both in vivo and in vitro.
As there tends to be considerable variability in gonadotrophin levels between animals,
this would have reduced that variability considerably. However, it was found that one
pituitary gland did not yield a sufficient amount of cells to perform experiments with,
and hence rats were randomly paired from each treatment group and two pituitary glands
were used for cell culture. As it has been shown that stimulation of the gonadotroph cell
line LPT2 or primary pituitary cells with GnRH treatment and/or activin treatment can
stimulate the release of gonadotrophin hormones (Turgeon et al., 1996; Nicol et ai,
2002; Okada et al., 2003), it was tested whether neonatal DES treatment would alter the
responsiveness of the primary pituitary cells to these treatments. GnRH was either
administered manually, or by co-culturing primary pituitary cells with hypothalamic
GnRH-producing GT1-7 cells, as this has been shown to stimulate gonadotrophin
production from primary pituitary cells in culture (Krsmanovic et al., 2000).
Thus, an in vivo and an in vitro approach was used in both male and female rats to test
whether neonatal DES treatment altered pituitary function on a permanent basis, and to
investigate whether neonatal DES treatment had differential effects on male and female
pituitary function.
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4.1.2 Summary of approaches used to investigate effects of neonatal DES
treatment on male and female rat pituitary function
In vivo rat study: Investigation into the chronic effects of neonatal DES treatments on
the hypothalamic-pituitary-gonadal axis, and in particular pituitary gonadotroph
function. In this study the primary goals were:
• Determination of adult (day 90) basal LH, FSH (by RIA), inhibin B and
testosterone (for males only) (by ELISA) concentrations.
• Assessment of changes in plasma FSH, LH, inhibin B and testosterone, in
response to an acute GnRH dose challenge to adult rats (lOOng GnRH for 30
minutes).
In vitro rat study: Investigation into the effects of neonatal DES treatments on adult
primary pituitary cell culture responsiveness. This study involved:
• Setting up primary pituitary cell culture and maintaining cells in culture for 7-10
days. Immunofluorescent staining for LH and FSH in adult pituitary cells in
culture to investigate whether bi-hormonal nature of gonadotrophs was
maintained.
• Measurement of mRNA for LH, FSH, and GnRH I receptor for pituitary cells in
culture.
• Assaying basal LH and FSH output from pituitary cells in culture from day 1 to
10.
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• Administering a range of GnRH pulses (various doses and time-points) to the
pituitary cells in culture and measuring LH and FSH output in response to each
GnRH pulse.
• Treatment of pituitary cells with activin, GnRH or GnRH with activin and
measurement of LH and FSH secretion in response to these treatments.
• Co-culturing primary pituitary cells with hypothalamic GnRH-secreting cells
(GT1 -7 cells) and measurement of LH and FSH output from pituitary cells in
culture.
• Extraction of pituitary LH and FSH cell content and Western Blot analysis of
GnRH I receptor in whole cell lysates in both primary pituitary cells and L(3T2
cells (control).
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4.2 In vivo male and female rat study: long-term effects of
neonatal DES treatments on the hypothalamic-pituitary-gonadal axis
In this first in vivo study, male rats were injected neonatally with either a low (0.1 fig) or
a high (lOpg) dose of the potent synthetic estrogen, DES. Female rats were injected
with just a low dose of DES, as unfortunately insufficient female animals were available
to inject also with the high dose of DES. In adulthood, when the rats were
approximately 90 days old, any DES-induced effects on the hypothalamic-pituitary-
gonadal (HPG) axis were evaluated by measuring plasma levels of gonadotrophins (LH
and FSH) and the gonadal hormones (inhibin B and testosterone). Subsequently, any
DES-induced effects on pituitary responsiveness to hypothalamic GnRH was tested by
measuring gonadotrophin output in response to a 30 minute lOOng GnRH pulse. After
these measurements were taken, pituitary glands were removed and were sub-cultured
for a number of days to evaluate the effects of these neonatal DES treatments solely on
the function of pituitary gland, isolating them from any feedback from the gonads or the
hypothalamus.
4.2.1 Animals and neonatal treatments
Neonatal male rats were injected s.c. on days 2 ,4 ,6 ,8 ,10 and 12 with either O.lpg DES
in 20jll corn oil, or lOpg DES in 20]il corn oil. Neonatal female rats were also injected
s.c. on days 2,4,6,8,10 and 12, but with just the low dose (O.lpg) of DES. Control
neonatal rats were injected with just 20(0.1 corn oil. When these rats reached adulthood
(approximately day 90), they were anaesthetized with flurothane and blood samples
were collected from the tail vein with a heparinized syringe. Plasma was separated from
these blood samples by centrifugation at 3000rpm for 30 minutes at 4°C, before storage
at -20°C. Subsequently samples were assayed for LH, FSH, testosterone and inhibin B.
Approximately 4 weeks later, these adult animals were injected s.c. with lOOqg GnRH
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in 200p,l sterile Phosphate Buffered Saline (PBS, Sigma UK). Thirty minutes after
injection, blood samples were collected from these animals and were assayed for LH,
FSH, inhibin B and testosterone. Three weeks after the GnRH injections, the rats were
killed by suffocation with C02, followed by cervical dislocation after which the
pituitaries were removed for primary pituitary cell culture.
4.2.2 Specific methods
Blood plasma levels of LH and FSH were measured by RIA, as described in detail in
Chapter 2 of this thesis. Briefly, 50jal of sample was diluted in lOOpl of assay buffer
(0.05M phosphate buffer pH7.5, 0.45M NaCl, 0.05% Tween, 0.1% BSA; Sigma UK)
using an automatic pipettor and added to plastic test tubes. Subsequently, 50jll of
primary antibody (NIDDK rLH-S-11 at 1:600 000 final dilution or NIDDK rFSH-S-11
at 1:100 000 final dilution) was added to each tube and incubated overnight at 4°C. LH
or FSH tracer diluted in assay buffer to give between 15000-21000 counts per minute
(cpm), was added to each tube and incubated overnight at 4°C. Then, 50(il of the
secondary antisera and 50|ll of normal serum (normal rabbit serum 1:400 and donkey
anti-rabbit serum 1:16, Scottish Antibody Production Unit, Carluke, Scotland) were
added to the tubes, mixed and incubated overnight at 4°C. Finally, immunocomplexes
were separated by addition of 1ml 0.9% saline, 4% PEG 6000 and 0.2% Triton-X
(Sigma, UK) and centrifugation at 3000rpm for 30 minutes. Supernatants were removed
and tubes were left to dry at room temperature prior to measuring radioactivity using a
1261 Multigamma counter.
Testosterone and inhibin B were measured using ELISA, the methods for this are
described in detail in Chapter 2.
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4.3.1 Effect of DES on plasma FSH levels before and after a GnRH
challenge in adult male rats
Basal FSH levels for male adult rats treated neonatally with either O.lpg or 10pg of DES
were significantly elevated in a dose-dependent manner (Figure 4.3.1a). The high dose
DES treated rats showed a more significant elevation (p=0.0039) in adult plasma FSH
concentrations than the low dose DES neonatally treated rats (p=0.05). This confirms
that DES-induced FSH elevation in adult males is a robust effect as the same
observations were made for the male in vivo DES study, described in Chapter 3.
Figure 4.3.1a: Mean basal FSH concentrations for adult male rats treated neonatally
with either 0.1|lg or 10pg DES. Values are the means ± SEM. For controls n=7, low
dose DES n=12, and high dose DES n=8. * p<0.05 and ** p<0.01, in comparison with
respective controls.
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When FSH concentrations were measured for these male rats after a 30 minute GnRH
challenge was administered (Figure 4.3.1b) there was a very small increase in FSH
levels for both male control and treated rats, however this increase was statistically not
significant. Since FSH secretion from pituitary gonadotrophs is not under direct control
of GnRH, this explains why there is only a nominal, statistically insignificant, increase
in adult plasma FSH levels in response to the 30 minute GnRH stimulus. Plasma FSH
levels after the GnRH challenge still showed the same basic pattern however, in that
FSH levels were elevated for the neonatally DES treated rats, especially for the high
dose DES treated rats (p=0.023). This again confirms that neonatal DES treatment has
potent and long-lasting effects on male adult rat FSH plasma levels, yet does not alter
the animal's response to GnRH challenges with respect to circulating FSH levels.
Figure 4.3.1b: Mean FSH concentrations after a GnRH challenge, for adult male rats
treated neonatally with DES. Values are the means ± SEM. For controls n=7, low dose
DES n=12, and high dose DES n=8. * p<0.05, in comparison with respective controls.
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4.3.2 Effect of DES on plasma FSH levels before and after a GnRH
challenge in adult female rats
There was no significant difference (p=0.4206) in FSH levels between adult control
females and adult females treated neonatally with DES (Figure 4.3.2a). As neonatally
DES-treated male rats showed a significant elevation in adult FSH levels (Figure 4.3.1a),
this suggests that neonatal DES treatment may have differential effects on adult male
and adult female gonadotrophin concentrations, with the male FSH levels being more
susceptible to alteration by DES treatment than the female FSH levels.
6
control DESO.ipg
Figure 4.3.2a: Mean basal FSH concentrations in adult female rats treated neonatally
with O.lpg DES. Values are means ± SEM. For controls n=6, low dose DES n=5.
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When FSH levels for these adult females were measured after a 30 minute lOOng GnRH
pulse (Figure 4.3.2b), there was no significant increase in FSH concentrations in
response to the GnRH pulse. This corresponds with the literature reviewed in Chapter 1,
and with observations made in the male rat, in that FSH secretion is not under direct
control of GnRH and hence no dramatic elevation in FSH was expected in response to
GnRH. Plasma FSH levels after the GnRH challenge still showed the same basic pattern
however, in that there was no significant change in FSH levels between control females
and females treated neonatally with O.ljag of DES (p=0.1302). However, the mean level
of FSH for the DES treated females was generally lower than in control animals, again
in contrast to the effects of DES on males. This suggests that DES treatment could have
differential effects on male and female plasma FSH levels.
control DESO.ipg
Figure 4.3,2b: Mean FSH concentrations after a 30 minute GnRH pulse in adult female
rats treated neonatally with 0.1p,g DES. Values are means ± SEM. For controls n=6,
low dose DES n=5.
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4.3.3 Effect of DES on plasma LH levels before and after a GnRH
challenge in adult male rats
Mean basal plasma LH levels for male adult rats treated neonatally with either 0.1 pg or
lOpg DES (Figure 4.3.3a), were elevated significantly for both doses of DES, with the
high dose of DES (p=0.0001) treated rats showing a greater elevation in LH levels than
the low dose (p=0.032) treated rats.
Figure 4.3.3a: Mean basal concentrations of LH for male adult rats treated neonatally
with DES. Values are the means ± SEM. For controls n=7, for low dose DES n=12, and
for high dose DES n=8. * p<0.05 and *** p<0.001, in comparison with respective
controls.
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When LEI concentrations were measured for these male rats after a 30 minute GnRH
challenge was administered (Figure 4.3.3b), there was a significant increase in LH levels
for both male control and DES treated animals (p<0.001). This observation corresponds
with the literature reviewed in Chapter 1, in that LEI production and secretion from
pituitary gonadotrophs, in contrast to FSH, is directly regulated by GnRH. Hence, when
there is a GnRH pulse, LH will be released from the gonadotroph cells in response to
that GnRH pulse. The adult male plasma LH levels after the 30 minute GnRH
stimulation showed the same trend as the male basal LH levels, in that LH
concentrations were significantly elevated for both 0. lpg (p=0.0329) and lOjig DES
(p=0.0001) treated rats. Thus, the DES treated male animals still retained a normal
physiological response to GnRH pulses.
control DESO.Ipg DES 10pg
Figure 4.3.3b: Mean concentrations of LH after a GnRH challenge, for adult male rats
treated neonatally with DES. Values are the means ± SEM. For controls n=7, for low
dose DES n=12, and for high dose DES n=8. * p<0.05 and *** p<0.001, in comparison
with respective controls.
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4.3.4 Effect of DES on LH plasma levels before and after a GnRH
challenge in adult female rats
There was no significant increase in adult LH levels between control females and
females treated neonatally with DES (p=0.800) (Figure 4.3.4a). This is in contrast to
what was observed in males (Figure 4.3.3a), as in adult males there was a significant
elevation in LH levels after neonatal treatment with DES. Therefore it appears that
female gonadotrophin levels are less susceptible to disruption by neonatal DES
treatment than male gonadotrophin levels. However, it is important to note the fairly
high SEM on the DES treated female levels for LH.
Figure 4.3.4a: Mean basal LH concentrations in adult female rats treated neonatally
with 0.1 jig DES. Values are means ± SEM. For controls n=6, low dose DES n=5.
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When LH concentrations were measured after a 30 minute GnRH pulse for the adult
female rats treated neonatally with the low dose of DES, there was a significant increase
in LH levels for both the control and DES treated rats (p=0.008), as shown in Figure
4.3.4b. This corresponds with the literature reviewed in Chapter 1, in that LH secretion
(unlike FSH secretion) is directly controlled by GnRH pulses. Therefore, neonatal DES
treatment appears to have not affected LH release in response to the GnRH pulse.
Plasma LH levels after the GnRH challenge still showed the same basic pattern
however, in that there was no significant change in LH levels between control rats and
rats treated neonatally with DES.
Figure 4.3.4b: Mean LH levels after a 30 minute GnRH pulse for adult female rats
treated neonatally with 0. l|ig of DES. Values are means ± SEM. For controls n=6, low
dose DES n=5.
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4.3.5 Summary of the percentage changes in gonadotrophins induced by a
GnRH challenge
Treatment FSH LH
Male Female Male Female








10pg DES 0% ~ 32% T
p<0.01
Table 4.3.5: Summary of the average percentage increases or decreases in LH and FSE1
concentrations after a 30 minute lOOng GnRH pulse, compared to mean basal LH and
FSH concentrations.
In control animals, basal concentrations of FSH and LH were significantly lower in
females compared to males, with adult female basal gonadotrophin levels being almost
50% lower than adult male gonadotrophin levels. After a 30 minute GnRH challenge,
the male rats showed a 9% elevation in FSH levels and a 67% elevation in LH levels in
response to the GnRH dose. This corresponds well with the literature reviewed in
Chapter 1, in that LH production and secretion is directly regulated by GnRH, whereas
FSH production and secretion is not directly controlled by GnRH. The female rats on
the other hand, showed no significant elevation in FSH levels in response to the acute
GnRH challenge (a slight 0.6% decrease even), but LH concentrations were elevated
significantly in response to the GnRH pulse (296%). This elevation in LH levels in
response to the acute GnRH challenge was much larger in the female control rats
(296%) than in the male control rats (67%), almost 4-fold higher in females than in
males.
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In the 0.1pg DES treated male animals, basal concentrations of FSH (p<0.05) and LH
(p<0.05) were significantly elevated compared to male control rats. However, in the
0.1 pg DES treated female rats, there was no significant change in basal gonadotrophin
levels compared to controls. In females, there was a small increase in basal LH levels
compared to controls and a slight decrease in basal FSH levels compared to controls, but
these differences were small and not statistically significant. After a 30 minute GnRH
challenge, in the male DES treated animals, there was a 2.3% elevation in FSH levels
and a 30% elevation in LH levels in response to the acute GnRH pulse. The increases in
LH and FSH concentrations in 0.1 pg DES treated male animals in response to the GnRH
pulse were almost 50% lower than the GnRH-induced increases observed in LH and
FSH levels in control male rats. This indicates that neonatal treatment with DES alters
the GnRH-responsiveness of these male rats in adulthood, diminishing their ability to
respond to GnRH and release LH (and FSH to a small extent) into the circulation. After
an acute GnRH challenge in the DES treated female rats, there was a 28% reduction in
FSH levels and a 181% elevation in LH levels in response to the GnRH. This, as for
males, corresponds with the literature reviewed in Chapter 1, in that production and
secretion of LH is directly controlled by GnRH. However, the increase in LH secretion
in response to GnRH was much lower in the DES treated females than in the female
control animals. Thus, as for the male rats treated with DES, neonatal DES treatment
reduced the capacity of GnRH to mediate LH release in adult females.
No comparisons between male and female animals could be made for the lOpg DES
treated animals as only male rats were treated with a high dose of DES, due to a shortage
in the number of female animals available. Similarly to the 0.1 pg treated males, there
was a significant elevation in adult basal gonadotrophin levels (LH p<0.001; FSH
p<0.01) for the lOpg DES treated rats. They showed a comparable impaired response to
the GnRH challenge as for 0.1 pg dose treated rats, in that there was approximately a
50% reduction in LH levels secreted in response to GnRH compared to the control
males.
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4.3.6 Effect of DES on plasma testosterone levels before and after a GnRH
challenge in adult male rats
Basal testosterone levels were suppressed for both the lOjig and 0.1 pg DES treated rats,
with the lower dose showing the greatest significant reduction in plasma testosterone
levels (p=0.0003). There was a relatively large SEM for the 10|lg DES treated rats
(Figure 4.3.6a), which is probably the reason why adult plasma testosterone levels were
reduced but not statistically significantly. Interestingly, these testosterone levels did not
show a direct correlation with the LH levels measured for these rats (Figure 4.3.6b).
Basal adult LH concentrations were dramatically elevated, thus it would have been
expected that testosterone concentrations would have risen accordingly. Therefore, this
finding suggests that there has been a definite alteration in the males' HPG axis, which
confirms the observations made at the level of the testis in Chapter 3.
Figure 4.3.6a: Mean basal testosterone levels for adult male rats treated neonatally with
DES. Values are means ± SEM. For controls n=7, low dose DES n=12, and high dose
DES n=8. *** p<0.001, in comparison with respective controls.
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Figure 4.3.6b: Graphical representation of the direct correlation between plasma LH
and plasma testosterone levels for adult male control rats, and the inverse relationship
between plasma LH and testosterone levels for adult male rats treated neonatally with
10|itg DES. For controls n=7 and for lOpg DES n=8.
After a 30 minute stimulation with GnRH, testosterone levels were still suppressed for
both the O.lpg (p=0.526) and the 10pg (p=0.747) DES treated rats, but not statistically
significantly (Figure 4.3.6c). However, testosterone concentrations after the 30 minute
GnRH pulse were significantly higher than the basal testosterone levels for both the
0.1 |lg (p=0.0001) and 1 OjLtg (p=0.05) DES treated rats. This corresponds with the LH
levels measured for these rats after the GnRH pulse (Figure 4.3.3b). LH levels rose in
response to the GnRH pulse and testosterone levels have risen accordingly. This
suggests that although DES has a long-lasting effect on plasma testosterone levels, it
does not appear to affect the general qualitative ability of the testicular Leydig cells to
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produce and secrete testosterone in response to hypothalamic GnRH and pituitary LH.
However it must be noted that the degree of GnRH-induced testosterone release was
lower than that in control animals, thus the DES treated animals could still respond to
GnRH yet the magnitude of the testosterone response was not as great as in controls
(O.lptg DES p<0.05 and 10|lg DES p<0.01).
control DES 0.1gg DES 10|ig
Figure 4.3.6c: Mean testosterone levels after a GnRH challenge for adult male rats
treated neonatally DES. Values are means ± SEM. For controls n=7, low dose DES
n=12, and high dose DES n=8.
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4.3.7 Effect of DES on plasma inhibin B levels before and after a GnRH
challenge in adult male rats
Basal inhibin B levels were dramatically suppressed for both the lOjig (p=0.024) and
0.1 pg (p=0.0086) DES treated male rats (Figure 4.3.7a). This effect corresponds with
the plasma FSH concentrations measured for these animals (Figure 4.3.1a), as these
were found to be significantly elevated in adulthood. This suggests that neonatal DES
treatment had long-lasting effects on inhibin B levels in male rats.
120
control DESO.lpg DES lOpg
Figure 4.3.7a: Plasma inhibin B concentrations in adult male rats treated neonatally
with DES. Values are the means ± SEM. For controls n=7, for low dose DES n=12, and
for high dose DES n=8. * p<0.05 and ** p<0.01, in comparison with respective
controls.
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After a 30 minute stimulation with GnRH, inhibin B levels were still dramatically and
statistically significantly suppressed for both the O.lpg (p=0.0001) and 10pg (p=0.0001)
DES treated rats (Figure 4.3.7b). There was no significant change in inhibin B levels in




control DES 0.1 pg DES lOpg
Figure 4.3.7b: Mean inhibin B levels after a GnRH challenge in adult male rats treated
neonatally with DES. Values are means ± SEM. For controls n=7, low dose DES
n=12, and high dose DES n=8. *** p<0.001, in comparison with respective controls.
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4.3.8 Effect of DES on plasma inhibin B levels before and after a GnRH
challenge in adult female rats
There was a small increase in inhibin B levels in DES treated female rats (Figure
4.3.8a), however this elevation was small and was not statistically significant (p=0.063).
This suggests that neonatal DES treatment had not caused any long-term effects on
inhibin B levels in the adult female rat. Surprisingly, this observation is the opposite of
the effects observed in male rats (Figure 4.3.7a). In DES treated males, there was a
significant suppression in inhibin B levels in adulthood (p<0.01 for 0.1 pig and p<0.05
for lOjLtg DES). This suggests that male levels of inhibin B are more susceptible to
DES-induced alterations than female plasma inhibin B levels.
120
control DES0.1p,g
Figure 4.3.8a: Plasma inhibin B concentrations in adult female rats treated neonatally
with 0.1 fig DES. Values are means ± SEM. For controls n=6, low dose DES n=5.
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Inhibin B concentrations were measured after a 30 minute lOOng GnRH pulse (Figure
4.3.8b). There was a significant increase in inhibin B levels for adult control females
(p=0.01), but there was no change in plasma inhibin B levels in response to GnRH for
DES treated females.
160
control DES 0.1 pg
Figure 4.3.8b: Plasma inhibin B concentrations after a 30 minute GnRH challenge in
adult female rats treated neonatally with 0.1 jig DES. Values are means ± SEM. For
controls n=6, low dose DES n=5.
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4.3.9 Summary of the percentage changes in plasma testosterone and
inhibin B levels induced by a GnRH challenge
Treatment Inhibin B Testosterone
Male Female Male
Control 1% T 112% T 45% T
p<0.001 p<0.01
0.1pg DES 9% T 1.3% I 25% T
p<0.05
lOpg DES 2% i - 48% T
p<0.01
Table 4.3.9: Summary of the average percentage increases or decreases in inhibin B
and testosterone concentrations after a 30 minute lOOng GnRH pulse, compared to mean
basal inhibin B and testosterone concentrations.
In adult control animals, basal inhibin B levels were higher for control male rats than
control female rats. After a 30 minute GnRH challenge, control female rats showed a
much greater GnRH-induced increase in plasma inhibin B than control males. Control
females showed a 112% elevation in inhibin B levels in response GnRH whereas the
control males only showed a 1% elevation in inhibin B levels in response to the GnRH
challenge.
In the 0.1 pg DES treated males, basal concentrations of inhibin B (p=0.032) and
testosterone (p=0.0086) were significantly suppressed compared to male control rats.
The female 0.1 pg DES treated rats on the other hand, showed no suppression of plasma
inhibin B. On the contrary, inhibin B levels were elevated slightly in the low dose
treated female rats, however these increases were only small and not statistically
significant. This suggests that neonatal DES treatment could have differential effects on
circulating levels of inhibin B in males and females. After a GnRH challenge, there was
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a 1.3% decrease in plasma inhibin B levels for the DES treated females in response to
GnRH, compared to control females where there was a 112% GnRH-induced elevation
in plasma inhibin B levels. In male DES treated animals however there was a 9%
elevation in inhibin B levels after a GnRH pulse, compared to only a 1% increase in
GnRH-induced inhibin B release in control males. This suggests that DES treatment
impairs the capacity of GnRH to mediate the release of inhibin B in female rats.
Testosterone levels after a GnRH pulse were elevated by 25% for the DES treated males,
compared to a 45% elevation for control male rats. This suggests that neonatal DES
treatment in male rats caused a significant reduction in the rats' capacity to release
testosterone in response to GnRH.
No comparison could be made between males and females for effects observed for the
10|LLg DES treatment regime, as there were no female animals available for treatment. In
the males treated with 10p.g of DES, basal inhibin B (p=0.0001) and testosterone
(p=0.02) levels were significantly suppressed, compared to control males. Unlike in the
0.1 pig DES treated males, there was no reduction in the rats' capacity to secrete
testosterone in response to a GnRH challenge.
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FSH (ng/ml) 8.8 ±0.97 9.6 ±0.72
(9%T)




76.3 ± 8.32 77.2 ±9.45
(1%T)
59.1 ±6.55 125.3 ±9.84
(112%T)
LH (ng/ml) 0.9 ±0.019 1.5 ± 0.17
(67%T)




1.9 ± 0.13 2.75 ±0.37
(45%T)
-
Table 4.3.10a: Mean concentrations of FSH, inhibin B, LH and testosterone before and
after a 30 minute GnRH pulse for control male and female rats. Values are the means ±
SEM.
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Hormone
measured

























93.1 ± 14.37 91.82 ± 11.9
(l.3%i)














Table 4.3.10b: Mean concentrations of FSH, inhibin B, LH and testosterone before and
after a 30 minute GnRH pulse for male and female rats treated neonatally with 0.1 pg
DES. Values are the means ± SEM.
10|ig DES males
Hormone measured Basal concentration Concentration after a
GnRH pulse
FSH (ng/ml) 12.5 ± 1.26 12.5 ± 1.32
(p=0.003) (p=0.023) (0%)
Inhibin B (pg/ml) 30.7 ± 12.0 29.8 ± 12.9
(p=0.0001) (0.0001) (2%i)
LH (ng/ml) 1.81 ± 1.29 2.4 ±1.17
(p=0.302) (p=0.747) (32%T)
Testosterone (ng/ml) 1.29 ± 1.09 1.91 ± 1.47
(p=0.0243) (p=0.0001) (48%t)
Table 4.3.10c: Mean concentrations of FSH, inhibin B, LH and testosterone before and
after a 30 minute GnRH pulse for male rats treated neonatally with lOpg DES. Values
are the means ± SEM.
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4.4 In vitro study: determination of effects of neonatal DES
treatments on adult rat pituitary primary cell culture
The aim of this in vitro study was to investigate the potential long-term effects of the
neonatal DES treatments upon pituitary cells isolated from any external systems, i.e.
hormonal signals from the gonads and hypothalamus. This was achieved by
investigating the tissue excision and cell sub-culture conditions required for an efficient
maintenance of anterior pituitary cells in a temporary primary tissue culture system.
This would enable us to evaluate directly if there were any chronic effects of neonatal
DES treatment on adult pituitary cells in culture conditions, separated from non-pituitary
hormonal feedback mechanisms.
As there was no specific pituitary primary cell culture method established at this present
time within this Unit, numerous modifications of methodology for pituitary cell
dispersal and culture were made, as outlined in section 4.4.1. The first aim of this study
was to demonstrate that a viable anterior pituitary cell sub-culture primary population
could be generated from tissue removed from a single animal, as this would allow us to
examine each rat individually both in vivo and in vitro. This would enable us to
eliminate any potential animal-based variability as each rat typically can display
divergent basal levels of gonadotrophins and hence any small DES-induced effects could
be missed due to inter-animal variability. Despite numerous attempts we have
demonstrated that typically one anterior pituitary gland failed to elicit sufficient tissue to
result in enough viable cells (bearing in mind that only 10% of pituitary cells are
gonadotrophs) to produce and secrete sufficient amounts of LH and FSH that were
within the detection limits of the gonadotrophin RIA. However upon modification of
the general protocol, by randomly pairing rats from each treatment group, we were able
to recover sufficient primary tissue-viable cells from which gonadotrophin hormones
could be measured. Employing this experimental paradigm we were able to retrieve
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viable pituitary gonadotrophs that demonstrated similar morphology to gonadotroph cell
lines (e.g. L(3T2 cells) in sub-culture and could be shown to contain gonadotrophin
hormones. Another important reason for minimizing the number of pituitaries used for
cell culture was the often limited number of suitable experimental animals. One primary
factor involved in this was connected with the early treatment regimes, i.e. with neonatal
treatments there was a high mortality rate of pups injected with compounds. It is
therefore evident that there were multiple technical problems to surmount, however with
the modifications made in the tissue excision and sub-culture techniques, it was found to
be possible to adequately produce primary culture tissue from only two adult rat anterior
pituitary glands.
As it has been shown previously that GnRH and activin (either separately or combined)
treatments can stimulate murine L(3T2 cells (a gonadotroph cell line established from
male murine pituitary) to produce and secrete LH and FSH (Pernasetti et al., 2001; Liu
et al., 2002; Nicol et al., 2002), it was decided to test whether this too was the case for
primary pituitary cells and whether the neonatal DES treatments would interfere with
pituitary responsiveness to GnRH and/or activin. Activin (and its counterpart inhibin) is
a member of the transforming growth factor-(3 family and it plays an important role in
the modulation of hormone secretion from pituitary gonadotrophs. Activin stimulates
the synthesis of FSH (Ling et al., 1986) whereas inhibin represses the synthesis of FSH
in the pituitary (Carroll et al., 1989; Vale et al., 1992). Activin is secreted by the gonads
and within the pituitary gland, where it acts as an autocrine and/or paracrine regulator of
the reproductive axis (Mathews, 1994).
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4.4.1 Cell culture methodologies
Adult rats were sacrificed as previously described in the general methods section
(Chapter 2). Before individual whole anterior pituitaries were removed using autoclaved
surgical instruments, both the rats and the surrounding bench area were swabbed
thoroughly with 70% ethanol. Each surgical instrument was soaked in 70% ethanol
before use on each rat to minimise the risk of transferring an infection into the cell
culture system. The pituitaries were placed in ice-cold (4°C) tissue culture media for
transportation back to the cell culture facility. All processing took place in a laminar
flow sterile tissue culture hood and dedicated primary culture room.
Initially primary cell cultures were maintained in 12-well plates for up to a week.
Elowever, after the first 2 days LH and FSH levels were barely detectable by RIA.
Hence it was decided to only culture cells short-term and use assay media from the first
day of culture for comparisons between controls and treated. Basal LH and FSH output
from these cells was measured to investigate whether the neonatal DES treatment would
have any long-term effect on the function of primary pituitary cells in culture.
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4.4.2 Methodologies for primary pituitary cell culture set-up
The numerous methods tested for pituitary cell dispersion and cell culture are
summarized in Table 4.4.2.






20-60mg trypsin (with or
without heating at 37°C for 5
minutes)





12-well plates coated with
Matrigel
Enzymatic: 20mg trypsin and
20mg DNase, heated at 37°C
for 5-10 minutes
12-well plates coated with
poly-L-lysine
Enzymatic and Mechanical
cell dispersion: Using scalpel




Table 4.4.2: Summary of methods attempted to set up primary pituitary cell culture.
The final pituitary cell culture method found to successfully isolate and maintain the
largest amount of viable cells will be detailed in section 4.4.2.3 of this chapter.
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4.4.2.1 Pituitary gland volume and eventual cell retrieval
As part of the preliminary studies of the pituitary primary cell culture system the relative
effects of the number of initial whole pituitaries upon the eventual total cell retrieval in
sub-culture was assessed. The eventual number of viable cells retrieved upon day 1
from the specific number of pituitary gland was measured using a Trypan Blue dye to
differentiate between viable and non-viable cells. As can be seen from Table 4.4.2.1, it
was evident that when the initial amount of pituitary tissue used was high, i.e. 4-5
pituitaries, a much greater viable cell yield was attained. Presumably this may be due to
an effect in which during the mechanical dispersal process large pieces of tissue would
initially show signs of deterioration at their edges while the cells at the core of the tissue
remained relatively healthy. It would have been ideal if 5 to 6 pituitaries for each
primary pituitary cell culture could have been used, however due to the lack of animals
available, especially animals treated neonatally with specific compounds such as DES,
two pituitaries were used for each primary pituitary cell culture. However it was found
that with only two pituitaries a sufficient amount of cells could be retrieved with which
sufficient experiments could be performed.
Males Females
Number of pituitaries
Number of viable cells/ml Number of viable cells/ml
1 4 x 105 6 x 105
2 8 x 105 13 x 105
4 29 x 105 36 x 105
5 37 x 10s 46 x 105
Table 4.4.2.1: Average number of viable adult male and female rat pituitary cells
isolated from 1-5 pituitaries.
An interesting phenomenon noted during the set-up of this primary pituitary cell culture
system was that there was always a higher number of viable cells isolated from female
rat pituitaries than from male pituitaries (Table 4.4.2.1). There were usually
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approximately 25% more viable cells isolated from female pituitaries than from male
pituitaries. The reason for this difference is unclear as there was no significant variation
in size between male and female rat pituitaries (visual assessment of pituitaries showed
that male rat pituitaries tended to be slightly larger than female pituitaries, but not
significantly) and the male and female pituitaries were processed in exactly the same
manner. However, this difference in the number of cells isolated from male and female
rat pituitaries did not affect the primary pituitary cell culture as the same number of cells
was plated out (onto 12-well plates) for both male and female rats, thus a direct
comparison could be made between them.
4.4.2.2 Effect of temperature upon pituitary cell retrieval
Since it was found that two whole pituitary glands supplied a sufficient number of
pituitary cells in sub-culture for experimentation, it was then investigated whether
treating the cells/tissues post animal excision at 4°C would cause any significant cell
mortality. Therefore two pituitaries were transported back to the cell culture facility
either at body core temperature (37°C) or at 4°C. It was noted that there was not any
appreciable loss of cell viability by transferring the tissue to 4°C. As can be seen in
Table 4.4.2.2, the dispersal and isolation at body core temperature resulted in retrieval of
less viable cells than when processed at 4°C. Thus it appears that reducing tissue
temperature increased the amount of retrieved tissue after removal from rat body core
temperature, possibly this was due to a reduction in cell death mediated by excessive
calcium influx inducing excitotoxic apoptosis.








Ice (4°C) 2 7 x 105 12 x 105
Room temperature 2 5x 105 7 x 105
Table 4.4.2.2: Comparison of storage methods for transporting isolated pituitaries back
to the cell culture facility.
4.4.2.3 Final method used for pituitary cell culture and treatments
administered to cells
The method found to yield the highest number of viable cells post excision was the
following. Two whole pituitaries, stored on ice, were mechanically dispersed using
syringes with 9-12 gauge needles attached. Cell clumps were passed through each
syringe 2 times in total. Subsequently, the cell suspension was centrifuged at lOOOg for
15 minutes at 4°C. The supernatant was aspirated off to remove cell debris and the cell
pellet was resuspended in 12ml of DMEM-F12. Adequate pellet resuspension was
obtained by passing the pellet and media 5 times through a syringe with 15 gauge needle
attached. Viable primary cultured anterior pituitary cells from two whole pituitaries were
counted (as detailed in Chapter 2) and then equally distributed between each well of a
12-well Matrigel coated culture plate. The cells were found to adhere to Matrigel coated
plates more rapidly than to Poly-L-lysine coated plates or uncoated plates. Matrigel
basement membrane matrix is a solubilised basement membrane preparation extracted
from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumour rich in extracellular
matrix proteins. Its major component is laminin, followed by collagen IV, heparan
sulfate proteoglycans, entactin and nidogen. It also contains TGF-beta, fibroblast
growth factor and tissue plasminogen activator. Matrigel has been shown to be very
effective for the attachment and differentiation of many cell types, including Sertoli cells
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and vascular endothelial cells. The pituitary cells were allowed to attach overnight to
the artificial cell matrix before any hormonal culture addition was made. All cells were
maintained in fetal calf serum-containing Dulbecco's modified Eagles medium, at 37°C
and 5% C02. Cells were left overnight to attach to the plates and stabilize. After
overnight culture, medium was removed and replaced with either fresh DMEM-F12
medium (controls), medium containing 20ng or 50ng activin, medium containing lOnM
GnRH or lOOnM GnRH, for 30 minutes, or medium containing 20ng or 50ng activin +
lOnM or lOOnM GnRH, for 30 minutes. The media was removed after 30 minutes and
was replaced with either DMEM-F12, or with DMEM-F12 + activin for the activin
treated cells. At the end of the day, media was collected from each well and was stored
at -20°C for subsequent LH and FSH RIA. The treatments and doses administered to the
cells are summarised in Table 4.4.2.3.
Hormonal treatment Dose administered Duration of treatment
Activin 20ng Continuously in culture
medium. Culture medium
changed daily.50ng
GnRH lOnM One GnRH pulse daily, for
30 minutes.
lOOnM
Activin + GnRH 20ng + lOnM Activin continuously in
culture medium + one




Table 4.4.2.3: Outline of hormonal treatments, doses and duration of treatment
administration.
All these treatments were administered to cells from control animals. As the lOnM
GnRH + 20ng of activin dose showed the best response in the cells (see Sections 4.4.3.1
and 4.4.3.2), all cells obtained from DES treated animals were administered these doses.
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4.4.2.4 Maintenance of primary cultured pituitary cells
The adult pituitary cells in culture were examined and photographed using a digital
camera (Kodak DCS330, Kodak USA) on days 2, 4 and 6 of culture, as depicted in
Figure 4.4.2.4a. On day 2 of culture, the cells were small and relatively round in
appearance. However after 4 days of culture many cells were more elongated and there
tended to be clusters of cells. After 6 days in culture, the cells were much larger and
more elongated and a heterogenous cell population was visible, with some cells being
oval shaped whereas others were elongated and tended to form clusters.
Mature gonadotroph cells are typically known to be bi-hormonal (Liu et al., 1988,
Currie and McNeilly 1995; Thomas and Clarke 1997). Thus, to investigate whether the
pituitary cells obtained in primary culture contained adequate numbers of gonadotroph
cells and to test whether these gonadotrophs had maintained their bi-hormonal nature
(i.e. contained both LH and FSH) in culture, the cultured pituitary cells were
immunostained on day 6 of culture for LH and FSH using TRITC and FITC fluorescent
markers. The methods used for immunofluorescent staining for LH and FSH in
gonadotrophs is detailed in Chapter 2.
Figure 4.4.2.4b depicts immunofluorescent staining for LH and FSH in vivo, in an adult
rat pituitary. Panel A shows fluorescent staining for LH, panel B shows staining for
FSH whereas panel C shows dual immunofluorescent staining for both LH and FSH,
demonstrating that both hormones are co-expressed within the same gonadotroph cell.
Figure 4.4.2.4c shows immunofluorescent staining at day 6 for adult primary cultured
pituitary cells. Panels A and C are phase-contrast pictures showing the gonadotroph cell
morphology. Panels B and E show immunofluorescent staining for LH and panels D
and F depict cells stained for FSH. Panel G shows a gonadotroph cell dual stained for
LH and FSH. This confirms that the bi-hormonal nature of gonadotroph cells is
maintained in culture and can be maintained for up to 6 days in culture.
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Figure 4.4.2.4a: Pituitary cell growth and morphology on day 2 (A), day 4 (B) and day
6 (C) of culture.
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Figure 4.4.2.4b: Immunofluorescent staining in an adult rat pituitary, A depicts single
staining for LH, B shows single staining for FSH and C shows dual staining for both LH
and FSH. Thus in vivo, LH and FSH are co-localised in gonadotrophs.
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Figure 4.4.2.4c: Immunofluorescent staining in cultured pituitary cells (day 6 of
culture). Panels A and C are phase-contrast pictures to depict cell morphology, panels B
and E show immunofluorescent staining for LH, D and F show staining for FSH and
panel G shows dual staining for LH and FSH. This confirms that gonadotrophs maintain
their bi-hormonal nature after 6 days of culture.
Chapter 4 Effect of neonatal DES on adult male and female pituitary cell culture 153
4.4.3 Measurement of LH and FSH from cells
The concentrations of LH and FSH in the cell culture media were measured by RIA, as
described in detail in Chapter 2. However, since most of the cell culture samples were
initially not within the detection limits of the RIA, the protocol had to be altered to some
extent. LH values were typically higher than the highest value on the standard curve,
whereas FSH levels were typically much lower than the lowest value on the standard
curve. Numerous dilutions were tested for the LH samples, including a 1:6 and a 1:24
dilution of the sample in assay buffer. Eventually a 1:12 dilution was found to be most
suitable as all the values read on the standard curve. As many samples were small in
volume (0.5ml), a different approach was first tried for FSH. This involved freeze-
drying the cell culture medium samples overnight and re-suspending the pellets in assay
buffer to reconstitute the samples. This made the samples more concentrated and hence
the values were within the detection limit of the assay. However, this method was
elaborate and time consuming, as only a small number of samples could be freeze-dried
at one time and each sample had to be reconstituted with assay buffer. Thus this
approach was not feasible for use with a large number of samples to be assayed. Hence,
a series of dilutions was tried and tested, including a 1.5-, 2-, and 3-fold increase in
sample concentration. The 3-fold more concentrated samples were found to lie within
the detection limits of the RIA and hence this dilution was applied to all the FSH
samples.
Culture media collected from day 1 to day 10 from control rat cells, isolated from two
pituitaries, were assayed for LH and FSH. This is depicted in Figures 4.4.3.1 and
4.4.3.2.
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4.4.3.1 LH levels in cell culture medium
LH concentrations were measured for cells isolated from 2 adult male or female
pituitaries maintained in culture for 10 days (Figure 4.4.3.1a). Media was collected and
changed daily and was assayed for LH by RIA. On the first day of culture LH levels
were in the range of 25ng/ml. However on day 2 of culture LH levels had almost
halved, to approximately 14ng/ml. After 3 days in culture, the LH levels were at the
lower end of the detection limit of the RIA. As LH is mainly stored within
gonadotrophs and produced and secreted mainly in response to GnRH (Burgess and
Kelly, 1987), this suggests that the gonadotroph cells were emptying their LH stores on
day one, hence the high concentration of LH in the culture medium. However, as LH
levels were very low after 3 days in culture, this could suggest that no LH was being
synthesised de novo by the gonadotrophs once they were removed from the donor
animal. This observation was made for primary pituitary cells cultured from both adult






Figure 4.4.3.1a: Mean LH concentrations for primary pituitary cells isolated from 2
male control adult pituitaries (day 90), cultured for 10 days. Values are means ± SEM.
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Male primary pituitary cells were also treated with activin and/or GnRH to test whether
these treatments would stimulate LEI production and secretion. However, these
treatments were not found to significantly stimulate LH secretion from these primary
pituitary cells (Figures 4.4.3. lb-e).
■ Basal LH levels
40
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Figure 4.4.3.1b: Mean LH concentrations for male primary pituitary cells isolated from
2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes with
lOnM GnRH. Values are the means ± SEM.
Figure 4.4.3.1c: Mean LH concentrations for male primary pituitary cells isolated from
2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes with
lOnM GnRH +20ng activin. Values are the means ± SEM.
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Figure 4.4.3.1d: Mean LH concentrations for male primary pituitary cells isolated from
2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes with
lOOnM GnRH. Values are the means + SEM.
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Figure 4.4.3.1e: Mean LH concentrations for male primary pituitary cells isolated from
2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes with
lOOnM GnRH + 50ng activin. Values are the means ± SEM.
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4.4.3.2 FSH levels in cell culture medium
FSH concentrations were measured for cells isolated from 2 adult male or female
pituitaries maintained in culture for 10 days (Figure 4.4.3.2a). Media was collected and
changed daily and was assayed for FSH by RIA. On the first day of culture FSH levels
were in the range of 7ng/ml. This was significantly lower than the FH levels measured
for these cells. Similarly to FH concentrations, as from day 3 media FSH concentrations
were at the lower end of the detection limit of the RIA. This suggests that there was no
steady state release of FSH. It is known that FSH is largely secreted from gonadotrophs
via a constitutive pathway, this means that FSH is not stored within gonadotrophs, but is
secreted from the cell in a continuous manner. FSH release is also not directly
controlled by GnRH (Childs et al., 1994; Farnworth 1995). This observation was made
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Figure 4.4.3.2a: Mean FSH concentrations for primary pituitary cells isolated from 2
male control adult pituitaries (day 90), cultured for 10 days. Values are means ± SEM.
Chapter 4 Effect of neonatal DES on adult male and female pituitary cell culture 158
The FSH levels in the media were measured for these cells after the activin and GnRH
treatments. Similarly for LH, these hormonal treatments were not found to significantly
stimulate the production and release of FSH from the primary pituitary cells.
I —T-^ 1^ 1^ 1
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Figure 4.4.3.2b: Mean FSH concentrations for male primary pituitary cells isolated
from 2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes
with lOnM GnRH. Values are the means ± SEM.
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Figure 4.4.3.2c: Mean FSH concentrations for male primary pituitary cells isolated
from 2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes
with lOnM GnRH + 20ng activin. Values are the means ± SEM.
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Figure 4.4.3.2d: Mean FSH concentrations for male primary pituitary cells isolated
from 2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes
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Figure 4.4.3.2e: Mean FSH concentrations for male primary pituitary cells isolated
from 2 control adult pituitaries, cultured for 3 days and stimulated daily for 30 minutes
with lOOnM GnRH + 50ng activin. Values are the means ± SEM.
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4.4.3.3 LH and FSH mRNA in primary pituitary cells
Reverse transcriptase PCR was used to determine mRNA levels for LH, FSH and GnRH
receptor I, for primary pituitary cells obtained from 2 male or 2 female rat pituitaries and
cultured for 6 days (Figures 4.4.3.3a and b), without the addition of any hormonal
treatments. The methods used for PCR are outlined in Chapter 2. After 6 days in
culture mRNA could still be detected for LH, FSH and GnRH receptor I in primary
pituitary cells from both males and females. Primary pituitary cells cultured from female
pituitaries tended to have more mRNA for LH and GnRH receptor type I than primary
pituitary cells cultured from adult male pituitaries.
Figure 4.4.3.3a: mRNA in male primary pituitary cells for GAPDH (A), FSH
(28kDA)(B), LH (28kDa) (C) and GnRH receptor I (38kDa) (D).
Figure 4.4.3.3b: mRNA in female primary pituitary cells for FSH (28kDa)(A), LH
(28kDa) (B), and GnRH receptor I (38kDa) (C).
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4.4.4 LH and FSH levels in primary pituitary cells cultured from rats
treated with DES neonatally
LH and FSH concentrations were assayed on day 1 of culture for both male and female
adult control pituitary cells and cells from adult animals treated neonatally with DES.
The cell culture medium was collected from the cells after they had been in culture for
23.5 hours and was replaced with fresh media. Subsequently, a 30 minute lOnM GnRH
pulse was administered to the cells and that media too was collected for subsequent
gonadotrophin RIA. Both the basal LH/FSH levels (after 23.5 hours of culture) and
LH/FSH levels after a 30 minute lOnM GnRH pulse were measured by RIA. After 23.5
hours in culture, there was no significant difference in LH levels between cells from
control rats and cells from DES treated rats, even with treatment with activin or GnRH
or with activin co-stimulation with GnRH. This was the case for both male and female
primary pituitary cells (Figures 4.4.4 a and c). However, basal LH levels were almost 4-
fold higher in cells isolated from male pituitaries (for both control pituitaries and DES
treated) than in cells isolated from female pituitaries. After an acute stimulation for 30
minutes with lOnM GnRH, low levels of LH were secreted in that period of time
(approximately 12ng/ml for males and 9ng/ml for females) in response to GnRH, but
there was no significant difference between the various treatment groups in their
response to a GnRH pulse.
When the basal measurements for the other major gonadotrophin, FSH, were made from
the same series of experiments it was also noted that despite the presence of viable cells,
immunoreactive for both gonadotrophin hormones (and highly characteristic of
functional gonadotrophs), there was also no significant effect for the cells isolated from
control rats and cells isolated from DES treated rats, even with treatment with activin or
GnRH or with activin co-stimulation with GnRH. This was the case for both male and
female primary pituitary cells (Figures 4.4.4b and d). However, basal FSH levels were
Chapter 4 Effect of neonatal DES on adult male and female pituitary cell culture 162
significantly higher in cells isolated from male rats (for both control and DES treated
rats) than in cells isolated from female rats. Similarly to LH, after a 30 minute GnRH
pulse there was a small quantity of FSH produced but there was no significant difference
between the different treatment groups.
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Figure 4.4.4.a: LH levels in male primary pituitary cells before and after a 30 minute
lOnM GnRH challenge. Values are the means ± SEM. A=control, B=activin, C=GnRH,
D=activin + GnRH. Red bars are control, blue O.lpg DES and green bars lOjig DES.
Units are ng/ml.
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Figure 4.4.4b: FSH levels in male primary pituitary cells before and after a 30 minute
lOnM GnRH challenge. Values are the means ± SEM. A=control, B=activin, C=GnRH,
D=activin + GnRH. Red bars are control, blue O.lpg DES and green bars 10p,g DES.
Units are ng/ml.
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Figure 4.4.4.c: LH levels in female primary pituitary cells before and after a 30 minute
lOnM GnRH challenge. Values are the means ± SEM. A=control, B=activin, C=GnRH,
D=activin + GnRH. Red bars are control, blue 0.1|lg DES. Units are ng/ml.
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Figure 4.4.4.d: FSH levels in female primary pituitary cells before and after a 30 minute
lOnM GnRH challenge. Values are the means ± SEM. A=control, B=activin, C=GnRH,
D=activin + GnRH. Red bars are control, blue 0. lpg DES. Units are ng/ml.
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4.4.5 Co-culturing primary pituitary cells with hypothalamic GnRH
producing GT1-7 cells
As 'manual' stimulation of the pituitary cells in culture with GnRH did not have an
apparent effect on LH and FSH secretion, it was decided to co-culture the adult primary
pituitary cells with hypothalamic GnRH-producing neuronal cells (GT1-7 cells), to
determine whether the pulsatile release of GnRH that occurs from these neuronal cells in
culture (Krsmanovic et al., 2000) would act as a better stimulus to maintain LH and FSH
secretion from the primary pituitary cells in culture. GT1-7 cells are a neuronal cell
population established through a targeted tumorigenesis approach (Mellon et al., 1990;
Radovick et al., 1991). This involved establishing stable cell lines by expressing a
potent viral transforming protein (i.e. the simian virus 40 large tumour antigen) in GnRH
neurons. Three cell lines (i.e. the GT1 lines including GT1-1, GT1-3 and GT1-7) were
derived from a female transgenic mouse that developed a forebrain tumour (post-
migration of the GnRH neurons) (Mellon et al., 1990). Cells within each of the GT1
subclones are homogenous, in that they all stain for GnRH (Mellon et al., 1990; Liposits
et al., 1991). The GnRH gene is expressed and the precursor protein is processed into
active GnRH (Wetsel et al., 1991; Weiner et al., 1992; Gautron et al., 1995). Recently,
GT1 cells have also been shown to co-express a low proportion of a second GnRH gene
(GnRH-II) (Chen et al., 2001). The secretion of GnRH from GT1 neurons is dependent
on external Ca2+ (Krsmanovic et al., 1992). GT1 cells in culture form networks
interconnected by synapse-like contacts (Mellon et al., 1990; Liposits et al., 1991;
Wetsel et al., 1992), gap junctions (Matesic et al., 1993; Hu et al., 1999), and tight
junctions (Liposits et al., 1991). They are highly differentiated, retaining many
characteristics of GnRH neurons in vivo (Liposits et al., 1991; Weiner et al., 1992),
including the expression of a variety of plasma membrane channels that endow them
with the ability to fire spontaneous action potentials (Mellon et al., 1990; Weiner et al.,
1992; Charles & Hales, 1995). In addition, GT1 cells have been found to further
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differentiate in situ and to restore reproductive function in adult hypogonadal (hpg) mice
following their direct introduction into the brain (Silverman et al., 1992). Thus, GT1
cells have been shown to be a successful model to investigate the hypothalamic-pituitary
feedback loop.
GT1-7 cells were grown on 12mm diameter inserts with 0.4|im pore size, as described in
Chapter 2, and placed in each well (over the pituitary cells, but not in direct contact) of
the 12-well plate, as shown in Figure 4.4.5a.
Figure 4.4.5a: Diagram depicting how inserts containing the hypothalamic GT1-7 cells
were placed above the primary pituitary cells, in each well of a 12-well plate.
The GT1-7 neuronal cells were plated out at different densities onto the inserts,
including 1 x 104 cells/ml, 5 x 104 cells/ml, 1 x 105 cells/ml, and 5 x 105 cells/ml. The
pituitary cells were plated out at a density of 7 x 10s cells/ml. Media was aspirated off
daily (and stored at ~20°C for subsequent LH and FSH analysis) and was replaced with
fresh media.
Insert
GT1-7 cells on insert
Pituitary cells
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4.4.5.1 LH and FSH levels in pituitary cells co-cultured with GT1-7 cells
LH and FSH levels were measured for male pituitary cells co-cultured with the GT1-7
cells plated out at the four different densities (Figures 4.4.5.la-h). As for the 'manual'
stimulation with GnRH, there was found to be no increase in LH (or FSH) levels after
the co-culture with the GnRH-producing neurons. There was also no significant
difference in LH (or FSH) levels for the different cell densities of GT1-7 cells. It is
possible that there were small changes in gonadotrophin levels in response to the
pulsatile release of GnRH from the GT1-7 cells, but that these were not apparent as
many of the gonadotrophin values measured were at the lower end of the sensitivity
scale of the RIA.
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Figure 4.4.5.1a: Mean LH concentrations for male pituitary cells (7 x 10s cells/ml) co-
cultured for 5 days with hypothalamic GT1-7 cells (1 x 104 cells/ml). Values are the
means ± SEM.
Figure 4.4.5.1b: Mean LH concentrations for male pituitary cells (7 x 105 cells/ml) co-
cultured for 5 days with hypothalamic GT1-7 cells (5 x 104 cells/ml). Values are the
means ± SEM.
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Figure 4.4.5.1c: Mean LH concentrations for male pituitary cells (7 x 105 cells/ml) co-
cultured for 5 days with hypothalamic GT1-7 cells (1 x 105 cells/ml). Values are the
means ± SEM.
Figure 4.4.5.1d: Mean LH concentrations for male pituitary cells (7 x 105 cells/ml) co-
cultured for 5 days with hypothalamic GT1-7 cells (5 x 105 cells/ml). Values are the
means ± SEM.
Figure 4.4.5.1e: Mean FSH concentrations for male pituitary cells (7 x 105 cells/ml) co-
cultured for 5 days with hypothalamic GT1-7 cells (1 x 104 cells/ml). Values are the
means ± SEM.
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Figure 4.4.5.1f: Mean FSH concentrations for male pituitary cells (7 x 105 cells/ml) co-
cultured for 5 days with hypothalamic GT1-7 cells (5 x 104 cells/ml). Values are the
means ± SEM.
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Figure 4.4.5.1g: Mean FSH concentrations for male pituitary cells (7 x 105 cells/ml) co-
cultured for 5 days with hypothalamic GT1-7 cells (1 x 105 cells/ml). Values are the
means ± SEM.
Figure 4.4.5.lh: Mean FSH concentrations for male pituitary cells (7 x 105 cells/ml)
co-cultured for 5 days with hypothalamic GT1-7 cells (5 x 10s cells/ml). Values are the
means ± SEM.
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4.4.5.2 Expression of GnRH receptor I in primary pituitary cells
It is possible that there was a potential functional deficit in the primary cultured cells in
that they appeared phenotypically correct yet, they seemed refractory to external GnRH
stimulation. One possible explanation for this could be the loss of GnRH receptor
protein from the membrane of the excised cells. The presence of mRNA has been
shown for the receptor (Figures 4.4.3.3a and b), this was however purely qualitative and
may not be directly correlated to the level of receptor protein present. Thus the lack of
appropriate control of receptor turnover, induced by removal of tissue from its native
condition, may have resulted in a rapid loss of receptor expression at the membrane, and
hence affected the cells' ability to respond to GnRH pulses. Therefore, the presence of
GnRH receptor on the primary pituitary cells and on LpT2 cells was investigated by
Western Blot analysis. The LPT2 gonadotroph cell line was used as a positive control as
L^T2 cells are known to express the GnRH receptor (Persanetti et al., 2001). The
GnRH receptor antibody was a gift from K. Catt (Krsmanovic et al., 1992).
A Western Blot was performed using LPT2 cells and primary pituitary cells from control
adult male rats. The Western Blot was performed as follows. LPT2 cell monolayers were
placed on ice, washed once with ice-cold Dulbecco's phosphate buffered saline (DPBS,
Sigma, UK) and lysed in an NP-40 based solubilisation buffer (250mM NaCl, 50mM
HEPES, 0.5% Nonidet-P-40 (NP-40), 10% glycerol, 2mM EDTA, pH 8.0 supplemented
with ImM sodium orthovanadate, ImM phenylmethysulphonyl fluoride and 1 jlg/ml
leupeptin). Solubilised lysates were clarified by centrifugation at 15000rpm for 15
minutes and diluted to an approximate concentration of lmg/ml protein. Protein content
was extracted from the cells cultured from two adult male rat pituitaries, as described in
detail in Chapter 2. Subsequently, a 40p,l aliquot of the clarified cell lysates was mixed
with an equal volume of 2x Laemmli sample buffer (8% SDS, 5% 2-P-mercaptoethanol,
10% glycerol, 25mM Tris pH 7.0, and a few grains of Bromophenol blue, Sigma, UK),
and were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The
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proteins from the gel were then electrotransferred to a polyvinylenedifloride (PVDF,
NEN Life Sciences, UK) membrane. The membrane was blocked for 1 hour at room
temperature with 4% BSA TBS-T blocking solution (150mM NaCl, lOmM Tris pH 7.0,
0.05% v/v Tween-20, and 0.05% v/v NP-40, Sigma, UK) before incubation for 1 hour
with a 1:1000 dilution of the anti-GnRH serum (gift from Kevin Catt, Bethesda, USA) in
the 4% BSA TBS-T solution. The antibody was washed off (5 washes for 5 minutes) in
TBS-T wash buffer, and was visualised by incubation with the secondary antibody, anti-
rabbit alkaline Phosphatase conjugate (1:10000, Sigma, UK) for 1 hour at room
temperature. Proteins were finally visualised by enzyme-linked chemifluorescence
(Amersham Pharmacia Biotech, UK) and were scanned using a Typhoon
phosphorimager.
The Western Blot analysis for the GnRH I receptor in primary pituitary cells and L|3T2
cells (Figure 4.4.5.2) showed that the GnRH I receptor was present in control L(3T2
cells, however only a very small amount was present in the primary pituitary cells. This
suggests that there may have been a loss of receptor expression on the membrane, which
could be a reason why there was no LH release in the primary pituitary cells in response
to GnRH (+ activin) treatment.
Figure 4.4,5.2: Western Blot analysis for the GnRH I receptor in whole cell lysates
from control L(TT2 cells and adult male rat primary pituitary cells.
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4.5 Discussion
The aims of these studies was to determine whether neonatal treatment with DES could
have direct effects on the function of pituitary gonadotroph cells, and to test whether
DES would have differential effects on male and female pituitary function. Both in vivo
and in vitro experiments were performed to test this hypothesis.
The data gathered from the in vivo part of this study confirmed that neonatal DES
treatment had life-long effects on circulating gonadotrophin levels in male rats. These
results confirm the observations made during the male DES study, as described in
Chapter 3 of this thesis. In the adult male rats, plasma FSE1 levels were found to be
elevated significantly for both doses of DES (0.1 p.g DES p<0.05; 10|ig DES p<0.01),
and after a 30 minute GnRH pulse the plasma FSH levels still showed the same basic
pattern as before the GnRH challenge, but there was no significant increase in plasma
FSH in response to GnRH. This corresponds with the present literature (Farnworth,
1995; Padmanabhan and McNeilly, 2001), in that FSH release from the pituitary gland is
not under direct control of GnRH. Interestingly however, DES treated females showed
no significant change in basal plasma FSH levels, in direct contrast to the DES treated
males. This demonstrates that DES treatment exerted a differential effect on male and
female circulating FSH concentrations. It appears therefore that male plasma FSH levels
are more susceptible to long-term disruption by DES than female plasma FSH levels.
In males, basal plasma LH levels showed the same pattern as basal FSH levels, in that
the LH levels were elevated significantly for the DES treated rats (0.lp.g DES p<0.05;
10|ig DES p<0.001). After the 30 minute GnRH challenge, there was an increase in
plasma LH levels, which was expected since it is known that LH is stored intracellularly
and is released mainly from the gonadotroph cells in response to pulses of GnRH via a
regulatory secretory pathway (Burgess and Kelly, 1987). However, the DES treated
Chapter 4 Effect of neonatal DES on adult male and female pituitary cell culture 175
males showed a considerably attenuated response to the GnRH pulse than the control
males. In control males plasma LH levels increased by 67% in response to GnRH
whereas in the DES treated males there was only a 30% increase in plasma LH levels in
response to GnRH. This demonstrates that in some manner the neonatal DES treatment
had altered the pituitary responsiveness to GnRH in these adult male rats. There are
several possible causes for such a phenomenon. For example, it has been demonstrated
that oestrogenic agents (especially in combination with progesterone) can attenuate the
expression of GnRH receptor on pituitary gonadotroph cells (Cheon et al., 2001; Kang et
al., 2001; Sun et al., 2001). Thus from the literature it appears that GnRH receptor
down-regulation is a likely cause for this phenomenon. Surprisingly, in females the
neonatal DES treatment showed no significant effect on basal plasma LH levels.
However, similarly to the males, the neonatal DES treatment was found to decrease
pituitary responsiveness to GnRH in females, as the DES treated females showed a
significant decrease (30% less) in their pituitary responsiveness to GnRH compared to
control females. This suggests that DES treatment not only had life-long effects on
basal gonadotrophin levels in male rats, but also that neonatal DES treatment decreased
the ability of the pituitary gonadotroph cells to secrete LH in response to GnRH in both
male and female DES treated rats. These results again correlate with studies also
performed by Register et al., and Faber et al., that showed that neonatal DES treatment
blunted LH secretion in response to a GnRH challenge (Register et al., 1995; Faber et
al, 1993).
The effects of neonatal DES treatment were also studied on the plasma levels of the
gonadal hormone inhibin B. It was noted that the circulating concentrations in the DES
treated males were significantly suppressed compared to control males (0.1 [ig DES
p<0.01; 10pg DES p<0.05). These findings reinforce the observations made previously
in Chapter 3, in that plasma inhibin B levels were significantly reduced in male DES
treated rats. This may potentially be due to a reduction in Sertoli cell proliferation in the
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testis caused by neonatal DES treatment (Sharpe, 1994). The reduced levels of Sertoli
cells in the adult testis then resulted in suppressed circulating levels of inhibin B. When
we compared the effects of DES upon plasma inhibin B levels in the females to the
males, we again showed that the DES treatment failed to alter the inhibin B levels while
causing a significant suppression in the males. Serum inhibin B levels are often used as
a direct indicator of testicular function due to its primary testicular origin. Diminished
serum inhibin B levels are therefore highly indicative of male gonadal dysfunction (Yalti
et al., 2002). Therefore the potential reduction of Sertoli cell proliferation, shown to be
induced by potent oestrogenic compounds (Sharpe, 1994) would result in a diminution
of testis cell types and general size (as shown in Chapter 3). Therefore, it seems most
likely that the DES treatment had profound effects on the male gonads while not
exerting such a detrimental effect on their growth in the female, and this could be the
primary cause in differences in circulating levels of inhibin B. Thus to address this
further, the plasma levels of testosterone were measured to reinforce the findings that
DES has caused significant male gonad dysfunction. It was found that (as would have
been expected) the plasma levels of testosterone were significantly suppressed in the
DES treated male rats (p<0.001).
During the set-up of the primary pituitary cell culture system, one interesting and
consistent observation was made, in that adult female pituitaries always yielded a higher
number of viable cells than adult male pituitaries, after extraction from the animal.
Generally there were approximately 25% more viable cells isolated from female
pituitaries than from male pituitaries. It is presently unclear why this is the case as the
pituitaries were treated in exactly the same manner. In addition, upon visual observation
we found that there was no significant difference in the original size of male and female
pituitaries. Again, fluorescent analysis of the cultured pituitary cells showed that the
cells maintained their bi-hormonal nature in culture, as the majority of pituitary cells in
vivo are known to contain both LH and FSH (Liu et al., 1988; Currie and McNeilly,
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1995; Thomas and Clarke, 1997). Initially LH and FSH levels were assayed from days 1
to 10 of culture, however after 3 days of culture the gonadotrophin levels were at the
lower end of the detection limit of the RIA. Therefore it was decided to measure LH
and FSH levels on day 1 of culture for the pituitary cells cultured from the DES treated
animals. Interestingly, there was found to be no significant difference in gonadotrophin
levels between cells from control animals and cells from neonatally DES treated
animals. Even treatment with GnRH and/or activin, which has been shown to stimulate
LH (and FSH) release from both primary pituitary cells and L(3T2 cell lines (Pernasetti
et al., 2001; Liu et al., 2002; Nicol et al., 2002), made no difference to LH and FSH
secretion from both control and DES treated primary pituitary cells. Co-culturing the
primary pituitary cells with hypothalamic GnRH-producing cells also had no significant
effect. Therefore it appears that in accordance with the majority of our data, the
neonatal DES treatment had only small functional effects upon the anterior pituitary.
This can be surmised from the fact that there was no significant change in anterior
pituitary morphology with DES, and no loss of gonadotrophin hormones from the
pituitary. However, it appears that there was potentially a subtle effect upon the anterior
pituitary, demonstrated by a reduction of anterior pituitary sensitivity to GnRH.
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Chapter five: effects of a neonatal GnRH antagonist or
GnRH antagonist with oestrogen treatment on male rat
pituitary function
5.1 Introduction
The aim of this chapter is to investigate the potential effects of neonatal treatment upon
pituitary gland function of either a long-acting GnRH antagonist alone treatment or in a
combination regimen with the potent oestrogen DES. In the first study, male rats were
treated with the long-acting GnRH antagonist Antarelix in neonatal life. Potential
transient or permanent effects on pituitary gland function were investigated by counting
the number of immunopositive gonadotroph cells shortly after treatment. In addition we
assessed if there were any effects of the treatments upon pituitary LH and FSH mRNA
levels and also the plasma levels of LH, FSH, inhibin B and testosterone in adulthood.
In parallel to this, testes data were collected from these animals by Richard Sharpe's
laboratory, including testis weight and the number of Leydig and Sertoli cells per adult
testis. This enabled potential GnRH antagonist-induced effects on anterior pituitary
gland function to be related to corresponding testes data and potential GnRH antagonist-
induced effects on the adult testes and vice versa.
We also performed an in vivo and an in vitro approach to investigate the potential long-
term effects upon the hypothalamic-pituitary-gonadal axis of neonatal GnRH antagonist
treatment combined with 0.1 p.g DES treatment. The rationale behind this study was to
examine whether neonatal DES treatment would entrain re-programming of pituitary
function in adulthood. The GnRH antagonist was administered in parallel to the DES to
block the hypothalamic GnRH output. This enabled us to shed light on any potential
DES-induced effects directly at the level of the anterior pituitary gland.
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For the in vivo experiments, male rats were treated neonatally with the GnRH antagonist
and 0.1 pg of DES. The plasma hormone levels (FH, FSH, inhibin B, testosterone) were
subsequently measured in adulthood before and after a 30 minute lOOng GnRH dose
challenge. The pituitaries were subsequently removed from these rats for primary
pituitary cell culture. The GnRH antagonist + O.lpg DES treatment regime enabled us
to directly investigate any DES-induced effects on pituitary function, without any
feedback from the testes hypothalamic stimulation. All retrieved pituitaries were
cultured and GnRH and activin treatments were administered to the primary pituitary
cells to test whether these treatment regimes would stimulate gonadotrophin secretion
from the primary cells. Media from these cells was subsequently collected and assayed
for LH and FSH.
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5.1.2 Summary of analysis methods for the male in vivo and in vitro GnRH
antagonist studies
In vivo male rat GnRH antagonist study: Investigation into the long-term effects of
neonatal treatment with the long-acting GnRH antagonist, Antarelix, on pituitary
function. The primary goals of this study were:
• Determination of basal plasma LH, FSH (by RIA), inhibin B and testosterone (by
ELISA) concentrations in adulthood (90 days of age).
• Real-Time PCR analysis of mRNA for LH and FSH in the adult male pituitary
after neonatal treatment with the GnRH antagonist Antarelix.
• Immunocytochemical analysis of LH and FSH immunopositive staining in the
pituitary, shortly after treatment with Antarelix (at 18 days of age). Unfortunately
no adult tissue was available for immunocytochemical analysis.
• Analysis of adult rat testis function, including testis weight, morphology, number
of Leydig and Sertoli cells per testis, after neonatal treatment with Antarelix,
using data obtained from Richard Sharpe's laboratory. This collaboration was to
investigate any potential effects along the pituitary-testicular axis after neonatal
treatment with a GnRH antagonist.
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In vivo and in vitro GnRH antagonist + DES study: Investigation into the long-term
effects of neonatal treatment with a low dose of DES and Antarelix (O.lpg DES + GnRH
antagonist) combined treatment on pituitary function. The main aims of this study were:
• Determination of basal plasma LH, FSH (by RIA), inhibin B and testosterone (by
ELISA) concentrations in adulthood (90 days of age).
• Assessment of changes in plasma LH, FSH, inhibin B and testosterone levels in
response to an acute GnRH dose challenge to adult rats (lOOng GnRH for 30
minutes).
• Culturing adult primary pituitary cells isolated from male pituitaries treated
neonatally with a low dose of DES and with Antarelix (0.1 jug DES + GnRH
antagonist).
• Treating primary cultured pituitary cells with activin, GnRH, or a combination of
both GnRH and activin to test whether this stimulates gonadotrophin production
by primary pituitary cells in culture.
• Measurement of basal gonadotrophin levels (RIA) secreted by these cells after
23.5 hours in culture. Administering a 30 minute lOnM GnRH challenge to
primary pituitary cells and measuring LH and FSH production in the cell culture
media in response to GnRH.
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5.2 In vivo male rat study: effects of neonatal treatment with a GnRH
antagonist or GnRH antagonist + DES on pituitary function
5.2.1 Animals and neonatal treatments
For the male Wistar rats treated neonatally with the just the GnRH antagonist, animals
were injected s.c. on days 2 and 6 with lOmg/kg of the long-acting GnRH antagonist
(Antarelix, Europeptides, Argenteuil, France) in 20pl 5% mannitol. The male rats
receiving the combined treatment of DES and GnRH antagonist were injected s.c. on
days 2 and 6 with O.lpg DES + lOmg/kg Antarelix in 20|il 5%mannitol. Control rats
were injected s.c. with 20|ll corn oil on days 2 and 6.
On the day of blood sampling, animals were anaesthetized with flurothane and blood
was collected from the heart into a heparinized syringe. Animals were subsequently
killed by cervical dislocation. Plasma samples were stored at -20°C until used for LH,
FSH, inhibin B and testosterone analysis.
The rats treated solely with the GnRH antagonist were either killed at day 18 (shortly
after the treatment) or at day 90 (adulthood). Pituitaries were removed at day 18 and
were used for immunocytochemical analysis (as detailed in Chapter 2). The number of
immunopositive LH and FSH pituitary gonadotroph cells was counted for both control
rats and rats treated neonatally with the GnRH antagonist. For the GnRH antagonist
treated rats that were kept until adulthood, blood samples were collected at day 90 and
assayed for LH, FSH, inhibin B and testosterone concentrations. The adult pituitaries
were collected and stored in liquid nitrogen for subsequent Real-Time PCR analysis of
mRNA for LH and FSH. The animals testes were removed, weighed and
immersion-fixed in Bouin's for 6 hours at room temperature before being processed in
an automated processor (as detailed in Chapter 4). These tissue sections were used for
cell quantification of the number of Leydig and Sertoli cells per testis.
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Blood was sampled at day 90 from male rats treated neonatally with a combination of
both DES and Antarelix and basal levels of LH, FSH, inhibin B and testosterone were
assayed by RIA (LH, FSH) or ELISA (inhibin B, testosterone). Approximately 4 weeks
later, these rats were injected s.c. with 100)ig GnRH in 200|al sterile Phosphate Buffered
Saline. Thirty minutes later, blood samples were collected from these animals and
stored at -20°C until they were assayed for LH, FSH, inhibin B and testosterone. Three
weeks after the GnRH injections, the rats were killed by suffocation with C02 followed
by cervical dislocation, after which the pituitaries were removed for primary pituitary
cell culture.
Primary pituitary cells were cultured as described in detail in Chapter 4 of this thesis.
Cells were plated out and were left overnight to attach to the 12-well plates and stabilize.
GnRH, activin or GnRH and activin treatments were administered to the primary
pituitary cells, as described in Chapter 4. Growth media was collected from these cells
and was subsequently assayed for LH and FSH.
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5.3 LH concentrations for male rats treated with the GnRH antagonist
Antarelix
For adult rats treated neonatally with the GnRH antagonist Antarelix, there was no
significant change in plasma LH (p=0.179) levels compared to those in control rats
(Figure 5.3). However there was a greater average level of circulating LH in the
Antarelix-treated rats.
Figure 5.3: Mean basal LH levels for adult male rats treated neonatally with a GnRH
antagonist. Values are means ± SEM. For control n=4, for GnRH antagonist n=3.
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5.3.1 FSH concentrations for male rats treated with the GnRH antagonist
Antarelix
Plasma levels of FSH were measured in animals sampled in adulthood (Figure 5.3.1).
FSH levels were significantly elevated (p=0.01) for the GnRH antagonist treated
animals, compared to the control rat plasma FSH levels.
Figure 5.3.1: Mean basal FSH levels for adult male rats treated neonatally with a
GnRH antagonist. Values are means ± SEM. For control n=4, for GnRH antagonist
n=3. ** p<0.01, in comparison to respective controls.
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5.3.2 Inhibin B concentrations for male rats treated with the GnRH
antagonist Antarelix
Plasma Inhibin B concentrations were measured in the adult animals treated neonatally
with the GnRH antagonist Antarelix (Figure 5.3.2). There was no significant difference
in plasma inhibin B levels compared to control animals (p=0.08), although inhibin B
levels tended to be lower in GnRH antagonist treated rats. As inhibin B is a negative
regulator of FSH and since FSH levels for these rats were significantly elevated (Figure
5.3.1), it would have been expected that inhibin B levels would have shown a mirror
image of FSH levels.
Figure 5.3.2: Mean basal inhibin B levels for adult male rats treated neonatally with a
GnRH antagonist. Values are means ± SEM. For control n=4, for GnRH antagonist
n=3.
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5.3.3 Testosterone concentrations for male rats treated with the GnRH
antagonist Antarelix
There was no significant difference in testosterone levels for adult rats treated neonatally
with Antarelix compared to controls (p=0.227), although the average testosterone
concentration was lower in the GnRH antagonist treated rats. This corresponds with the
LH levels measured in these rats (Figure 5.3), as there was no significant difference in
the LH levels compared to control rats.
Figure 5.3.3: Mean testosterone levels for adult male rats treated neonatally with a
GnRH antagonist. Values are means ± SEM. For control n=4, for GnRH antagonist n=3.
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5.3.4
Antarelix
LH and FSH mRNA levels for adult rats treated neonatally with
Using validated Real-Time PCR analysis, mRNA levels for LH and FSH in the pituitary
were determined for adult rats treated neonatally with the GnRH antagonist. There was
a significant increase in both FSH (p=0.02) and LH (p=0.0006) mRNA levels compared















Figure 5.3.4a: mRNA levels for LH for adult male rats treated neonatally with a GnRH
antagonist. There was a significant elevation in LH mRNA for the GnRH antagonist
treated rats (p=0.0006). Values are ± SEM. For control n=8, for GnRH antagonist n=3.
*** p<0.001, in comparison to respective controls.
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Figure 5.3.4b: mRNA levels for FSH for adult male rats treated neonatally with a
GnRH antagonist. Values are means ± SEM. For control n=8, for GnRH antagonist
n=3. * p<0.05, in comparison to respective controls.
Unfortunately, there were no adult GnRH antagonist treated pituitaries available for
immunocytochemical analysis and enumeration of FH and FSH immunopositive cells.
However, there were GnRH antagonist treated pituitaries available that were collected
shortly after the treatment period, on day 18. These pituitaries were immunostained for
FH and FSH (as described in Chapter 2) and the number of FH and FSH
immunopositive cells in each pituitary was counted.
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5.3.5 Percentage of LH and FSH immunopositive cells in 18 day old rats
treated with Antarelix
As shown in Figures 5.3.5a and b, when rats were treated neonatally with the GnRH
antagonist Antarelix, there was no significant effect on the percentage of LH (p=0.546)
and FSH (p=0.095) immunopositive cells in the anterior pituitary gland. However, there
was a change in the ratio of LH and FSH immunopositive cells between controls and
Antarelix treated rats, with the LH:FSH ratio for control rats (ratio= 1.6:1) being






















Figure 5.3.5a: Comparison of number of LH and FSH immunopositive gonadotroph
cells at 18 days of age in control rats and rats treated neonatally with the GnRH
antagonist Antarelix. Values are means ± SEM. For control n=6, treated n=5.
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Figure 5.3.5b: Immunocytochemical staining for LH and FSH immunopositive
pituitary gonadotrophs at 18 days of age, in control male rats and male rats treated
neonatally with the GnRH antagonist Antarelix. A=FH immunopositive cells in control
rats, B= FSH staining in control rats, C=HH immunopositive cells in GnRH antagonist
treated rats and D= FSH staining in GnRH antagonist treated rats.
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5.3.6 Summary of the effects of neonatal GnRH antagonist treatment on
hypothalamic-pituitary-testicular axis in adult male rats
To summarise, neonatal treatment with the long-acting GnRH antagonist Anatrelix
caused a marked elevation in plasma FSH levels, a marked reduction in corresponding
inhibin B levels, and a significant elevation in mRNA levels for FH and FSH in the
anterior pituitary. As demonstrated below in Table 5.3.6, there was also a significant
reduction in testis weight and in the number of Sertoli cells per testis. In contrast to the
effects on FSH we observed however no significant GnRH antagonist-induced effects
upon the number of Feydig cells per adult testis, adult plasma FH and testosterone
concentrations, although testosterone levels tended to be lower for GnRH antagonist
treated rats. Unfortunately no adult pituitaries were available for enumeration of FH and
FSH immunopositive cells due to a shortage in animals, but, at 18 days of age there was
found to be no significant effect of GnRH antagonist treatment on the number of FH and
FSH immunopositive cells in the pituitary.
Parameter Controls GnRH antagonist P
FH (ng/ml) 0.35 ± 0.03 0.39 ± 0.07
FSH (ng/ml) 8.78 ± 1.38 18.5 ±4.6 p<0.01
Inhibin B (pg/ml) 112+ 16.7 57 ±8.3
Testosterone (ng/ml) 2.05 + 0.31 1.25 ±0.58
mRNA LH 10.4 + 3.10 36.0 ±6.16 p<0.001
mRNA FSH 3.71 + 1.17 8.28 ±0.59 p<0.05
% FH cells day 18 21.02 ±3.2 18.4 ±2.7
% FSH cells day 18 12.82 ±2.4 6.51 ± 1.73
Testis weight (mg) 2000 ± 85 1000 ± 96 p<0.001
Feydig cells/testis
(106)
32.3 ±6.6 26.0 ±3.6
Sertoli cells/testis
GO6)
45 ± 7.7 25 ±3.6 p<0.001
Table 5.3.6: Summary of GnRH antagonist effects. Values are the means ± SEM.
Testis data were obtained from Atanassova et al., 1999.
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5.4.1 Effect of GnRH antagonist + O.lpg DES treatment on plasma LH
levels before and after a GnRH challenge in adult rats
There was no significant change observed in adult basal plasma LH levels between
control rats and rats treated neonatally with a GnRH antagonist + 0.1pg DES (Figure
5.4.1a). Therefore neonatal treatment with a GnRH antagonist combined with O.lpg of
DES did not have long lasting effects on plasma LH concentrations in the adult animals.
Figure 5.4.1a: Mean basal LH concentrations in adult male rats treated neonatally with
GnRH antagonist Antarelix + O.lpg DES. Values are means ± SEM. For controls n=6,
for GnRH antagonist + O.lpg DES n=3.
194
Plasma LH levels were measured for the animals in this specific study, after a 30 minute
lOOng GnRH challenge (Figure 5.4.1b). There was found to be a significant increase in
plasma LH levels for both control rats (p<0.001) and GnRH antagonist + 0.1 pg DES
(p<0.05) treated rats. This corresponds positively with the literature reviewed in
Chapter 1, in that LH secretion is under direct control of GnRH. This demonstrates that
the GnRH antagonist + O.lpg DES treatment does not greatly affect the pituitary
gonadotrophs' ability to respond to a GnRH pulse, however it must be noted that the
GnRH antagonist + O.lpg DES treated rats showed a greater magnitude of response to
GnRH than controls.
Figure 5.4.1b: Mean LH concentrations after a 30 minute GnRH challenge in adult
male rats treated neonatally with the GnRH antagonist Antarelix + 0.1 pg DES. Values
are means ± SEM. For controls n=6, for GnRH antagonist + 0. lpg DES n=3.
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5.4.2 Effect of GnRH antagonist + 0.1|ig DES treatment on plasma FSH
levels before and after a GnRH challenge in adult rats
When basal plasma FSH levels were measured for adult rats treated neonatally with
GnRH antagonist + O.lpg DES (Figure 5.4.2a), there was found to be no significant
change in FSH concentrations. This would tend to suggest that neonatal treatment with





control GnRH antagonist + DES
Figure 5.4.2a: Mean basal FSH concentrations in adult male rats treated neonatally
with GnRH antagonist Antarelix + 0.1 pg DES. Values are means ± SEM. For controls
n=6, for GnRH antagonist + 0.1 pg DES n=3.
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However, when FSH levels were measured for these rats after a 30 minute GnRH
challenge (Figure 5.4.2b), there was found to be no significant change in plasma FSH
levels in response to GnRH. This finding is in accordance with the literature reviewed
in Chapter 1, in that FSH secretion is not primarily under direct control of hypothalamic
GnRH. Plasma FSH levels after the GnRH challenge still showed the same basic pattern
however, in that there was no significant difference in FSH levels between control and
treated rats.
Figure 5.4.2b: Mean FSH concentrations after a 30 minute GnRH challenge, in adult
male rats treated neonatally with the GnRH antagonist Antarelix + 0.1|lg DES. Values
are means ± SEM. For controls n=6, for GnRH antagonist + 0.1 |ig DES n=3.
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5.4.3 Effect of GnRH antagonist + O.lpg DES treatment on plasma inhibin
B levels before and after a GnRH challenge in adult rats
When we assayed plasma inhibin B levels we noted no significant effect on basal plasma
levels for adult rats treated neonatally with GnRH antagonist + 0.1 fig DES. This
observation coherently relates with the plasma FSH concentrations measured for these
animals (Figure 5.4.2.a), as there was no significant GnRH antagonist + 0.1 fig DES
effect on circulating FSH levels.
Figure 5.4.3a: Mean basal inhibin B concentrations in adult male rats treated neonatally
with GnRH antagonist Antarelix + 0.1(lg DES. Values are means ± SEM. For controls
n=6, for GnRH antagonist + 0.1 jig DES n=3.
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After a 30 minute lOOng GnRH challenge, there was a small increase in inhibin B levels
for both control (29% increase) and GnRH antagonist + DES (30 % increase) treated
rats. However, this change was small and not statistically significant.
Figure 5.4.3b: Mean inhibin B concentrations after a 30 minute GnRH challenge, in
adult male rats treated neonatally with the GnRH antagonist Antarelix + O.ljlg DES.
Values are means ± SEM. For controls n=6, for GnRH antagonist + 0.1|ig DES n=3.
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5.4.4 Effect of GnRH antagonist + O.ljxg DES treatment on plasma
testosterone levels before and after a GnRH challenge in adult rats
When the plasma testosterone levels in the neonatally treated rats were assayed we
found that there was a significant decrease (p<0.001) in plasma testosterone
concentrations for the adult rats treated with GnRH antagonist + 0.1 (ig DES (Figure
5.4.4a) compared to control rats. This demonstrates that neonatal GnRH antagonist +




control GnRH antagonist + DES
Figure 5.4.4a: Mean basal testosterone concentrations in adult male rats treated
neonatally with GnRH antagonist Antarelix + O.ljig DES. Values are means ± SEM.
For controls n=6, for GnRH antagonist + 0. lpg DES n=3. *** p<0.001, in comparison
to respective controls.
Chapter 5 Effect of a GnRH Antagonist on Pituitary Function 200
As shown in Figure 5.4.4b, plasma testosterone levels were elevated markedly in
response to a 30 minute GnRH challenge. The GnRH antagonist + 0.1 pig DES treated
animals showed a greater rise in plasma testosterone levels (527 % increase, p<0.001)
than control animals (44% increase). This shows that neonatal GnRH antagonist +
0.1 pg DES treatment significantly increased the capacity of acute GnRH administration














control GnRH antagonist + DES
Figure 5.4.4b: Mean testosterone concentrations after a GnRH challenge in adult male
rats treated neonatally with GnRH antagonist Antarelix + O.lpg DES. Values are means
± SEM. For controls n=6, for GnRH antagonist + O.ljlg DES n=3. *** p<0.001, in
comparison to respective controls.
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5.4.5 Summary of effects of GnRH antagonist + DES treatment on adult
plasma hormone levels
To summarise the pertinent results from this section we found that neonatal treatment
with GnRH antagonist and 0.1 jig of DES caused a significant and permanent decrease in
plasma testosterone concentrations. However, this treatment regime had no significant
or permanent effects on circulating levels of FSH, LH, or inhibin B. Generally, GnRH
antagonist + 0.1 jig DES treatment caused a greater magnitude of response to a 30
minute lOOng GnRH pulse, with plasma LH (104% increase) levels and plasma
testosterone (527% increase) levels showing the greatest GnRH-induced increases.
Hormone
measured











FSH (ng/ml) 10.76 ±0.49 9.02 + 0.67
(16% I)
12.14 ± 0.72 15.88 ±5.36
(30% T)
LH (ng/ml) 0.93 + 0.06 1.45 ± 0.11
(55% T)
p<0.001





76.2 ± 10.04 62.5 ±9.4
(18% I)




1.88 + 0.17 2.71 ±0.53
(44% t)
0.74 ±0.13 4.64 ± 0.48
(527% T)
p<0.001
Table 5.4.5: Mean concentrations of FSH, inhibin B, LH and testosterone before and
after a 30 minute lOOng GnRH pulse. Values are the means ± SEM.
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5.4.6 LH and FSH levels in primary pituitary cells from rats treated with
GnRH antagonist +0.1pg DES neonatally
The pituitary organs from control and GnRH antagonist + 0.1 pig DES treated animals
were removed and cultured in 12-well plates. The primary cultured cells were
subsequently subjected to hormonal treatments as described in detail in Chapter 4.
Briefly, the pituitary cells were allowed to attach overnight to the artificial cell matrix
(Matrigel) before any hormonal culture addition was made. Cells were maintained in
fetal calf serum-containing Dulbecco's modified Eagles medium-F12, at 37°C in a
humidified incubator in a 5% CO, atmosphere. After overnight culture, medium was
removed and replaced with either fresh DMEM-F12 medium (controls), medium
containing 20ng activin, medium containing lOnM GnRH (30 minutes) or medium
containing 20ng activin + lOnM GnRH (30 minutes). The specific medium was then
removed after 30 minutes and was replaced with either DMEM-F12, or with
DMEM-F12 + activin for the activin treated cells. At the end of the day, the medium
was collected from each well and stored at -20°C. LH and FSH concentrations in the
culture media were assayed before and after the GnRH pulse for both control pituitary
cells and cells cultured from adult animals treated neonatally with GnRH antagonist +
0.1pg DES.
There was a significant decrease (p<0.001) in LH concentrations observed in the culture
media from rats treated neonatally with GnRH antagonist + DES (Figure 5.4.6a)
compared to controls. Neonatal DES treatment on its own had no significant effect on
LH levels in culture media (Figure 4.4.4c, Chapter 4). This suggests that this significant
suppression of LH levels was either due to a GnRH antagonist effect, or that GnRH had
'compensated' for a DES effect in the DES treated animals and that this effect only
became apparent when the functional effects of GnRH release was blocked by an
antagonist. The GnRH antagonist + DES treatment had no significant effects on FSH
levels in the culture media (Figure 5.4.6b).
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Ideally, pituitary cells should also have been cultured from animals treated neonatally
with GnRH antagonist on its own. However, there was a shortage of available animals
for treatment and hence this treatment group could not be included in the study.
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Figure 5.4.6a: LH levels in male primary pituitary cells before and after a 30 minute
lOnM GnRH challenge. Values are means ± SEM. A=control, B= 20ng activin, C=10
nM GnRH, D= 20 ng activin + 10 nM GnRH. Red bars are controls and yellow bars are
GnRH antagonist + 0.1 pig DES treated rats. *** p<0.001, in comparison to respective
controls. Units are ng/ml.
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Figure 5.4.6b: FSH levels in male primary pituitary cells before and after a 30 minute
lOnM GnRH challenge. Values are means ± SEM. A=control, B= 20ng activin, C=10
nM GnRH, D= 20 ng activin + 10 nM GnRH. Red bars are controls and yellow bars are
GnRH antagonist + O.lpg DES treated rats. Units are ng/ml.
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5.5 Discussion
Treatment of neonatal male rats with a GnRH antagonist on its own resulted in a
significant elevation of plasma FSH levels (P<0.01), with no significant change in
plasma FH levels. Circulating inhibin B and testosterone levels tended to be lower for
the GnRH antagonist treated animals, however this change was not statistically
significant. Interestingly, pituitary mRNA levels for FH and FSH were found to be
elevated significantly (LH p<0.001 and FSH p<0.05). This may have occurred due to an
autoregulatory increase in the sensitivity of the hypothalamic-pituitary axis in an attempt
to compensate for the reduced GnRH input in the presence of Antarelix. Therefore as
the GnRH receptor antagonist would reduce the ability of GnRH from the hypothalamus
to mediate gonadotropin release from the gonadotroph cells the cells were responding to
this perturbation by elevating their capacity to release gonadotropins by up-regulating
the transcription of FH and FSH. Thus despite a diminished GnRH input to the
gonadotrophs any stimulatory input, extant in the presence of Antarelix, would have an
abnormally large store of gonadotropins to release into the circulation. A compensatory
elevation in the transmitter levels, in this case FH/FSH, in response to a perturbation in
the hypothalamic-pituitary gonadal axis with Antarelix, is reminiscent of the effects of
other scenarios in which neurotransmitter, e.g. serotonin, functions are modulated in the
central nervous system (Eide and Hole, 1993). Unfortunately there were no adult
pituitaries available of neonatally GnRH antagonist treated animals for
immunocytochemical analysis. However, there were pituitaries available for analysis of
18 day old treated rats. Immunopositive staining for FH and FSH in these pituitaries
showed that FSH immunostaining tended to be lower in GnRH antagonist treated rats
than in control rats, however this difference was not significant. Analysis of the testes in
adulthood of these animals revealed that testis weight was significantly reduced in
GnRH antagonist treated rats (PcO.OOl) and that there was a significant reduction in the
number of Sertoli cells per testis for the GnRH antagonist treated rats (p<0.001).
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Therefore it would seem likely that the Antarelix blockade of the hypothalamic GnRH
input to the anterior pituitary would reduce the initial effective amount of LH circulated
to the testes thus resulting in a restricted pubertal gonadal development. However as
discussed previously even in the face of diminished hypothalamic GnRH input to the
pituitary (caused by Antarelix), the pituitary gland itself may eventually attempt to adapt
to this. This may occur by an increase in the amount of gonadotrophin hormone, e.g.
LH, synthesized and thus available for any subsequent release mediated by a GnRH
'breakthrough' in the presence of Antarelix. This would theoretically thus result in an
eventual recuperation of the plasma levels of LH, which indeed was noted. There was
found to be no significant change in the number of Leydig cells between control and
GnRH antagonist treated rats. These observations correspond well with data obtained by
Richard Sharpe's laboratory, which showed that neonatal GnRH antagonist resulted in
elevated plasma FSH levels (p<0.001) and suppressed plasma inhibin B levels (p<0.05),
but no significant changes in plasma LH and testosterone concentrations. Analysis of
the testes showed that testis weight was significantly reduced in GnRH antagonist
treated rats (p<0.001), and that the number of Sertoli cells per testis (p<0.001) and total
germ cell volume per testis (p<0.001) were also significantly reduced, with no
significant change in Leydig cell number per testis (Atanassova et al., 1999; Sharpe et
al, 2003b).
Neonatal treatment of GnRH antagonist with O.ljlg DES resulted in a significant
reduction of basal plasma testosterone levels (p<0.001) compared to control animals.
However, neonatal GnRH antagonist with 0.1 jig DES treatment was found to have no
significant effects on basal plasma LH, FSH and inhibin B levels. Interestingly, after a
30 minute lOOng GnRH pulse, the GnRH antagonist with 0.1 jig DES treated rats
showed a much greater increase in plasma LH (104% increase p<0.05) and plasma
testosterone levels (527% increase p<0.001) than control animals. This suggests that
GnRH antagonist with 0.1 jig DES treatment made the gonadotroph cells more
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responsive to a GnRH challenge than gonadotrophs in control animals. There are
several mechanisms by which such a heightened functional sensitivity to GnRH could
occur, e.g. via an elevation in pituitary GnRH receptor expression, an increase in the LH
content of each secretory vesicle or an increase in the number of secretory vesicles
released during a GnRH pulse. From the data gathered it is possible to hypothesize,
without any additional experiments that, in part, this effect could be mediated by the
enhanced transcription of LH/FSH and therefore increased gonadotropin content and/or
number of secretory vesicles.
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Chapter six: effects of phytoestrogens on male
marmoset and male rat pituitary function
6.1 Introduction
This chapter investigates whether phytoestrogens, in particular genistein and soy
formula milk, administered in early life, can have any effects on the hypothalamic-
pituitary-testicular axis, with particular emphasis on pituitary function.
Phytoestrogens are polyphenolic non-steroidal plant compounds with oestrogen-like
biological activity. The oestrogenic properties of certain plants have been recognised for
more than fifty years. In the mid-1940's, an infertility syndrome in sheep occurred that
has been attributed to the ingestion of clover containing high levels of the isoflavones
formononetin and biochanin (Adams, 1995). More recently, an increasing number of
epidemiological and experimental studies have suggested that the consumption of
phytoestrogen-rich diets may have protective effects on oestrogen-related conditions,
such as menopausal symptoms (Baird et al., 1995), and oestrogen-related diseases such
as prostate (Denis et al., 1999) and breast cancers (Lee et al., 1991), osteoporosis (Potter
et al., 1998), and cardiovascular diseases (Bakhit et al., 1994). However, concerns have
been raised about the potential dangers of consuming high levels of these compounds,
especially during early life (Abe, 1999). Consequently, phytoestrogens are currently
under active investigation for their role on human health.
Isoflavones are the most studied group of phytoestrogens and are found almost
exclusively in the family Leguminosae (King & Young, 1999). Soybeans are a very rich
source of isoflavones and contain approximately 2 grams of isoflavones per kilogram
fresh weight (Reinli & Block, 1996). However, the isoflavone content of soy products
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can vary greatly between different soybean varieties and through soybean processing
(Wang et al., 1994). Consequently, not all soy protein sources are equal with respect to
their isoflavone content and this should be taken into account when conducting and
analysing experimental studies on soy.
A large number of isoflavones have been identified from plants, with daidzein (Denis et
al., 1999) and genistein (Lee et al., 1991) as the principal isoflavones. They occur in
plants as the inactive glycosides daidzin (Potter et al., 1998) and genistin (Bakhit et al,,
1994), and their 4'-methyl ether derivatives formononetin and biochanin A. Other
members of the isoflavone family are coumestans, with coumestrol (King & Young,
1999) and 4'-0-methylcoumestrol (Reinli & Block, 1996) being the principle ones.
They exhibit close structural similarity to isoflavones (see Figure 6.1) (Davis et al.,
1999) and their main dietary sources are alfalfa, soybean and clover sprouts.
Figure 6.1: Classification of dietary oestrogens, including the phytoestrogen family.
(From Cos et al,, 2003).
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Presently there are concerns that the high isoflavanoid phytoestrogen content of soy
formula milk might exert adverse effects on the developing infant (Irvine et al., 1995,
1998; Setchell et al., 1997,1998). Soy formula milk was initially developed for infants
unable to tolerate the proteins in cow's milk-based formulas, however, soy based
formulas are now used more widely and account for approximately 25% of infant
formulae sold in the United States (Klein, 1998; Lonnerdal, 1994). Millions of
American infants have been fed soy formula over the past three decades. Several studies
so far have demonstrated that soy formula supports normal growth and development in
term infants (Fomon, 1993; Businco et al., 1992; Churella et al., 1994; Kohler et al.,
1984, Graham et al., 1970). When growth was studied over the first year of life, body
weight gains and the body length of infants were virtually the same whether the infants
were fed soy formula milk or cow's milk formula or breastfed (Lasekan et al., 1999).
Recently a study determining the long-term health consequences of early soy intake was
reported on 811 young adults (between 20 and 34 years old) who were fed cow's milk
based formula or soy formula as infants. This study by Strom et al. (Strom et al., 2001)
showed that there were a few statistically significant differences between the cow's milk
and the soy formula groups, but no differences were found in growth, development,
puberty, reproductive function, or pregnancy outcomes. However, it must be taken into
account that the number of subjects was low and they were too young to determine the
risk of developing any chronic diseases that occur in later life.
As no major adverse effects of feeding soy formula milk have come to light since its
widespread introduction more than 30 years ago, it has been argued that adverse effects
are probably unlikely (Klein, 1998). Despite numerous studies performed on rodents
examining the effects of exposure to phytoestrogens during the neonatal period (Whitten
and Naftolin, 1998), it is unclear whether these are relevant to humans as the route and
mode of administration are generally not comparable. In rodents, phytoestrogens have
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generally been injected rather than being consumed orally by pups and also, neonatal
pups are relatively undeveloped when compared with neonatal humans.
Therefore, these studies were carried out on both rodents (rats) and non-human primates,
(marmosets), as neonatal marmosets are developmentally comparable to neonatal
humans and they could be hand-fed soy formula milk orally, whereas rats couldn't.
Also, marmosets, like humans (and unlike rats), have a prolonged 'neonatal testosterone
rise', when testosterone levels increase to low adult levels during the first 4 to 6 months
of life, which is associated with activation of gonadotrophin secretion (Winters et al.,
1979; Mann and Fraser, 1996; Andersson et al., 1998), Sertoli cell proliferation (Cortes
et al., 1987; Sharpe et al., 1999) and an elevation in the secretion of inhibin B by the
latter cells (Andersson et al., 1998).
Two short-term studies are described in this chapter. The first study was a rat study, in
which neonatal rats were injected s.c. with the phytoestrogen genistein, and pituitary
function was evaluated shortly after treatment by counting the number of LH and FSH
immunopositive cells and measuring plasma FSH levels. The second study was a more
elaborate marmoset study where co-twin marmosets were reared on soy formula milk in
early life, and pituitary function was subsequently investigated. The number of FH and
FSH immunopositive cells was counted for each co-twin marmoset and the findings at
the level of the pituitary were brought into context by including data from analyses of
the testes of these animals, done in parallel by Richard Sharpe's laboratory.
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6.1.2 Summary of analysis methods for determining the effects of feeding
rats and marmosets phytoestrogens
Rat genistein study: investigation into the effects of neonatal genistein treatment on
pituitary function. In this study the primary goals were:
• Immunocytochemistry for LH and FSH in the anterior pituitary at days 10, 18
and 25. Enumeration of LH and FSH immunopositive cells at days 10, 18
and 25. Measurement of plasma FSH levels at day 18.
Marmoset soy study, investigation into the effects of rearing infant marmosets soy
formula milk on pituitary function. This study involved:
• Immunocytochemistry for LH and FSH in the marmoset anterior pituitary at
days 35-40.
• Enumeration of LH and FSH immunopositive gonadotroph cells at days 35-
40 for infant marmosets fed either cow's milk or soy formula milk.
• Measurement of bodyweight, daily formula intake and testis weight at days
35-40 for infant marmosets fed either standard cow's milk formula or soy
formula milk.
• Determination of plasma testosterone levels (and relationship to soy formula
intake).
• Quantification of number of Leydig and Sertoli cells per testis for control
marmosets and those weaned on soy formula milk.
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6.2 Outline of treatments administered
For the rat study, all-male litters of 8-12 pups were generated by cross-fostering pups on
the first day of birth. They were maintained under controlled conditions at 22-23°C
ambient temperature, 55-60% relative humidity, 12L:12D cycle and were supplied with
a standard diet (rat and mouse breeding diet; SDS, Dundee, UK) that contains soya meal.
Soya-free control animals were maintained on a soya-free diet (rat and mouse soya-free
breeding diet, SDS, Dundee, UK). From days 2 to 17 rats were injected s.c. with
4mg/kg/day of genistein (Sigma, UK). Blood samples were collected from the tail vein
at day 18 and stored at -20°C for subsequent FH and FSH measurements. Animals were
killed either at day 10, 18 or 25 by COz inhalation and cervical dislocation. The whole
pituitary was removed and the right testis was dissected out and weighed. The
pituitaries and testes were subsequently fixed for 5 hours in Bouin's fixative. After
fixation, the tissues were transferred into 70% ethanol before being processed for 17.5
hours in an automated TP 1050 processor (Leica Corp., Deerfield, IF) and embedded in
paraffin wax. Sections of 5|im thickness were cut, floated onto slides coated with 2% 3-
aminopropyltriethoxysilane (Sigma), and dried at 50°C overnight before being used for
immunohistochemistry as described in Chapter 2.
For the marmoset study, 13 pairs of newborn male marmoset co-twins were used, as
detailed in Chapter 2. Marmosets tend to show a considerable amount of between-
animal variability, thus co-twins were used to minimize the between-animal variability
and hence to reduce the total number of animals required to perform this study. One
infant co-twin was weaned on standard cow's formula milk (SMA) and the other co-twin
was fed soy formula milk (SFM). This enabled a pair-wise evaluation and hence a direct
comparison could be made between co-twins. The treatment schedule is summarized in
Figure 6.2. Treatments commenced on days 4 or 5 of age. Infants were separated from
their mothers at set-intervals and were hand-fed with either standard cow's milk based
Chapter 6 Effect of phytoestrogens on rat and marmoset pituitary function 215
formula milk (SMA) or with soy formula milk (SFM) from day 4 or 5 until days 35 to
45. Infants could drink as much as they wanted to and the amount of formula milk taken
up was measured and recorded. Infants were fed daily, three or four times during
weekdays and once or twice at weekends. After the last feed of the day, the infants were
returned to the mothers and she was allowed to breastfeed them until the following day.
Approximately half way through the study, on days 18 to 20, a 0.2ml blood sample was
collected from the femoral vein of each infant. Then on days 35 to 45 the marmosets
were killed via i.p. injection of an overdose of sodium pentobarbitone. Immediately
after death, a blood sample was collected by cardiac puncture.
Day 0
Day 4 to 40
Days 18 to 20




Figure 6.2: Summary of treatment schedule for infant marmosets weaned on cow's
milk (SMA) or soy formula milk (SFM).
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6.2.1 Specific methods
The general methods (gonadotroph immunostaining and plasma testosterone assay) used
in this chapter are detailed in Chapter 2. However the specific methods for tissue
collection and processing, Leydig and Sertoli cell immunostaining and enumeration,
performed by Richard Sharpe's laboratory, are detailed in this section.
Testes with the epididymides attached, as well as the pituitary gland, were dissected free
of connective tissue and were immersion-fixed for either 5.5 hours (left testis, pituitary
gland) or 24 hours (right testis) in Bouin's fixative, after which each testis was dissected
away from the epididymis and weighed. The left testis and the pituitary were processed
for 17.5 hours in an automated Leica TP-1050 processor and embedded in paraffin wax.
Sections of 5(im thickness were cut on a microtome and were then floated onto slides
coated with 2% 3-aminopropyltriethoxy-silane (Sigma, UK) before being dried
overnight at 50°C.
6.2.3 Determination of the number of Sertoli cells per testis
After fixation, the right testis was sampled in a random systematic manner, i.e. of four
transverse slices, either slices, 1 and 3 or slices 2 and 4 were sampled. These were
processed through graded ethanols before infiltration with JB4 resin (TAAB,
Aldermaston, UK). After polymerisation of the JB4 resin, 20|im sections were cut on a
Reichart 2050 microtome using a Diatome Histoknife, mounted onto glass slides and
stained with Harris' haematoxylin. Sertoli cells were then counted using the optical
dissector method. An Olympus BH2 microscope fitted with an automatic stage (Prior
Scientific Instruments, Cambridge, UK) and Image Proplus software (Media
6.2.2 Tissue collection and processing
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Cybernetics, Silver Spring, MD) was used for the dissector method. Using a graticule
with 121 points and 40x objective, 10 fields on testicular cross sections were selected
randomly and subjected to standard point-counting; the number of fields examined was
based on power calculations derived from Wreford (Wreford, 1995). After
determination of the percentage volume per testis for each of the components counted
(Sertoli cell nucleus, germ cell nuclei, seminiferous epithelium, interstitium), total
volume per testis was determined by multiplying the percentage value by fixed testis
weight. Sertoli cell number per testis was then calculated as described by Wreford
(Wreford, 1995), using the value for mean nuclear volume derived above.
6.2.4 Determination of the number of Leydig cells per testis
Leydig cells were stained for 3(3-hydroxysteroid dehydrogenase (3(3-HSD), which is a
marker for Leydig cells. A rabbit anti-human 3(3-HSD antibody was used, which was a
gift from Prof. Ian Mason (Department of Clinical Biochemistry, University of
Edinburgh, UK). 5jim sections were mounted on slides coated with 3-aminopropyl
triethoxy-silane (Sigma, UK) and were dried overnight at 50°C. Before incubation with
primary antibodies, sections were dewaxed, rehydrated in graded ethanols, and washed
in water and TBS (0.05M Tris-HCl pH 7.4 and 0.85% NaCl). All sections were blocked
using normal swine serum (DAKO, High Wycombe, UK) diluted 1:5 in TBS. The
primary antibody was diluted 1:1000 in normal swine serum in TBS before incubation
on sections under plastic coverslips overnight at 4°C. The following day, coverslips
were removed, and sections were washed twice in TBS (5 minutes each), incubated for
30 minutes with biotinylated swine anti-rabbit Ig (DAKO,UK) diluted 1:500 in TBS,
then washed again in TBS (twice for 5 minutes each time). For detection of bound
antibodies, sections were first incubated with Avidin-biotin complex conjugated with
horseradish peroxidase for 30 minutes and washed twice in TBS (5 minutes each time).
A colour reaction product was developed by incubating sections in a mixture of 0.05%
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(wt/vol) 3,3'-diaminobenzidine tetrahydrochloride (Sigma, UK) in 0.05M Tris-HCl pH
7.4 and 0.01% hydrogen peroxide. After 5-15 minutes, sections were washed in water,
counterstained with hematoxylin, dehydrated in graded ethanols, cleared in xylene, and
coverslipped using Pertex mounting medium (Cell Path, Hemel Hempstead, UK). The
specificity of the antibodies was confirmed using normal rabbit serum instead of the
primary antibodies, no staining was observed in these controls.
Ueydig cell volume per testis was determined using the Area Fraction Probe in the
Stereologer software programme (Systems Planning and Analysis Inc., Alexandria, VA,
USA) and utilised an Olympus BHS microscope fitted with an automatic stage (Applied
Scientific Instrumentation Inc., Eugene, OR, USA). The area fraction probe places a
grid in the frame and the Object Area fraction is determined by clicking each 'X' that
touches the object of interest (in this case, the cytoplasm or nucleus of 3(3-HSD-positive
cells). The number of frames per slide counted was 5-13 and was determined by the
programme after taking into account the spacing between points, objects counted per
frame and the size of the section. Frames for evaluation were selected automatically. A
coefficient of error (CE) was calculated at intervals in the counting procedure and, if this
exceeded the maximum acceptable value (0.15), then different settings recommended by
the programme were utilized in order to obtain the optimum CE. Once completed,
Stereologer automatically displays the results including area fraction and CE. The
values for area fraction were then converted to absolute volumes per testis by reference
to testis volume (=weight). Average nuclear diameter was then determined by
measuring the diameter of 100 random nuclei of 3(3-HSD-positive cells for each animal
and then converting Leydig cell nuclear volume per testis to Leydig cell number per
testis (Wreford, 1995).
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6.3 Percentage of LH and FSH immunopositive cells in 18 day old rats
reared on a soya free diet during neonatal life
At day 18, there was no significant difference in the percentage of LH (p=0.614) and
FSH (p=0.612) immunopositive cells between rats reared neonatally on a soya-free diet
and control rats (fed standard rat chow which contains soya). There was also no
significant change in the ratio of LH to FSH immunopositive cells between controls





















Figure 6.3: Comparison of percentage of LH and FSH immunopositive gonadotroph
cells at 18 days of age in control rats and rats fed a soya-free diet in neonatal life. Values
are means ± SEM. For control n=6, treated n=3.
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6.3.1 Percentage of LH and FSH immunopositive cells in 10 day old rats
treated neonatally with genistein
At day 10, there was no significant difference in the percentage of LH (p=0.436) and
FSH (p=0.109) immunopositive cells between control and genistein treated rats. A slight
change in the ratio of LH to FSH cells between controls and treated animals was
observed, i.e. there was a higher ratio of LH to FSH immunopositive cells in controls





Figure 6.3.1: Comparison of number of LH and FSH immunopositive gonadotroph
cells at 10 days of age in control rats and rats treated neonatally (days 2-17) with
genistein. Values are means ± SEM. For control n=6, treated n=4.
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6.3.2 Percentage of LH and FSH immunopositive cells in 18 day old rats
treated neonatally with genistein
Similar observations were made for 18 day old rats that had been treated neonatally with
genistein, as shown in Figure 6.3.2. Again, there was no significant difference in the
percentage of LH (p=0.453) and FSH (p=0.746) immunopositive cells between control
and treated rats. Similarly to the 10 day old rats treated neonatally with genistein, there
was also a small change in ratio of LH to FSH immunopositive cells between control
and treated rats, there was a higher ratio of LH to FSH cells in controls (ratio=1.6)























Figure 6.3.2: Comparison of number of LH and FSH immunopositive gonadotroph
cells at 18 days of age in control rats and rats treated neonatally (days 2-17) with
genistein. Values are means ± SEM. For control n=6, treated n=4.
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6.3.3 Percentage of LH and FSH immunopositive cells in 25 day old rats
treated neonatally with genistein
As demonstrated in Figure 6.3.3, for 25 day old rats treated neonatally with the
phytoestrogen genistein, there was no significant difference in the percentage of LH
(p=0.436) immunopositive cells between control rats and those administered genistein.
However, there was a small significant decrease (p=0.05) in the percentage of FSH
immunopositive gonadotrophs between control and genistein treated rats. There was also
a small change in the ratio of LH to FSH immunopositive cells, with the LH:FSH ratio
being lower for controls (ratio=1.6) than for genistein treated rats (ratio=2), however this





Figure 6.3.3: Comparison of number of LH and FSH immunopositive gonadotroph
cells at 25 days of age in control rats and rats treated neonatally (days 2-17) with
genistein. Values are means ± SEM. For control n=5, treated n=3. * p<0.05, in
comparison with respective control.
Chapter 6 Effect of phytoestrogens on rat and marmoset pituitary function 223
6.3.4 Plasma FSH levels at day 18
Plasma FSH levels were measured for soy-free control and genistein treated rats at 18
days of age. There was a marked and significant reduction in plasma FSH




Soy-free control 7.77 ± 2.78 18
Genistein 4.16 ± 1.73 10
Table 6.3.4: Plasma FSH levels for soy-free controls and genistein treated rats at 18
days of age.
6.3.5 Summary of effects of genistein treatment on percentage of
gonadotroph cells
Day Treatment % LH cells in
treated rats
% LH cells in
control rats
P




















Table 6.3.5a: Summary of the mean percentages ± SEM of FH immunopositive cells in
the pituitary gland in relation to the neonatal treatment.
224
Day Treatment % FSH cells in
treated rats
% FSH cells in
control rats
P





















Table 6.3.5b: Summary of the mean percentages ± SEM of FSH immunopositive cells
in the pituitary gland in relation to the neonatal treatment.
To summarise, there was no significant effect of neonatal genistein treatment on the
number of immunopositive gonadotrophs in the pituitary gland at days 10 and 18.
However, there was a small significant reduction in pituitary FSH staining at day 25 for
genistein treated rats in comparison to controls. Plasma FSH levels at 18 days of age
were reduced significantly (p<0.001) in genistein treated rats.
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6.4 Percentage of FSH and LH immunopositive cells in 35 to 40 day old
marmosets weaned on soy formula milk
There were no significant differences at 35 to 40 days of age in the number of FSH
immunopositive gonadotroph cells for the cow's formula milk and soy formula milk
weaned infants (Figure 6.4a). For many of the co-twin sets the number of FSH
immunopositive cells tended to be lower in the soy formula fed infants, but this
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Figure 6.4a: Pituitary cell counts for FSH at the end of the feeding period (35-40 days
of age) in co-twin marmosets fed with either standard cow's milk formula (SMA) or soy
formula milk (SFM). Each bar represents one co-twin and overall mean levels for each
treatment group are shown to the right. P values are based on co-twin comparisons
using the paired t-test.
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The number of LH immunopositive cells was also counted after the treatment period (at
days 35 to 40), as shown in Figure 6.4b. As for FSFI, there was no significant change in
the number of LFI immunopositive gonadotrophs for control cow's formula milk and soy
formula milk fed infant animals. There was a small reduction in the number of LH
immunopositive gonadotrophs for 4 out of the 7 co-twin sets, however this was only a
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Figure 6.4b: Pituitary cell counts for LH at the end of the feeding period (35-40 days of
age) in co-twin marmosets fed with either standard cow's milk formula (SMA) or soy
formula milk (SFM). Each bar represents one co-twin and overall mean levels for each
treatment group are shown to the right. P values are based on co-twin comparisons
using the paired t-test.
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To investigate whether the bi-hormonal nature of the gonadotroph cells was maintained
after infant treatment with soy formula milk, the pituitaries for all the co-twins were dual
stained for both LH and FSH after the treatment period, using the fluorescent markers
TRITC and FITC. As depicted in Figure 6.4d, pituitary gonadotrophs maintained their
bi-hormonal nature, as FH and FSH were still co-localised within the same gonadotroph
cell after neonatal treatment with soy formula milk.
From the DAB immunostained pituitaries the ratio of FSH immunopositive to FH
immunopositive cells was calculated for each co-twin (shown in Figure 6.4c). There
was no significant change in FSH to FH ratio for the soy formula treated animals. The
FSH to FH ratio was lower for 6 out of 9 marmosets, however this reduction was small
and not statistically significant. Representative sections showing DAB
immunocytochemistry for FH and FSH in the pituitaries of control cow's formula milk
and soy formula milk treated animals are included in Figures 6.4e and 6.4f respectively.
1 2 3 4 5 6 7
Figure 6.4c: Ratio of FSH to FH immunopositive gonadotrophs at the end of the
feeding period (35-40 days of age) in co-twin marmosets fed with either standard cow's
milk formula (SMA) or soy formula milk (SFM). Each bar represents one co-twin and
co-twin comparisons were performed using the paired t-test.
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Figure 6.4d: Immunofluorescent staining after soy treatment for LH and FSH in
gonadotrophs of soy formula fed infants. A=LH staining, B=FSH staining, Odual
staining for LH and FSH. Note bi-hormonal nature of gonadotrophs is maintained.
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Figure 6.4e: Representative sections of the pituitary immunostained for FSH at age 35
to 40 days in one set of marmoset co-twins fed either with control cow's milk formula
(A) or with soy formula milk (B). There was no statistically significant difference in the
number of FSH immunopositive cells, however the soy formula treated aninals tended
to have slightly less FSH immunopositive staining. But this reduction was small and not
statistically significant.
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Figure 6.4f: Representative sections of the pituitary immunostained for LH at age 35 to
40 days in one set of marmoset co-twins fed either with control cow's milk formula (A)
or with soy formula milk (B). There was no statistically significant difference in the
number of LH immunopositive cells, however the soy formula treated aninals tended to
have slightly less LH immunopositive staining. But this reduction was small and not
statistically significant.
Chapter 6 Effect of phytoestrogens on rat and marmoset pituitary function 231
6.4.1 Plasma testosterone levels at days 35-40 for marmoset infants fed
either cow's milk formula or soy formula milk
Plasma testosterone levels were measured (as depicted in Figure 6.4.1) twice during this
study for marmosets fed either cow's milk formula or soy formula milk during neonatal
life. The first time was in the middle of the study, at days 18 to 20, and the second time
was at the end of the study, at days 35 to 40. There was a wide variation in plasma
testosterone levels between co-twins, reflecting the episodic nature of testosterone
production and secretion from the testicular Leydig cells. A paired comparison of
testosterone levels in co-twins at days 35 to 40 showed that there was a dramatic 55%
reduction (p=0.018) in plasma testosterone levels for soy formula milk fed marmosets.
However, a similar comparison done at days 18 to 20, when plasma testosterone levels
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Figure 6.4.1: Plasma testosterone levels at the end of the feeding period (35-40 days)
for co-twin marmosets fed either standard cow's milk formula (SMA controls) or soy
formula milk (SFM). P values are based on co-twin comparison using the paired t-test
(Sharpe et al., 2002).
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6.4.2 Mean bodyweights at 35-40 days of age, for marmosets fed cow's
milk formula or soy formula milk
The bodyweights for control cow's milk and soy formula milk fed infant marmosets
were comparable, both at the start (33.3g ±3.1 for SMA and 34.3g ±1.8 for SFM) and
at the end (75.6g ±9.1 for SMA and 77.6g ± 7.5 for SFM) of the treatment period. The
increase in bodyweight during this 35 to 40 day period was also very similar, as shown
in Figure 6.4.2. The bodyweight increments were well within the normal limits of this
marmoset colony. All the animals that took part in this study appeared healthy and no
unforeseen problems were encountered with the animals.
Figure 6.4.2: Mean bodyweights for control infant marmosets fed either with cow's
milk formula (SMA) or with soy formula milk (SFM) at the start (day 3 or 4) and at the
end (days 35 to 40) of the treatment period. There was no significant difference in body
weight before or after the treatment period between control infants and those weaned on
SFM. Values shown are means ± SEM. SMA n=9 and SFM n=9 (Sharpe et al., 2002).
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6.4.3 Mean testis weight at 35-40 days of age, for marmosets fed cow's
milk formula or soy formula milk
The testes were weighed, as shown in Figure 6.4.3, for each of the marmosets weaned
either on cow's milk formula or soy formula milk after the treatment period, when
marmosets were 35-40 days old. There was no statistically significant difference in
mean testis weight after the treatment period between the control (21.5g ± 6.5) and
treated (21.6g ± 4.0) marmosets.
30
SMA SFM
Figure 6.4.3: Mean testis weight after treatment period at days 35-40 for infant
marmosets weaned either on cow's formula milk or soy formula milk. There was no
significant difference in mean testis weight after the treatment period between control
animals and those weaned on soy formula milk. Values are means ± SEM. For SMA
n=9 and for SFM n=9 (Sharpe et al., 2002).
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6.4.4 Formula intake for marmoset infants fed either cow's milk formula
or soy formula milk
Formula intake was measured for each infant marmoset co-twin, as shown in Figure
6.4.4. There was considerable variation between twins in the level of formula intake,
with some twins taking in significantly lower amounts than other twins. However, in
most cases this variability in formula intake applied equally to both co-twins. In most
infants, formula intake per gram of bodyweight was higher in the second half of the
study (after day 18 to 20, when first blood samples were collected) than in the first half
of the study. Some co-twins were more restrained in taking in the feed (both cow's milk
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Figure 6.4.4: Daily formula intake for co-twin infant marmosets weaned on cow's milk
(SMA) formula or soy formula milk (SFM). Each bar represents one co-twin whilst
overall mean levels for each treatment group are shown to the right. Note that results are
plotted in order of descending intake of SFM/g bodyweight by the SFM-fed co-twin.
NS = not significant (Sharpe et al., 2002).
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6.4.5 Summary of measurements for bodyweight, testis weight, formula
intake and plasma testosterone levels
Parameter Control marmosets Soy formula fed
(SMA) marmosets (SFM)
Bodyweight at start (g) 33.3 ±3.1 34.3 ± 1.8
Bodyweight at end (g) 75.6 ±9.1 77.6 ±7.5
Daily Formula intake 93 ± 19 93 ±23
(pl/g/day)
Testis weight (mg) 21.5 ±6.5 21.6 ±4.0
Testosterone (ng/ml)
Day 18-20 3.1 ±4.2 2.9 ±2.2
Day 35-45 2.8 ±3.9 1.3 ±2.1 (p=0.018)
Table 6.4.5: Summary of mean body weight parameters, formula milk intake and
plasma testosterone levels during the study and testis weight at days 35-45 in marmosets
fed with either standard (cow) formula milk (SMA controls) or soy formula milk (SFM).
Values are ± SEM (Sharpe et al., 2002).
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6.4.6 Number of Leydig cells per testis at days 35-40, for infant marmosets
fed either cow's milk formula or soy formula milk
The number of Leydig cells per testis was counted at days 35-40 for infants weaned on
either cow's milk formula or soy formula milk, as shown in Figure 6.4.6. There was a
marked and consistent increase of 74% in the average number of Leydig cells (p=0.006).
Note the discrepancy between testicular Leydig cell numbers and the corresponding
plasma testosterone concentrations, produced by the Leydig cells. This suggests that the
dramatic reduction in testosterone levels observed for these marmosets was not due to a
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Figure 6.4.6: Leydig cell numbers for co-twin infant marmosets fed either cow's
formula milk (SMA) or soy formula milk (SFM). There is a significant increase in
Leydig cell numbers for marmosets fed soy formula milk. P values are based on co-twin
comparison using a paired t-test. N/A = not available due to processing error (Sharpe et
al., 2002).
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6.4.7 Number of Sertoli cells per testis at days 35-40, for infant marmosets
fed either cow's milk formula or soy formula milk
The number of Sertoli cells per testis at days 35-40 was counted for infant marmosets
weaned either on control cow's milk formula or on soy formula milk, as depicted in
Figure 6.4.7. The cell counts showed that there was no significant consistent change in
average Sertoli cell number between cow's milk and soy formula fed animals. This
could suggest that the phytoestrogen soy had very local effects at the level of the testis,
as Sertoli cell number was not affected whereas Leydig cell number was dramatically
increased.
j | Cow's milk formula tSMA)
1345689 Means
Figure 6.4.7: Sertoli cell numbers for co-twin infant marmosets fed either cow's
formula milk (SMA) or soy formula milk (SFM). There was no significant difference in
Sertoli cell numbers for control marmosets and those fed soy formula milk. P values are
based on co-twin comparison using a paired t-test. NS = not significant (Sharpe et ai,
2002).
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6.4.8 Summary of effects observed after the treatment period for the cow's
milk formula and soy formula treated infant marmosets
Parameter Cow's milk formula Soy formula milk
(SMA) (SFM)
Bodyweight at start (g) 33.3 ±3.1 34.3 ± 1.8
Bodyweight at end (g) 75.6 ±9.1 77.6 ±7.5
Bodyweight increment (g) 42.3 ±7.1 43.3 ±7.1
Formula intake (pl/g/day) 93 ± 19 93 ±23
Testis weight (mg) 21.5 ±6.5 21.6 ±4.0
Plasma testosterone (ng/ml)
Day 18-20 3.1 ±4.2 2.9 ±2.2
Day 35-40 2.8 ±3.9 1.3 ±2.1 (p=0.018)
Sertoli cell number (106) 18.0 ±4.9 17.0 ±3.7
Feydig cell number (106) 0.6 ± 0.09 1.3 ±0.11 (p=0.006)
Pituitary FH +ve cells 11.1 ±3.2 14.2 ±4.1
Pituitary FSH +ve cells 18.5 ±5.2 14.9 ±4.9
Pituitary FSH:FH ratio 1.9 ±0.14 1.5 ± 0.12
Figure 6.4.8: Summary of parameters measured and results obtained at 35-40 days of
age for control cow's milk formula (SMA) and soy formula (SMF) fed infant marmosets
(Sharpe et al., 2002). Values are the means ± SEM.
To summarise, neonatal treatment with soy formula milk caused a marked suppression
in plasma testosterone levels at days 35-40 of age and increased the number of Leydig
cells per testis significantly after the treatment period. However, soy formula fed
marmosets showed no significant changes in the number of pituitary LH and FSH
immunopositive cells, testis weight or the in the number of Sertoli cells per testis.
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6.5 Discussion
The objective of this comprehensive study was to address health concerns about feeding
human infants soy formula milk, which contains weak phytoestrogens. Marmosets were
used for the main study as marmosets (especially male marmosets ) tend to have similar
reproductive physiology to humans, in terms of exhibiting a period of neonatal hormone
activity, which is characterised by a significant prolonged surge in testosterone levels
(Dixson, 1986; Lunn et al, 1994; Mann and Fraser, 1996; McKinnell et al., 2001a) and
proliferation of testicular Sertoli cells (Sharpe et al., 2000). Thus, on a developmental
level, neonatal marmosets tend to be comparable to neonatal humans, more so than
neonatal rodents. However, a small genistein study in rats was also performed in
parallel to the marmoset study as presently there are no working assays for
gonadotrophins in marmoset plasma. Hence plasma gonadotrophin levels were
measured in rats treated with genistein to shed some light on phytoestrogen effects on
circulating levels of LH and FSH, in relation to any changes in pituitary morphology in
general and gonadotroph cell populations in particular.
The prolonged neontal testosterone rise is unique only to male primates, as this event
does not occur in female primates. The role of this prolonged testosterone rise in male
primates has yet to be elucidated, but it is not thought to play a role in masculinisation of
sexual behaviour, as this is determined during fetal life rather than in neonatal life as is
the case for rodents (Meisel et al., 1984). Numerous studies using GnRH analogues to
block the testosterone surge in the marmoset have reported relatively minor (Eisler et al.,
1993) or no (Funn et al., 1994) effects in adulthood on sexual behaviour, with no major
effects also on sperm counts in adulthood and fertility (Mann et al., 1993; Funn et al.,
1994,1997; Mann and Fraser, 1996). However, a prolonged rise of testosterone levels in
puberty (Mann et al., 1989,1993; Lunn et al., 1994; Mann and Fraser, 1996) and
significant changes in testicular cell composition, including an increase in Leydig cell
numbers (Sharpe et al., 2000) have been observed.
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The marmosets in this study administered the soy formula milk neonatally showed
normal growth and development, as their starting bodyweights, bodyweight increments,
end bodyweights and testicular weights were comparable to the control marmosets fed
the cow's milk formula. These observations correspond with other observations made
by other groups, where several studies so far have demonstrated that soy formula milk
supports normal growth and development in term infants (Fomon, 1993; Businco et al.,
1992; Churella et al., 1994; Kohler et al., 1984). Another study monitoring growth,
bodyweight and body length of infants during the first year of life, found that these were
virtually the same for either infants fed on soy formula milk or infants fed on cow's milk
formula (Lasekan et al., 1999).
However, one important observation made during this study was that neonatal feeding
with soy formula milk resulted in a significant suppression of the testosterone surge at
days 35-40 (at the end of the study). Interestingly, there was no such suppression in
testosterone levels at days 18-20 (in the middle of the study). It is presently still unclear
why testosterone levels are suppressed at 35 to 40 days of age and not at 18 to 20 days of
age in the soy formula fed marmosets. One possibility is that at 35 to 40 days of age the
marmosets had consumed more soy formula milk than at 18 to 20 days of age (49%
higher intake), and hence the dose and duration of exposure to the phytoestrogens in the
soy formula milk was now large enough to have a visible effect.
The effects of soy formula milk feeding on the testicular Leydig and Sertoli cells were
quite surprising, as there was a significant increase in Leydig cell numbers per testis for
the soy formula milk fed co-twins compared to those fed the cow's milk formula. As
Leydig cell numbers were increased and the testosterone surge was suppressed for the
soy formula milk fed co-twins, this suggests that soy formula milk might be affecting
Leydig cell function as opposed to cell number. There was no overall change in the
number of Sertoli cells per testis between soy formula milk and cow's milk formula fed
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marmosets. This might indicate that the soy milk formula treatment might have very
local effects on the testis, with some cell types being more susceptible than others.
To investigate eventual effects of neonatal soy formula feeding on pituitary function and
to gain some insight into feedback between the pituitary and testes, the numbers of LH
and FSH immunopositive gonadotroph cells were counted for each co-twin fed either
cow's milk formula or soy formula milk. These cell counts showed that there was no
significant consistent change in numbers of LH and FSH immunopositive gonadotroph
cells in the soy formula milk fed co-twins when compared to their cow's milk formula
fed brothers. However, the numbers of LH and FSH immunopositive gonadotrophs
tended to be lower in most of the soy formula milk fed co-twins, but this was only a
small reduction and was not statistically significant. Similar observations were made at
day 18 for the rats treated neonatally with genistein, however, plasma FSH levels were
significantly elevated (pcO.OOl) at day 18 in genistein treated rats compared to controls.
Thus, the marmoset pituitary gonadotroph findings cannot be interpreted as reflecting no
change in LH and/or FSH secretion, as neonatal genistein treated 18 day old rats showed
no change in gonadotroph cell number but an elevation in plasma FSH concentrations.
It has also been shown by other groups that s.c. administration of genistein at
2.5mg/kg/day to adult mice can reduce both blood testosterone levels and pituitary LH
content (Strauss et al, 1998). Thus at this present time there is no solid explanation as
to why feeding infant marmosets soy formula milk resulted in a significant and
consistent increase in testicular Leydig cell numbers and in a dramatic suppression of the
neonatal testosterone surge. What the long-term consequences of these effects could be
is also unclear, but hopefully some of these uncertainties should be resolved when their
other treated brothers go through puberty and reach adulthood. Observations of these
animals so far have shown that they proceed through puberty in the normal manner (data
not shown).
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Although this study has demonstrated significant effects of feeding soy formula milk to
infant marmosets, it still remains difficult to predict whether these findings will also
hold true for humans and whether there would be any long-term effects of feeding
human infants soy formula milk. The evidence available on sexual and reproductive
outcomes associated with infant soy formula milk feeding in humans is presently
extremely limited. One study on the possible reproductive effects of soy formula milk
has described high circulating levels of isoflavone metabolites in infants (Setchell et al.,
1998). They found that infants exclusively fed soy-based diets are exposed to high
concentrations of isoflavones relative to their body weight (Setchell et al., 1998; Knight
et al., 1998). Although human metabolism of soy isoflavones is presently not well
understood, there is evidence that these compounds are biologically active in adults and
may influence reproductive hormone levels (Cassidy et al., 1994; Baird et al., 1995). It
has been shown that infants absorb and excrete soy isoflavones, but it is not known to
what extent they are able to metabolize and deconjugate these compounds to
biologically active forms (Klein, 1998; Setchell et al., 1998, 1997; Irvine et al., 1998).
Some in vitro and animal studies on non-soy phytoestrogens such as coumestans, have
led to speculation that isoflavones may adversely affect developmental processes
influenced by sex steroids, with potential consequences perhaps manifested only in
puberty or adulthood (Irvine et al., 1998). However, comparisons between species
might be difficult and inappropriate because there are known differences in metabolism
and developmental norms (Klein, 1998). Furthermore, some results of some animal
studies on possible sexual and reproductive effects of soy isoflavones have been
inconsistent, hinting that there could be substantial variation within and across species,
and differing also by dose and timing of exposure (Klein, 1998).
In conclusion, the findings from this short-term study have shown that feeding neonatal
marmosets soy formula milk can cause a significant suppression of the neonatal
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testosterone surge and a significant elevation in Leydig cell number at 35 to 40 days of
age. Future studies should bring to light the long-term consequences of infant soy
formula milk feeding and until more is known about eventual long-term effects of soy
formula feeding, it would be wise to err on the side of caution and avoid using soy
formula milk if possible.
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Chapter seven: general discussion
The main objectives of the studies conducted for this thesis were to investigate whether
oestrogen treatment during the neonatal period of development could re-programme
pituitary function on a permanent basis, and to test whether potential pituitary re-
programming was due to a direct oestrogen-induced effect on the pituitary gland or via
oestrogen-induced altered feedback along the HPG axis. The potent synthetic oestrogen,
DES, was used throughout these studies as a model for neonatal oestrogen disruption.
At this present time there is only a limited amount of information available as to whether
neonatal oestrogen administration has any effects on pituitary gonadotroph function and
whether potential effects are direct or indirect. Most of the studies to date have focussed
mainly on the effects of neonatal oestrogen exposure on the reproductive tract. In male
rodents, neonatal DES treatment has been shown to cause a range of reproductive tract
abnormalities, including overgrowth of the rete testis, reduced epithelial cell height in
the efferent ducts, epididymis, vas deferens, seminal vesicles and prostate (Atanassova
et al., 1999, 2001; Williams et al., 2001; McKinnell et al., 2001a,b), a loss of expression
of androgen receptor in the testis (Williams et al., 2001; McKinnell et al., 2001a,b) and
changes in circulating reproductive hormone concentrations (Atanassova et al., 1999;
Rivas et al., 2002). Evidence has also been obtained from humans, e.g. the sons of
mothers exposed to DES during pregnancy have been shown to possess abnormalities in
the structure and function of their reproductive organs (Arai et al., 1983), including an
increased incidence of hypospadias, epididymal cysts, hypoplastic testes,
cryptorchidism, and abnormal semen parameters. Neonatal exposure of females to DES
has also been shown to result in abnormalities of the reproductive tract, including
vaginal lesions (Bern et al., 1987), uterine hypoplasia (Medlock et al., 1992), and a loss
of oestrogen receptors (Medlock et al., 1992).
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In our current experimental paradigm of neonatal disruption of male rodents with DES,
it was shown to significantly reduce FSH immunopositive staining and FSH mRNA
levels in the anterior pituitary, shortly after treatment (at 18 days of age). At 26 days of
age, plasma levels of both LH and FSH were found to be suppressed in the DES treated
rats. It has been documented in the literature that rodent Sertoli cells proliferate mainly
during the neonatal period of development and that plasma FSH levels play an important
role in this process (Sharpe, 1994). In DES treated animals in adulthood, there was a
significant reduction in testis weight and in the total number of Sertoli cells per testis.
This probably demonstrates that the reduced plasma FSH levels during neonatal life,
caused by DES disruption, resulted in diminished Sertoli cell proliferation during
neonatal life and hence resulted in a lower number of Sertoli cells per testis and thus
lower eventual testis weight in adulthood. This corresponds well with the plasma
inhibin B concentrations measured for these DES treated animals, as circulating inhibin
B levels were found to be significantly suppressed in adulthood, and this suppression
may well have been due to a reduction in total number of Sertoli cells per testis.
Interestingly, there was found to be no significant change in the total number of Leydig
cells present per testis, however, plasma testosterone levels were shown to be
significantly reduced. This demonstrates that the suppressed plasma testosterone levels
were probably due to a DES-induced functional deficit in the Leydig cells to efficiently
produce and secrete testosterone. Since inhibin B and testosterone exert potent
hormonal feedback onto the pituitary, the reduced circulating levels of these gonadal
hormones will have resulted in a distorted feedback onto the pituitary gonadotrophs
resulting in a permanent elevation of plasma LH and FSH levels.
To investigate whether neonatal DES treatment in these male rats had altered pituitary
gland sensitivity to GnRH, all rats were administered a short GnRH pulse and plasma
LH and FSH levels in response to this GnRH challenge were assayed. Interestingly, it
was found that the male DES treated rats showed a significantly attenuated response to
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GnRH, with GnRH-induced LH release being approximately 50% lower in the DES
treated rats. This result correlates well with current literature which has demonstrated
that GnRH-induced LH release has been shown to be blunted by neonatal DES treatment
(Register et al., 1995; Faber et al., 1993). A possible cause for this effect is that
neonatal DES treatment caused a (permanent) downregulation of GnRH receptors on
gonadotroph cells, as oestrogenic agents have been shown to diminish GnRH receptor
expression on pituitary gonadotrophs (Kang et al., 2001; Cheon et al., 2001).
In vitro culture of the adult pituitaries of the neonatally DES treated male rats showed
that there was no significant change in LH and FSH output from the pituitary cells
isolated from controls or from DES treated rats. Additionally, treatment of these cells
with GnRH and/or activin, which have been shown to stimulate LH and FSH secretion
from both L(3T2 cells and primary pituitary cells (Pernasetti et al., 2001; Liu et al., 2002;
Nicol et al., 2002), also showed no significant change in LH and FSH output. Thus it
appears that in accordance with the in vivo data obtained for these rats, that neonatal
DES treatment had only subtle functional effects upon the anterior pituitary, as there was
found to be no significant loss of gonadotrophin hormones from the adult primary
pituitary cells isolated and cultured from neonatally DES treated male rats. However
both the in vivo and in vitro data show that there was possibly a disruption in anterior
pituitary sensitivity to GnRH due to a potential attenuation of GnRH receptor expression
on pituitary gonadotroph cells.
Neonatal DES treatment of female rats was found to cause less significant physiological
changes than in male DES treated animals. In direct contrast to the DES treated males,
neonatal DES treatment was found to have no significant effects on basal levels of
circulating LH, FSH, and inhibin B levels. This demonstrates that plasma hormone
levels in male rats were more susceptible to permanent disruption by neonatal DES
administration than female DES treated rats. However, similarly to the DES treated
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males, the pituitary sensitivity to GnRH was found to be significantly attenuated in the
DES treated females, with GnRH-induced LH release being 50% lower in the DES
treated females. In a similar manner, in vitro analysis of LH and FSH output from adult
primary pituitary cells cultured from neonatally DES treated female rats showed that
there was no significant change in LH and FSH output between the control and DES
treated cells, even with GnRH and/or activin treatment. Thus, this demonstrates that
neonatal treatment of female rats with DES had no permanent and significant effects on
gonadotrophin release from the pituitary.
The reason for neonatal DES treatment exerting differential effects in males and females
could be due to a number of causes. It has been well documented that females
experience oestrogen exposure during all stages of development (Corbier et al., 1990;
Faiman & Winter, 1974), whereas males do not (Mann & Fraser, 1996). It is therefore
possible that males are more susceptible to oestrogen disruption during neonatal life than
females as they are not used to experiencing high oestrogen levels during development.
It has also been shown that males have a lower level of GnRH receptor expression in the
pituitary and throughout the central nervous system compared to females (Lopez de
Maturana et al., 2003, in review), thus this might result in male pituitaries having a
lower tolerance of detrimental oestrogenic effects upon GnRH receptor expression and
therefore gonadotroph functional capacity compared to females. In addition, male gonad
development is largely dependent upon testosterone (Mann & Fraser, 1996), thus high
circulating levels of DES around the body might reduce the bio-availability, plasma half-
life and distribution of testosterone, due to DES binding to sex hormone binding
globulins or albumin. The direct effects of DES, via occupation of oestrogen receptors
in the gonads also may contribute to the detrimental effects of DES upon the male
gonads while clearly not exerting a commensurate disruptive effect in the female.
Another possible cause for the differential DES induced effects in males and females
could be due to the fact that neonatal DES treatment in male rats is known to virtually
Chapter 7 General discussion 248
wipe out the expression of androgen receptors throughout the testis and reproductive
tract. It has been shown that this reduction in androgen receptor expression largely
accounts for the detrimental effects of DES treatment in male rats (McKinnell et al.,
2001a,b; Rivas et al., 2002). It is possible that a similar DES induced suppression of
androgen receptor expression might occur in the pituitary gland of male rats. It would
be interesting to investigate whether the pituitary gland contains androgen receptors and
whether neonatal DES treatment would alter pituitary androgen receptor expression. As
androgen receptor expression is less extensive in female animals, this might account for
some of the differences in DES induced effects between male and female animals.
During a small pilot study performed for this thesis, DES-induced pituitary effects were
investigated further in male rats by treating them with either a long-acting GnRH
antagonist (Antarelix) on its own or in combination with a low dose of DES. The GnRH
antagonist treatment was found to significantly elevate plasma FSH levels in adulthood
Immunocytochemical analysis of the pituitaries of these animals showed that mRNA
levels for LH and FSH were significantly elevated. A possible explanation for this
observed effect is that there was an autoregulatory increase in sensitivity of the
hypothalamic-pituitary axis in an attempt to compensate for the reduced GnRH input
due to the presence of the GnRH antagonist. This could have resulted in the
upregulation of mRNA for LH and FSH in the pituitary that we observed. Neonatal
treatment with a GnRH antagonist has been shown to reduce testis weight significantly,
to reduce the number of Sertoli cells per testis, to delay sexual maturation, and induce
infertility (Atanassova et al., 1999; Kolho and Huhtaniemi, 1989). With respect to this
action of GnRH antagonists we noted that the male rats treated neonatally with both
GnRH antagonist and DES showed no significant changes in plasma levels of LH, FSH,
inhibin B or testosterone. However, the pituitary sensitivity to GnRH for these treated
animals was found to be much higher than control animals as the treated rats showed a
significantly larger release in LH (and testosterone) in response to a GnRH pulse.
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These DES studies provided a solid basis to address recent health concerns of feeding
human infants soy formula milk (SFM), which contains high concentrations of
phytoestrogens. Although phytoestrogens are not as potent at the synthetic oestrogen
DES, there are presently concerns that feeding male infants with SFM might exert
harmful effects on the developing FIPG axis. The SFM study performed in infant
marmosets showed that neonatal phytoestrogen exposure resulted in a marked
suppression of plasma testosterone levels at 35-40 days of age and significantly
increased the total number of Leydig cells present per testis. What the long-term effects
are of neonatal testosterone suppression are as yet unclear, however neonatal
testosterone is thought to play a role in masculinisation of sexual behaviour (Meisel et
al., 1984). Immunocytochemical analysis of the pituitary glands of these animals
showed that there was no significant change in the number of LH and FSH
immunopositive cells between control marmosets and SFM treated marmosets.
Although this study has demonstrated significant effects of feeding SFM to infant
marmosets, it still remains uncertain whether these findings will also hold true for
humans and whether there would be any long-term consequences of feeding human
infants soy formula milk. Flopefully some of these uncertainties should be resolved
when other SFM treated infants reach adulthood.
These studies have shown that neonatal oestrogen exposure can have marked effects on
the HPG axis. Future studies that could be performed to elucidate in more depth the
effects of neonatal HPG axis disruption could include:
• Treating neonatal female rats with androgens, in a converse study to this present
one, to test whether this would cause similar effects to those observed in DES
treated male rats.
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• Investigating expression of pituitary GnRH receptors, oestrogen receptors and
androgen receptors in response to neonatal DES treatment. In addition, an
investigation into the effects of neonatal DES treatment on LH and FSH receptor
expression in the gonads would be most revealing.
• Investigate potential DES-induced effects on other anterior pituitary cells types.
For example lactotrophs.
• Administer DES treatment in combination with androgen treatment to neonatal
male rats to test whether this treatment regime could counteract the DES-induced
effects on the HPG axis. Treatment of neonatal male rats with both DES and
FSH could also be performed to investigate whether this would counteract DES-
induced suppression of FSH levels and hence reduced proliferation of Sertoli
cells.
The results from these studies suggest that both neonatal DES treatment and neonatal
phytoestrogen exposure can have significant effects along the HPG axis. Especially
DES treatment has been shown to cause potent and life-long effects on the HPG axis.
DES has been shown to cause direct effects on pituitary function at the time of
treatment for a short period of time, and on testicular function, with male gonads
being more susceptible to neonatal endocrine disruption with DES.
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Appendix I: Anastrazole and Tamoxifen
A small study was performed using two other treatments to investigate the effects of
neonatal oestrogen disruption on the function of the pituitary gland. These treatments
were Anastrazole, an aromatase inhibitor used mainly in treatment of breast cancer, and
Tamoxifen, an oestrogen receptor antagonist also used to treat breast cancer. Male rats
were injected s.c. with either 25mg/kg/day from days 2 to 17 with Anastrazole (gift from
Astra Zeneca), or with lmg/kg/day of Tamoxifen (Sigma) from days 2 to 12. Pituitaries
were removed at day 18, were processed and sectioned, and the number of LH and FSH
immunopositive cells was counted for each animal.




Control 21.0 ± 3.21 12.8 ±2.72
n=6 n=6
Anastrazole 19.3 ± 1.31 10.1 ±0.88
n=3 p=0.722 n=3 p=0.524
Tamoxifen 25.5 ±3.74 8.61 ± 1.07
n=4 p=0.400 n=4 p=0.264
Appendix I: Mean percentages of LH and FSH immunopositive cells in 18 day old
male rats treated neonatally with Anastrazole or Tamoxifen. Values are the means ±
SEM.
Neonatal treatment of male rats with Anastrazole or Tamoxifen was found to have no
significant effect on the number of LH and FSH immunopositive gonadotrophs present
in the anterior pituitary of 18 day old rats. Unfortunately no adult pituitaries or blood
samples were available for analysis.
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Appendix II: Pituitary Aromatase Staining
Appendix II: Preliminary evidence from Richard Sharpe's laboratory showed that there
was possibly aromatase P450 present within the adult rat pituitary, and hence this
observation was investigated further. However, no aromatase was detected in the
anterior pituitary. Panel A depicts attempted aromatase staining in the adult male rat
pituitary. No aromatase staining was detectable, however it has been reported recently
by Carretero and colleagues that aromatase P450 is present within the adult male rat
pituitary (Carretero et al., 1999). Panel B shows the control slide with aromatase
immunopositive staining in the ovary. Details of antibodies and methods used for




Appendix III: Pituitary ERa Staining
Appendix III: Oestrogen receptor a (ERa) staining in the male rat and male marmoset
pituitary gland. Panel A depicts ERa staining in 18 day old rat pituitaries, whereas
panel B shows staining in adult rat pituitaries (day 90). Panel C depicts staining for
ERa in 35 week old marmosets. Panel D is a control section, showing staining for ER a
in the rat uterus. Immunocytochemistry methods and antibody dilutions are detailed in
Chapter 2.
254
Appendix IV: Commercial Suppliers
AB Gene (UK) Ltd
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